JP2012526097A - GPR119 regulator - Google Patents

Abstract

Described herein are compounds of formula (I) that modulate the activity of G protein-coupled receptor GPR119 and its use for the treatment of diseases associated with modulation of G protein-coupled receptor GPR119 in animals.
[Chemical 1]

Description

  The present invention relates to a novel class of condensed pyrrolidines, pharmaceutical compositions containing these compounds, and their use to modulate the activity of the G protein coupled receptor GPR119.

  Diabetes is a disorder where there is a high concentration of blood glucose as a result of abnormal glucose homeostasis. The most common forms of diabetes are type I diabetes (also called insulin dependent diabetes) and type II diabetes (also called non-insulin dependent diabetes). Type II diabetes, which accounts for approximately 90% of all diabetes cases, is associated with microvascular complications (including retinopathy, neuropathy, and kidney damage), and macrovascular complications (accelerated atherosclerosis, coronary heart) Serious progressive disease that causes disease and stroke).

  There is currently no cure for diabetes. Standard treatments for this disease are limited and focus on controlling blood glucose levels to minimize or delay complications. Current therapies target either insulin resistance (metformin, thiazolidinedione) or insulin release from beta cells (sulfonylurea, exanatide). Sulfonylureas and other compounds that work through β-cell depolarization stimulate hypoglycemia because they stimulate insulin secretion independent of circulating glucose concentration. One of the approved drugs, exanatide, stimulates insulin secretion only in the presence of high glucose but lacks oral bioavailability and must be injected. Sitagliptin, a dipeptidyl peptidase IV inhibitor, is a new drug that increases blood levels of incretin hormones, which can increase insulin secretion and decrease glucagon secretion and are less characterized It may have other effects that are not done. However, sitagliptin and other dipeptidyl peptidase IV inhibitors can also affect the tissue concentrations of other hormones and peptides, and the long-term consequences of this broader effect have been well investigated. Absent.

  In type II diabetes, muscle cells, adipocytes, and hepatocytes do not respond normally to insulin. This condition (insulin resistance) may be due to a decrease in the number of cellular insulin receptors, disruption of cellular signaling pathways, or both. Initially, β cells make up for insulin resistance by increasing insulin production. Eventually, however, β cells fail to produce enough insulin to maintain a normal glucose concentration (normoglycemia), indicating progression to type II diabetes.

  In type II diabetes, fasting hyperglycemia occurs due to insulin resistance combined with β-cell dysfunction. There are two modes of abnormal β-cell dysfunction. Namely, 1) increased basal insulin release (which occurs at non-irritating low glucose concentrations) (which is observed not only in type II diabetes but also in the insulin-resistant prediabetic stage of obesity), and 2) hyperglycemic load In response, the insulin release does not increase above the already elevated basal level (this phenomenon does not occur in the pre-diabetic phase, but transitions from the insulin-resistant phase of normoglycemia to overt type II diabetes May be a precursor). Current therapies treating the latter embodiment include administration of an inhibitor of ATP-sensitive β-cell potassium channel to induce the release of endogenous stored insulin and exogenous insulin. Neither of them achieves accurate normalization of blood glucose concentration, and involves the risk of causing hypoglycemia.

  Therefore, there is great interest in discovering drugs that function in a glucose-dependent manner. Physiological signaling pathways that function in this way are well known, including the intestinal peptides GLP-1 and GIP. These hormones signal through the homologous G protein coupled receptor to stimulate the production of cAMP in pancreatic β cells. Increasing cAMP does not appear to stimulate insulin release during fasting or pre-meal conditions. However, several biochemical targets of cAMP, including ATP-sensitive potassium channels, voltage-sensitive potassium channels, and the exocytosis mechanism, are regulated so that postprandial glucose-stimulated insulin secretion is significantly enhanced. Thus, novel β-cell GPCR agonist modulators, including GPR119, that function similarly also stimulate endogenous insulin release and promote normalization of glucose concentrations in type II diabetic patients. For example, it has also been found that increasing cAMP as a result of stimulation with GLP-1 promotes β-cell proliferation, suppresses β-cell death, and thus improves islet mass. This positive effect on beta cell mass should be beneficial in type II diabetes, where insulin is not fully produced.

  It is well known that metabolic diseases adversely affect other physiological systems, such as complex disease states (eg, “Syndrome X” type I diabetes, type II diabetes, insufficient glucose tolerance, insulin resistance Secondary disease that occurs following diabetes, such as hyperglycemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, dyslipidemia, obesity, or cardiovascular disease), or kidney disease or peripheral neuropathy Often accompanied. Accordingly, treatment of diabetic conditions should be beneficial for such interrelated disease states.

  According to the present invention, a new class of GPR regulators has been discovered. These compounds have the formula (I)

［式中、
Ｘは、

[Where:
X is

であり、
Ｒ^１は、ＣＯ−Ｏ−Ｒ^５、または

And
R ¹ is CO—O—R ⁵ , or

であり、
Ｒ^２は、水素、シアノ、またはメチルであり、
Ｒ^３は、水素、ＯＨ、ハロゲン、シアノ、ＣＦ_３、ＯＣＦ_３、Ｃ_１〜Ｃ_５アルコキシ、またはＣ_１〜Ｃ_５アルキルであり、
Ｒ^４は、存在しない、または−ＣＯ−ＮＲ^８Ｒ^９、トリアゾール、テトラゾール、Ｃ_１〜Ｃ_５アルキル、ＮＨ_２、−ＮＨ−Ｃ_１〜Ｃ_５アルキル、−Ｎ（ＣＨ_３）−ＣＯ−Ｏ−Ｃ_１〜Ｃ_５アルキル、−ＮＨ−ＣＯ−Ｃ_１〜Ｃ_５アルキル、もしくは−Ｎ（ＣＨ_３）−ＣＯ−Ｃ_１〜Ｃ_５アルキルであり、
Ｒ^５は、Ｃ_１〜Ｃ_５アルキル、Ｃ_３〜Ｃ_６シクロアルキル、またはシクロアルキル部分の１個の炭素原子がメチルもしくはエチルで置換されていてもよいＣ_３〜Ｃ_６シクロアルキルであり、
Ｒ^６は、ＣＦ_３、Ｃ_１〜Ｃ_５アルキル、ハロゲン、シアノ、またはＣ_３〜Ｃ_６シクロアルキルであり、
Ｒ^７は、Ｃ_３〜Ｃ_６シクロアルキル、Ｃ_１〜Ｃ_５アルキル、ＮＨ_２、または（ＣＨ_２）_２−ＯＨであり、
Ｒ^８は、水素またはＣ_１〜Ｃ_５アルキルであり、
Ｒ^９は、水素、Ｃ_１〜Ｃ_５アルキル、Ｃ_３〜Ｃ_６シクロアルキル、−ＣＨ_２−ＣＨ_２−ＯＨ、−ＣＨ_２−ＣＨ_２−Ｏ−ＣＨ_３、−ＣＨ_２−ＣＨ_２−ＣＨ_２−Ｏ−ＣＨ_３、−ＣＨ_２−ＣＨ_２−ＣＨ_２−ＯＨ、３−オキセタニル、または３−ヒドロキシシクロブチルであり、
Ｒ^１０は、水素、シアノ、ニトロ、ＣＦ_３、ＯＣＦ_３、Ｃ_３〜Ｃ_６シクロアルキル、Ｃ_１〜Ｃ_５アルコキシ、またはＣ_１〜Ｃ_５アルキルであり、
Ｒ^１１は、水素、Ｃ_１〜Ｃ_５アルキル、またはハロゲンであり、
Ａ^１、Ａ^２、Ａ^３、およびＡ^４は、それぞれ独立に、ＣＨ、Ｎ−オキシド、またはＮであり、
但し、
ａ）Ａ^１、Ａ^２、Ａ^３、およびＡ^４のうちの２つ以下は、Ｎであり、
ｂ）Ａ^１、Ａ^２、Ａ^３、およびＡ^４のうちの１つ以下は、Ｎ−オキシドである］
または薬学的に許容できるその塩
によって表すことができる。

And
R ² is hydrogen, cyano, or methyl;
R ³ is hydrogen, OH, halogen, cyano, CF ₃ , OCF ₃ , C ₁ -C ₅ alkoxy, or C ₁ -C ₅ alkyl,
R ⁴ is absent or —CO—NR ⁸ R ⁹ , triazole, tetrazole, C ₁ -C ₅ alkyl, NH ₂ , —NH—C ₁ -C ₅ alkyl, —N (CH ₃ ) —CO—O -C ₁ -C _{5 alkyl, -NH-CO-C 1 ~C} 5 alkyl, or _-N (CH 3) a _-CO-C 1 ~C ₅ alkyl,
R ⁵ _is C 1 -C _{5 alkyl,} C 3 -C ₆ cycloalkyl or one carbon atom may be substituted with methyl or ethyl _C 3 -C ₆ cycloalkyl cycloalkyl moiety,
R ⁶ is CF ₃ , C ₁ -C ₅ alkyl, halogen, cyano, or C ₃ -C ₆ cycloalkyl,
R ⁷ is C ₃ -C ₆ cycloalkyl, C ₁ -C ₅ alkyl, NH ₂ , or (CH ₂ ) ₂ —OH;
R ⁸ is hydrogen or C ₁ -C ₅ alkyl;
R ⁹ is hydrogen, C ₁ -C ₅ alkyl, C ₃ -C ₆ cycloalkyl, —CH ₂ —CH ₂ —OH, —CH ₂ —CH ₂ —O—CH ₃ , —CH ₂ —CH ₂ —CH. _2- O—CH ₃ , —CH ₂ —CH ₂ —CH ₂ —OH, 3-oxetanyl, or 3-hydroxycyclobutyl,
R ¹⁰ is hydrogen, cyano, nitro, CF ₃ , OCF ₃ , C ₃ -C ₆ cycloalkyl, C ₁ -C ₅ alkoxy, or C ₁ -C ₅ alkyl,
R ¹¹ is hydrogen, C ₁ -C ₅ alkyl, or halogen;
A ¹ , A ² , A ³ , and A ⁴ are each independently CH, N-oxide, or N;
However,
a) no more than ^{two of} A ¹ , A ² , A ³ , and A ⁴ are N;
b) No more than one of A ¹ , A ² , A ³ , and A ⁴ is an N-oxide]
Alternatively, it can be represented by a pharmaceutically acceptable salt thereof.

  The compounds of formula I modulate the activity of G protein coupled receptors. More particularly, compounds of formula I modulate GPR119. Therefore, the compounds are useful for the treatment of diseases such as diabetes where GPR119 activity contributes to the pathology or symptoms of the disease. Examples of such conditions include hyperlipidemia, type I diabetes, type II diabetes, idiopathic type I diabetes (type Ib), adult latent autoimmune diabetes (LADA), early-onset type 2 diabetes (EOD) ), Juvenile atypical diabetes (YOAD), juvenile-onset diabetes (MODY), malnutrition-related diabetes, gestational diabetes, coronary heart disease, ischemic stroke, restenosis after angioplasty, peripheral vascular disease, intermittent Lameness, myocardial infarction (eg, necrosis and apoptosis), dyslipidemia, postprandial lipemia, impaired glucose tolerance (IGT) condition, fasted plasma glucose glucose condition, metabolic acidosis, ketosis, arthritis, Obesity, osteoporosis, hypertension, congestive heart failure, left ventricular hypertrophy, peripheral arterial disease, diabetic retinopathy, macular degeneration, cataract, diabetic kidney , Glomerulosclerosis, chronic renal failure, diabetic neuropathy, metabolic syndrome, syndrome X, premenstrual syndrome, coronary heart disease, angina, thrombosis, atherosclerosis, transient ischemic attack, stroke Vascular restenosis, hyperglycemia, hyperinsulinemia, hyperlipidemia, hypertriglyceridemia, insulin resistance, impaired glucose metabolism, impaired glucose tolerance, abnormal fasting plasma glucose, obesity, erectile dysfunction, Examples include skin and connective tissue disorders, foot ulceration and ulcerative colitis, endothelial disorders, and vasodilatory disorders. The compounds of formula I can also be used for the treatment of neurological disorders such as Alzheimer's disease, schizophrenia, cognitive impairment. The compounds of formula I are also beneficial in gastrointestinal diseases such as inflammatory bowel disease, ulcerative colitis, Crohn's disease, irritable bowel syndrome. As mentioned above, the compounds of formula I can also be used to stimulate weight loss in obese patients, in particular obese patients suffering from diabetes.

  Another embodiment of this invention is directed to a pharmaceutical composition containing a compound of formula I. Such formulations usually contain a compound of formula I admixed with at least one pharmaceutically acceptable excipient. Such formulations may also contain at least one additional agent (described herein). Examples of such agents include antiobesity agents and / or antidiabetic agents (discussed below). An additional aspect of the invention relates to the use of a compound of formula I in the preparation of a medicament for treating diabetes and related conditions described herein.

  The present invention can be understood more readily by reference to the following detailed description of illustrative embodiments of the invention and the examples contained therein.

  It should be understood that the present invention is not limited to a particular synthetic manufacturing method, which can of course vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting. Plural and singular terms should be treated as interchangeable except indicating numbers.

  The headings in this document are only used to help readers read the document quickly. These headings should not be construed as limiting the invention or the claims in any way.

Definitions and examples a. “Halogen” refers to a chlorine, fluorine, iodine, or bromine atom.
b. “C ₁ -C ₅ alkyl” means a branched or straight chain alkyl group containing 1 to 5 carbon atoms, for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, Refers to pentyl, etc.
c. “C ₁ -C ₅ alkoxy” means a straight or branched alkoxy group containing 1 to 5 carbon atoms, such as methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, Refers to pentoxy and the like.
d. “C ₃ -C ₆ cycloalkyl” refers to a non-aromatic ring that is fully hydrogenated and exists as a single ring. Examples of such carbocycles include cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
e. “Therapeutically effective amount” means (i) treating or preventing a particular disease, condition or disorder, (ii) alleviating and ameliorating one or more symptoms of a particular disease, condition or disorder, Or (iii) means the amount of a compound of the invention that prevents or delays the onset of one or more symptoms of a particular disease, condition, or disorder described herein.
f. “Patient” refers to warm-blooded animals such as guinea pigs, mice, rats, gerbils, cats, rabbits, dogs, monkeys, chimpanzees, and humans.
g. “Treat” refers to the ability of a compound to reduce, eliminate or slow the progression of a patient's disease (or condition) or any tissue damage associated with the disease.
h. The terms “modulated”, “modulating”, or “modulate”, as used herein, unless otherwise indicated, refer to activation of the G protein-coupled receptor GPR119 using a compound of the present invention. .
i. “Pharmaceutically acceptable” means that the substance or composition must be chemically and / or toxicologically compatible with the other ingredients that make up the formulation and / or the mammal to be treated therewith. Indicates.
j. “Salt” shall refer to pharmaceutically acceptable salts and salts suitable for use in industrial processes such as the preparation of compounds.
k. "Pharmaceutically acceptable salt" shall refer to either a pharmaceutically acceptable acid addition salt or a "pharmaceutically acceptable base addition salt" depending on the actual structure of the compound.
l. "Pharmaceutically acceptable acid addition salt" shall correspond to any non-toxic organic or inorganic acid addition salt of the base compound represented by formula I or any of its intermediates. Illustrative inorganic acids that form suitable salts include hydrochloric acid, hydrobromic acid, sulfuric acid, and phosphoric acid, and acid metal salts such as sodium monohydrogen orthophosphate and potassium hydrogen sulfate. . Illustrative organic acids that form suitable salts include mono, di, and tricarboxylic acids. Examples of such acids are, for example, acetic acid, glycolic acid, lactic acid, pyruvic acid, malonic acid, succinic acid, glutaric acid, fumaric acid, malic acid, tartaric acid, citric acid, ascorbic acid, maleic acid, hydroxymaleic acid, Benzoic acid, hydroxy-benzoic acid, phenylacetic acid, cinnamic acid, salicylic acid, 2-phenoxybenzoic acid, p-toluenesulfonic acid, and sulfonic acids such as methanesulfonic acid and 2-hydroxyethanesulfonic acid. Such salts may exist in either a hydrated or substantially anhydrous form. In general, acid addition salts of such compounds are soluble in water and various hydrophilic organic solvents.
m. "Pharmaceutically acceptable base addition salt" shall correspond to any non-toxic organic or inorganic base addition salt of the compound represented by formula I or any of its intermediates. Examples of bases that form suitable salts include alkali metal or alkaline earth metal hydroxides such as sodium hydroxide, potassium, calcium, magnesium, barium; ammonia; and methylamine, dimethylamine, trimethylamine, picoline, and the like , Aliphatic, cycloaliphatic, or aromatic organic amines.
n. “Compounds of formula I”, “compounds of the invention”, and “compounds” are used interchangeably throughout the application and should be treated as synonyms.
“Isomers” means “stereoisomers” and “geometric isomers” as defined below.
o. “Stereoisomer” refers to a compound having one or more chiral centers, each center may exist in the R or S configuration. Stereoisomers include all diastereoisomers, enantiomers, and epimeric forms, and racemates and mixtures thereof.
p. “Geometric isomers” refers to compounds that may exist in the form of cis, trans, anti, syn, entgegen (E), and xanthmen (Z), and mixtures thereof.

  Some of the compounds of formula (I) may exist as geometric isomers. The compounds of formula (I) have one or more asymmetric centers and may therefore exist as two or more stereoisomeric forms. The present invention includes all individual stereoisomers and geometric isomers of the compounds of formula (I) and mixtures thereof. Individual enantiomers can be obtained by chiral separation or using related enantiomers in the synthesis.

  In addition, the compounds of the present invention may exist in unsolvated forms or in solvated forms with pharmaceutically acceptable solvents such as water and ethanol. In general, the solvated forms are considered equivalent to the unsolvated forms for the purposes of the present invention. A compound may exist in one or more crystalline states, ie, polymorphs, or may exist as an amorphous solid. All such forms are encompassed by the claims.

  Many of the compounds of Formula I contain a 3-oxa-7-azabicyclo [3.3.1] nonane ring attached to the pyrimidine ring via an ether linkage, as illustrated below. The azabicyclo-nonane exists as a geometric isomer and can exist as either the syn or anti isomer illustrated below.

  All of the compounds of Formula I contain a phenyl ring or nitrogen-containing aromatic fused to the pyrrolidine moiety, as illustrated below.

A ^{1 to} A ⁴ can be up to two nitrogen atoms, and the remainder is CH. That is, the aromatic portion of the fused ring can be, for example, phenyl, pyridyl, pyrimidinyl, pyridazinyl, or pyrazinyl. R ³ may be hydrogen or one of the substituents defined above. When R ³ is not hydrogen, up to two substitutions optionally attached to any carbon atom of the fused ring (except for the two carbons in the ring condensation (ie, forming a fused pyrrolidinyl moiety)) It can be based. R ⁴ may or may not be present, and if present, may be attached to any carbon atom on the ring (except for the two carbons forming the fused pyrrolidinyl moiety).

In addition, ^one of A ¹ -A ⁴ may be an N-oxide moiety. In any situation where the aryl moiety represented by A ¹ to A ⁴ is substituted, as readily apparent to those skilled in the art, the relevant carbon atom, CR ³ or CR ^4, and the not CH.

  Examples of such nitrogen-containing fused rings include the following.

  In a more detailed embodiment of the invention, X is 3-oxa-7-azabicyclo [3.3.1] nonane shown below, and the remaining variables are as defined above.

他の実施形態では、Ｘは、

In other embodiments, X is

によって表されるピペリジンである。

It is a piperidine represented by

In a more detailed embodiment,
a) R ¹ is —C (O) —O—R ⁵ , X is piperidine or 3-oxa-7-azabicyclo [3.3.1] nonane, R ² is hydrogen or cyano, ¹ to a ⁴ form a phenyl ring,
b) R ¹ is —C (O) —O—R ⁵ , X is piperidine or 3-oxa-7-azabicyclo [3.3.1] nonane, R ² is hydrogen or cyano, A ¹ to a ⁴ forms a pyridyl ring,
c) R ¹ is —C (O) —O—R ⁵ , X is piperidine or 3-oxa-7-azabicyclo [3.3.1] nonane, R ² is hydrogen or cyano, A ^{1 to} A ⁴ form a pyridyl ring, R ³ is hydrogen, methyl or cyano, and R ⁴ is absent,
d) R ¹ is —C (O) —O—R ⁵ , X is piperidine or 3-oxa-7-azabicyclo [3.3.1] nonane, R ² is hydrogen or cyano, R ¹⁰ is hydrogen, A ^{1 to} A ⁴ form a phenyl ring, R ³ is hydrogen, R ⁴ is present, and is represented by NH— (CH ₂ ) ₂ —OH.

In other embodiments, A ¹ -A ⁴ form a phenyl ring.

In another ^embodiment, A 1 to A ^{4 are,} A ^1, A 2, one of ^{A 3} and ^{A 4} or two to form a ring which is N.

In still other embodiments, A ¹ -A ⁴ form a pyridyl ring.

In other embodiments, R ⁴ is absent or is —CO—NR ⁸ R ⁹ .

In other embodiments, R ¹ is —C (O) —O—R ⁵ .

In other embodiments, R ³ is fluoro or hydrogen.

In other embodiments, R ² is hydrogen or cyano.

Synthesis The compounds of the present invention can be synthesized by synthetic routes that include methods similar to those well known in the chemical art, particularly in light of the description contained herein. Starting materials are generally available from commercial sources such as Aldrich Chemicals (Milwaukee, Wis.), Or are readily prepared using methods known to those skilled in the art (eg, Louis F. Fieser and From Mary Fieser, Reagents for Organic Synthesis, Volumes 1-19, Wiley, New York (1967-1999), or Beilsteins Handbuch der organischen Chemie, 4th edition, Berlin, published by Spring-Verlag. Prepared by the methods generally described in the

  For illustrative purposes, the reaction scheme illustrated below illustrates potential routes to synthesize the compounds of the invention as well as key intermediates. See the Examples section below for a more detailed description of the individual reaction steps. One skilled in the art will appreciate that other synthetic routes may be used to synthesize the compounds of the invention. Detailed starting materials and reagents are shown in the scheme and discussed below, but can be readily replaced with other starting materials and reagents to provide various derivatives and / or reaction conditions. In addition, many of the compounds prepared by the methods described below can be further modified in light of this disclosure using conventional chemistry well known to those skilled in the art.

  Compounds of formula I can be prepared using methods of ether formation that are also known in the art. 1) Hughes, D .; L. , Organic Reactions 1992, 42, Hoboken, NJ, USA 2) Tikad, A .; Routier, S .; Aksira, M .; Leger, J .; -M. l, Jarry, C .; Guillaumet, G .; Synlett 2006, 12, 1938-42, and 3) Loksha, Y .; M.M. Globisch, D .; Pedersen, E .; B. La Colla, P .; Collu, G .; Roddo, R .; , J .; Het. Chem. Look to textbooks that describe these reactions in more detail, such as 2008, 45, 1161-6.

  Reaction Scheme I immediately below illustrates an alternative method for assembling compounds of Formula I. The central part of the molecule is an optionally substituted pyrimidine ring. Compounds of formula I are produced by forming both ether and amino bonds with pyrimidines as shown below. The order in which this series of reactions is performed is not critical.

The starting material of Reaction Scheme I is a dihydroxy-pyrimidine of structure 1 where R ² and R ¹⁰ are usually the same substituents as desired in the final product. Such methods for producing pyrimidines are known in the art.

The chlorination reaction of Step A is performed as known in the art. A compound of structure 1 is reacted with a chlorinating reagent such as POCl ₃ (phosphorus oxychloride) (Matulenko, MA, et al., Bioorg. Med. Chem. 2007, 15, 1586-1605) to form a dichloropyrimidine of structure 2. Is generated. The chlorinating agent is used in excess, with or without additives such as triethylamine, N, N-dimethylaniline, diisopropylethylamine, or in a solvent such as toluene, benzene, xylene. This reaction can be carried out at temperatures ranging from room temperature to 140 ° C., depending on the choice of conditions. Alternative chlorinating reagents include PCl ₃ (phosphorus trichloride), POCl ₃ / PCl ₅ (phosphorus pentachloride), thionyl chloride, oxalyl chloride, or phosgene. In some cases, the structure 2 dichloropyrimidine can also be obtained from commercial sources. Optionally, the dichloropyrimidine of structure 2 may be isolated and recovered from the reaction and further purified as is known in the art. Alternatively, unpurified material may be used in Step B described below.

In Step B, an amino bond is formed between the condensed pyrrolidine of structure 3 and the dichloropyrimidine of structure 2. In the condensed pyrrolidine of structure 3, A ¹ , A ² , A ³ , A ⁴ , R ³ , and R ⁴ are usually the same substituents as desired in the final product. Such pyrrolidine derivatives are known in the art and are described in (a) Zhao, H .; Thrkauf, A .; He, X .; Hodgetts, K .; Zhang, Xi. Rachwal, S .; Kover, R .; X. Hutchison, A .; Peterson, J .; Kieltyka, A .; Brodbeck, R .; Primus, R .; Wasley, J .; W. F. Bioorg. Med. Chem. Lett. 2002, 12, 3105, (b) Nomura, S .; Yamamoto, Y .; WO2006608577, (c) Gribble, G .; Hoffman, J .; H. Synthesis 1983, 13, 489, (d) Sassatelli, M .; Bouchikhi, F .; Messaudidi, S .; Anizon, F .; Debiton, E .; Barthomeuf, C .; Prudhomme, Moreau, P .; Eur. J. et al. Med. Chem. 2006, 41, 88. The examples also provide additional teaching and references for such preparation.

  Amino bonds are obtained in polar protic solvents such as ethanol, propanol, isopropanol, butanol, and equivalent amounts of compounds of structures 2 and 3 at temperatures ranging from 0 ° C to 120 ° C depending on which solvent is used. Formed by contact for 0.5-24 hours. A typical condition utilized for this reaction is the use of isopropanol as a solvent heated at 108 ° C. for 1 hour. Alternatively, an amine base such as triethylamine or diethylisopropylamine, or an inorganic base such as sodium bicarbonate, potassium carbonate, sodium carbonate may be added to the reaction. When one of the above amines or inorganic bases is used, the solvent is a polar aprotic solvent such as acetonitrile, N, N-dimethylformamide (“DMF”), tetrahydrofuran (“THF”), 1,4-dioxane ( 0 to 100 ° C. for 0.5 to 24 hours). Typical conditions utilized for this reaction include the use of diethyl isopropylamine in acetonitrile for 3 hours at room temperature. The use of hydrochloric acid in polar protic solvents alone or in combination, such as water, methanol, ethanol, propanol, etc. can also be used for this conversion at temperatures between 0 ° C and 110 ° C. Typical conditions are those using water at 78 ° C. in ethanol. The intermediate of structure 5 can be isolated and recovered from the reaction and further purified as is known in the art. Alternatively, unpurified material may be used in Step B described below.

In Step C, an ether bond is formed between the intermediate of structure 5 and the alcohol of structure 4 to produce a compound of formula I. The alcohol of structure 4 is 3-oxa-7-azabicyclo [3.3.1] nonanol or a hydroxy-substituted piperidine, depending on the desired end product. In these heterocycles, R ¹ and R ¹¹ are usually the same substituents as desired in the final product. Reaction Scheme II below teaches how to produce 3-oxa-7-azabicyclo [3.3.1] nonanol. Hydroxyl substituted piperidines are well known in the art and are described in (a) Gharbaoui, T .; Sengupta, D .; Lally, E .; A. Kato, N .; S. Carlos, M .; Rodriguez, N .; US 2006154940, (b) Wessig, P .; Moellnitz, K .; Eiserbeck, C .; Chem. Eur. J. et al. 2007, 13, 4859, (c) Kreidler, B .; Baro, A .; Christoffers, J .; Eur. J. et al. Org. Chem. 2005, 24, 5339, (d) Jingyuan, M .; A. Rabbat, C.I. J. et al. Song, J .; Chen, X .; Nashashibi, I .; Zhao, Z .; Novack, A .; Shi, D .; F. Cheng, P .; Zhu, Y .; Murphy, A .; WO2009014910, (e) Schliinger, N .; Thegysen, M .; B. Pawlas, J .; Badalassi, F .; Lewinsky, R .; Lund, B .; W. Olsson, R .; , And published in publications such as WO2006076317.

  In Step C, sodium hydride; sodium and potassium tert in a solvent such as DMF, THF, 1,2-dimethoxyethane, 1,4-dioxane, N, N-dimethylacetamide, dimethyl sulfoxide (“DMSO”) -Butoxide; sodium, potassium, and lithium bis (trimethylsilyl) amide; an equivalent amount of reactant is contacted in the presence of a base such as sodium, potassium, and lithium tert-amyl oxide. Typical conditions for this conversion include the use of sodium bis (trimethylsilyl) amide in dioxane at 105 ° C. for 1 hour.

  After the reaction is complete, the desired compound of formula I can be recovered and isolated as is known in the art. The compound can be recovered by evaporation, extraction, etc., as is known in the art. The compound may optionally be purified by chromatography, recrystallization, distillation, or other techniques known in the prior art.

As will be readily appreciated by those skilled in the art, many of the substituents represented by R ¹ and R ⁴ can be manipulated after generating the nucleus of formula I. For example, a sulfonyl moiety can be generated by oxidizing a thioether. Such variations are well known to those skilled in the art and should be considered part of the present invention.

In the alternative synthesis shown above in Reaction Scheme I, the dichloro-pyrimidine of structure 2 is first contacted with the alcohol of structure 4 to produce the intermediate shown by structure 6. As in Step C, the alcohol of structure 4 is 3-oxa-7-azabicyclo [3.3.1] nonanol or hydroxyl substituted piperidine, depending on the desired end product. In these heterocycles, R ¹ is usually the same substituent as desired in the final product.

  Equivalent structures 2 and 4 are reacted in the presence of a polar aprotic solvent and a base to produce the intermediate of structure 6 shown in Step D. As a suitable system, sodium hydride; sodium in a solvent such as DMF, THF, 1,2-dimethoxyethane, 1,4-dioxane, N, N-dimethylacetamide, DMSO at a temperature of 0 ° C. to 140 ° C. And potassium tert-butoxide; sodium, potassium, and lithium bis (trimethylsilyl) amide; bases such as sodium, potassium, and lithium tert-amyl oxide. Typical conditions for this transformation include the use of potassium tert-butoxide in THF at 0 ° C. to room temperature for 14 hours. The intermediate of structure 6 can be isolated and recovered from the reaction and further purified as is known in the art. Alternatively, unpurified material may be used in Step E described below.

  The compound of formula I can then be generated by contacting the intermediate of structure 6 with the condensed pyrrolidine of structure 3 previously described above. Usually, an equivalent amount of the condensed pyrrolidine of structure 3 is reacted with the chloro intermediate of formula 6 in the presence of a base. Suitable bases are sodium hydride; sodium or potassium tert in a solvent such as DMF, THF, 1,2-dimethoxyethane, 1,4-dioxane, N, N-dimethylacetamide, or DMSO, or mixtures thereof. -Butoxide; sodium, potassium, or lithium bis (trimethylsilyl) amide; and sodium, potassium, or lithium tert-amyl oxide. These reactions can be carried out at a temperature in the range of −10 ° C. to 150 ° C. depending on the solvent used. Usually, the reaction is allowed to proceed for a time in the range of 15 minutes to 24 hours in an inert atmosphere. Suitable conditions include sodium bis (dimethylsilyl) amide in dioxane at 105 ° C. for 1 hour.

  Alternatively, this reaction is carried out by heating the intermediate of structure 6 and the condensed pyrrolidine of structure 3 in a polar aprotic solvent such as methanol, ethanol, propanol, isopropanol, butanol for 0.5-24 hours. May be. Typical conditions for this conversion are heating in isopropanol at 108 ° C. for 2 hours.

This reaction can also be carried out using a transition metal catalyst for the formation of important substituted amine bonds found in compounds of formula I. The transition metal catalyst includes, but is not limited to, Pd (PPh ₃ ) ₄ , PdCl ₂ , Pd (OAc) ₂ , Pd ₂ (dba) ₃ , CuI, Cu (OAc) ₂ , and Cu (OTf) ₂ It can be. Usually, these reactions utilize a base. Suitable bases for use with the palladium catalyst are sodium tert-butoxide, potassium tert-butoxide, potassium tert-amyl oxide, or K ₃ PO in a suitable solvent such as dioxane, THF, 1,2-dimethoxyethane, toluene. ₄ can be used. For the use of a copper catalyst, a suitable base may consist of an alkaline base such as sodium carbonate, potassium carbonate, cesium carbonate in a suitable solvent such as DMF, DMSO, dimethylacetamide.

Usually, when a ligand is added, an amine formation reaction can be promoted. The ligand for the reaction catalyzed by palladium is not limited, but 9,9-dimethyl-4,5-bis (diphenylphosphino) xanthene (xanthophos), 2,2′-bis (diphenylphosphino) ) -1,1′-binaphthyl (BINAP), 1,1′-bis (diphenylphosphino) ferrocene (DPPF), 2,8,9-triisobutyl-2,5,8,9-tetraaza-1-phos Fabicyclo [3.3.3] undecane (P [N (i-Bu) CH ₂ CH ₃ ] ₃ N), tri-tert-butylphosphine (tBu ₃ P), (biphenyl-2-yl) bis (tert -Butyl) phosphine (JohnPhos), Pd-PEPPSI ™ -SIPr: (1,3-bis (2,6-diisopropylphenyl) -4,5-dihydroimida Lumpur-2-ylidene) (3-chloropyridyl) can be mentioned palladium (II) dichloride. Examples of the ligand suitable for the reaction using copper as a catalyst include, but are not limited to, L-proline, N-methylglycine, and diethylsalicylamide. A suitable condition for the production of the compound of formula I is the use of Pd ₂ (dba) ₃ in toluene with sodium tert-butoxide at 120 ° C. for 12 hours.

  After completing the reaction, the desired compound of formula I can be recovered and isolated as is known in the art. The compound can be recovered by evaporation, extraction, etc. as is known in the art. The compound may optionally be purified by chromatography, recrystallization, distillation, or other techniques known in the prior art.

Also, as will be readily appreciated by those skilled in the art, many of the substituents represented by R ¹ and R ⁴ can be manipulated after generating the nucleus of formula I. Such variations are well known to those skilled in the art and should be considered part of this invention. In many cases, compounds of formula I are substituted with R ³ or R ⁴ equivalent to a thioalkyl (S-alkyl) moiety. This group can be oxidized to R ³ or R ⁴ equivalent to an alkylsulfone (SO ₂ -alkyl) group. It is typical for this oxidation to utilize 2-4 equivalents of an oxidizing agent such as metachloroperbenzoic acid (mCPBA) in a chlorinated solvent such as dichloromethane, chloroform, 1,2-dichloroethane. Suitable conditions include 2.7 equivalents of mCPBA in dichloromethane at room temperature for 1 hour.

  Immediately following Reaction Scheme II teaches a method for producing 3-oxa-7-azabicyclo [3.3.1] nonanol, described as Structure 4 above. The compounds of structure 7 shown below are known in the art. Its synthesis is described in Arjunan, P .; Berlin, K .; D. Barnes C .; L. Van der Helm, D.C. J. et al. Org. Chem. 1981, 46, 3196-3204.

  As indicated above, the first step in the reaction is to remove the benzyl protecting group from structure 7. This can be realized by hydrogenolysis to obtain compound 8. Typical conditions for this reaction include the use of hydrogen and palladium catalysts such as 5-20% palladium on carbon and 10-20% palladium hydroxide. Typical solvents for this reaction are ethanol, methanol, tetrahydrofuran, or ethyl acetate.

  If a pyrimidine substituent is desired in the final product, carbonic acid in a protic solvent such as ethanol or methanol or in a polar aprotic solvent such as 1,4-dioxane, tetrahydrofuran, dimethylformamide, dimethyl sulfoxide. Compound 8 can be added to an appropriately substituted 2-chloropyrimidine shown as structure 9 in the presence of a base such as cesium or diisopropylethylamine to produce structure 10. Such a reaction can be carried out at a temperature ranging from room temperature to 110 ° C. Alternatively, heating the compounds of Structure 8 and Structure 9 together in the presence of a base such as diisopropylethylamine without using a solvent, or without using a base or solvent if compound 8 is used in excess. You can also.

  If a carbamate substituent is desired in the final product, an equivalent amount of the alkyl haloformate formate of structure 11 in the presence of a base such as diisopropylethylamine, triethylamine, pyridine, etc. in dichloromethane or chloroform Contact with 8 compounds. Alternatively, di-tert-butyl dicarbonate (BOC anhydride) or dicarbonate in the presence of an amine base such as diisopropylethylamine, pyridine, 2,6-lutidine, or triethylamine in a solvent such as dichloromethane, chloroform, or tetrahydrofuran. A compound of structure 12 can also be produced from a compound of structure 8 using a dialkyl dicarbonate such as diisopropyl carbonate.

  The final structure 10 or 12 (ie structure # 1 of reaction scheme 1) can be isolated and purified as is known in the art. If desired, this final structure can be subjected to a separation step to obtain the desired syn or anti isomer and then utilized in Reaction Scheme I.

  As will be readily appreciated by those skilled in the art, it may be necessary to protect the distal functional groups (eg, primary or secondary amines) of the intermediate. The need for such protection will vary depending on the nature of the distal functional group and the conditions of the preparation methods. Suitable amino protecting groups (NH-Pg) include acetyl, trifluoroacetyl, t-butoxycarbonyl (BOC), benzyloxycarbonyl (CBZ), and 9-fluorenylmethyleneoxycarbonyl (Fmoc). Similarly, “hydroxy protecting group” refers to a substituent of a hydroxy group that blocks or protects the hydroxy functionality. Suitable hydroxyl protecting groups (O—Pg) include, for example, allyl, acetyl, silyl, benzyl, para-methoxybenzyl, trityl and the like. The need for such protection is readily determined by one skilled in the art. For a review on protecting groups and their uses, see T.W. W. See Greene, Protective Groups in Organic Synthesis, John Wiley & Sons, New York, 1991.

  As mentioned above, some of the compounds of the present invention are acidic and form salts with pharmaceutically acceptable cations. Some of the compounds of this invention are basic and they form a salt with a pharmaceutically acceptable anion. All such salts are within the scope of the present invention, and the acidic and basic entities are usually separated by conventional methods, eg, in an aqueous, non-aqueous, or partially aqueous medium, as appropriate. Can be prepared by combining them in a stoichiometric ratio. The salt is recovered by filtration, precipitating with a non-solvent, filtration after evaporation, evaporation of the solvent, or lyophilization in the case of an aqueous solution. The compound is obtained in crystalline form according to procedures known in the art, such as dissolving in a suitable solvent (s) such as ethanol, hexane, water / ethanol mixtures.

  As mentioned above, some of the compounds exist as isomers. Such isomer mixtures can be separated into their individual isomers based on their physicochemical differences by methods well known to those skilled in the art such as chromatography and / or fractional crystallization. Enantiomers are converted to diastereomeric mixtures by reacting the enantiomeric mixture with a suitable optically active compound (eg, chiral auxiliaries such as chiral alcohols or Mosher's acid chlorides). Isomers can be separated and separated by converting (eg, hydrolyzing) the individual diastereoisomers to the corresponding pure enantiomers. Enantiomers can also be separated using a chiral HPLC column. Alternatively, by using optically active starting materials, asymmetric synthesis using optically active reagents, substrates, catalysts, or solvents, or conversion of one stereoisomer to the other by asymmetric rearrangement These stereoisomers can also be synthesized.

The present invention is identical to those listed herein except that one or more atoms are replaced with atoms whose atomic mass or mass number is different from the atomic mass or mass number normally found in nature. Also included are isotopically-labeled compounds of the present invention. Examples of isotopes that can be incorporated into the compounds of the present invention include ² H, ³ H, ¹¹ C, ¹³ C, ¹⁴ C, ¹³ N, ¹⁵ N, ¹⁵ O, ¹⁷ O, ¹⁸ O, ³¹ P, ³² P. , ³⁵ S, ¹⁸ F, ¹²³ I, ¹²⁵ I, ³⁶ Cl, and the like, respectively, are the isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, iodine, and chlorine.

Certain isotopically-labeled compounds of the present invention (eg, compounds labeled with ³ H and ¹⁴ C) are useful in compound and / or substrate tissue distribution assays. Certain isotopically-labeled ligands incorporating tritium, ¹⁴ C, ³⁵ S, and ¹²⁵ I could be useful in radioligand binding assays. Tritiated (ie ³ H) and carbon 14 (ie ¹⁴ C) isotopes are particularly preferred because they are easy to prepare and have good detectability. In addition, substitution with heavier isotopes such as deuterium (ie ² H) may lead to certain therapeutic advantages that result from higher metabolic stability (eg, increased in vivo half-life or reduced dosage requirements). ) And thus may be preferred in some circumstances. Positron emitting isotopes such as ¹⁵ O, ¹³ N, ¹¹ C, ¹⁸ F are useful in Positron Emission Topography (PET) studies for examining receptor occupancy. The isotopically-labeled compounds of the present invention generally follow a procedure similar to that disclosed in the schemes and / or examples below, using isotope-labeled reagents instead of non-isotopically labeled reagents. Can be prepared.

  Certain compounds of the present invention may exist in more than one crystal form (commonly referred to as “polymorphs”). Polymorphs can be obtained by crystallization under various conditions, for example, during crystallization, different recrystallization solvents or solvent mixtures, crystallization at different temperatures, and / or ultra-fast to ultra-slow cooling. A range of different cooling modes can be used to prepare. Polymorphs can also be obtained by heating or melting a compound of the invention and then slowly or rapidly cooling it. The presence of polymorphs can be determined by solid probe NMR spectroscopy, IR spectroscopy, differential scanning calorimetry, powder X-ray diffraction, or other such techniques.

Medical Use The compounds of the present invention modulate the activity of the G protein coupled receptor GPR119. Therefore, the compound is useful for the prevention and treatment of diseases such as diabetes in which the activity of GPR119 contributes to the pathology or symptoms of the disease. Accordingly, another aspect of the present invention is a method of treating metabolic diseases and / or metabolism related disorders in an individual, wherein an individual in need of such treatment is provided with a therapeutically effective amount of a compound of the present invention, It includes a method comprising administering a salt of a compound, or a pharmaceutical composition containing such a compound. Metabolic diseases and metabolism-related disorders include, but are not limited to, hyperlipidemia, type I diabetes, type II diabetes, idiopathic type I diabetes (type Ib), adult latent autoimmune diabetes (LADA), early onset Type 2 diabetes (EOD), juvenile atypical diabetes (YOAD), juvenile-onset adult diabetes (MODY), malnutrition-related diabetes, gestational diabetes, coronary heart disease, ischemic stroke, restenosis after angioplasty, Peripheral vascular disease, intermittent claudication, myocardial infarction (eg, necrosis and apoptosis), dyslipidemia, postprandial lipemia, impaired glucose tolerance (IGT) state, fasting plasma glucose abnormal state, metabolic acidosis, ketosis, arthritis Obesity, osteoporosis, hypertension, congestive heart failure, left ventricular hypertrophy, peripheral arterial disease, diabetic retinopathy, macular degeneration, cataract, diabetic nephropathy, glomerulosclerosis, chronic renal failure, diabetic Neuropathy, metabolic syndrome, syndrome X, premenstrual syndrome, coronary heart disease, angina, thrombosis, atherosclerosis, myocardial infarction, transient ischemic attack, stroke, vascular restenosis, hyperglycemia, high Insulinemia, hyperlipidemia, hypertriglyceridemia, insulin resistance, impaired glucose metabolism, impaired glucose tolerance, abnormal fasting plasma glucose, obesity, erectile dysfunction, skin and connective tissue disorders, foot injury Selected from ulceration, endothelial damage, hyper apo B lipoproteinemia, and vascular extensibility disorders. Furthermore, the compounds of the present invention can also be used for the treatment of neurological disorders such as Alzheimer's disease, schizophrenia and cognitive impairment. The compounds of the present invention are also beneficial in gastrointestinal diseases such as inflammatory bowel disease, ulcerative colitis, Crohn's disease, irritable bowel syndrome. As mentioned above, the compounds of the invention can also be used to stimulate weight loss in obese patients, particularly obese patients suffering from diabetes.

  In accordance with the foregoing, the present invention further provides a method of preventing or ameliorating a symptom of any of the aforementioned diseases or disorders in a subject in need thereof, comprising a therapeutically effective amount of a compound of the present invention. A method comprising administering to a subject is provided. Another aspect of the invention involves the preparation of a medicament for treating diabetes and its associated complications.

  In order to exhibit the above therapeutic properties, the compound needs to be administered in an amount sufficient to modulate the activation of the G protein coupled receptor GPR119. This amount can vary depending on the particular disease / condition being treated, the severity of the patient's disease / condition, the patient, the particular compound being administered, the route of administration, and the presence of other underlying conditions within the patient, and the like. When administered systemically, the compound typically exhibits its effect in a dosage range of about 0.1 mg / kg / day to about 100 mg / kg / day for any of the diseases or conditions listed above. Daily continuous administration may be desirable and will depend on the conditions outlined above.

  The compounds of the present invention can be administered by a variety of routes. The compounds of the present invention can be administered orally. The compounds of the present invention can also be administered parenterally (ie, subcutaneously, intravenously, intramuscularly, intraperitoneally, or intrathecally), rectally, or topically.

Co-administration The compounds of the invention can also be used with other agents for treating the diseases, conditions, and / or disorders described herein. Accordingly, there is also provided a method of treatment comprising administering a compound of the present invention in combination with other agents. Suitable drugs that can be used in combination with the compounds of the present invention include anti-obesity drugs (including appetite suppressants), anti-diabetic drugs, anti-hyperglycemic agents, anti-hyperlipidemic drugs, And antihypertensive drugs.

  Suitable antidiabetic agents include acetyl-CoA carboxylase 2 (ACC-2) inhibitors, diacylglycerol O-acyltransferase 1 (DGAT-1) inhibitors, phosphodiesterase (PDE) 10 inhibitors, sulfonylureas (eg, acetohexa Mido, Chlorpropamide, Diabines, Glibenclamide, Glipizide, Glyburide, Glimepiride, Gliclazide, Glipentide, Glyquidone, Glysolamide, Tolazamide, Tolbutamide, Meglitinide, α-Amylase inhibitors (eg, tendamistat) tendamistat), trestatin, and AL-3688), alpha-glucoside hydrolase inhibitors (eg acarbose), alpha-glucosidase Pesticides (eg, adiposine, camiglybose, emiglitate, miglitol, voglibose, prazimicin Q, and salvostatin), PPARγ agonists (eg, valaglitazone, ciglitazone, darglitazone, isglitazone, isaglitazozone, isaglitazozone, Rosiglitazone, and troglitazone), PPARα / γ agonists (eg, CLX-0940, GW-1536, GW-1929, GW-2433, KRP-297, L-79449, LR-90, MK-0767, and SB- 219994), biguanides (eg, metformin), glucagon-like peptide 1 (GLP-1) agonists (eg, exendin 3 and exendin 4) Protein tyrosine phosphatase 1B (PTP-1B) inhibitors (eg, Troduschemine, hirtiosal extract, and Zhang, S. et al., Drug Discovery Today, 12 (9/10), 373-381) ), SIRT-1 inhibitors (eg, reservatrol), dipeptidyl peptidase IV (DPP-IV) inhibitors (eg, sitagliptin, vildagliptin, alogliptin, and saxagliptin), insulin secretion Stimulant, fatty acid oxidation inhibitor, A2 antagonist, c-jun amino terminal kinase (JNK) inhibitor, insulin, insulin mimetic, glycoge Phosphorylase inhibitors, VPAC2 receptor agonists, and SGLT2 inhibitors (sodium-dependent glucose transporter inhibitors such as dapagliflozin). Preferred antidiabetic agents are metformin and DPP-IV inhibitors (eg, sitagliptin, vildagliptin, alogliptin, and saxagliptin).

Suitable anti-obesity agents include 11β-hydroxysteroid dehydrogenase 1 (11β-HSD type 1) inhibitor, stearoyl CoA desaturase 1 (SCD-1) inhibitor, MCR-4 agonist, cholecystokinin A (CCK-A) agonist Drugs, monoamine reuptake inhibitors (such as sibutramine), sympathomimetic drugs, β ₃ adrenergic drugs, dopamine agonists (such as bromocriptine), melanocyte stimulating hormone analogs, 5HT2c agonists, melanin-concentrating hormone antagonists, leptin ( OB protein), leptin analogs, leptin agonists, galanin antagonists, lipase inhibitors (such as tetrahydrolipstatin, ie orlistat), appetite suppressants (such as bombesin agonists), neuropeptide Y antagonists (eg, NPY Y5 antagonists) medicine, PYY _{3 36} (including analogs thereof), thyromimetic agents (Thyromimetic agent), dehydroepiandrosterone or an analog thereof, glucocorticoid agonists or antagonists, orexin antagonists, glucagon-like peptide 1 agonists, ciliary nerve Nutritional factors (such as Axokine ™ available from Regeneron Pharmaceuticals, Inc., Tarrytown, NY, and Procter & Gamble Company, Cincinnati, Ohio), human agouti related protein (AGRP) inhibitors, ghrelin antagonists, histamine 3 antagonists or Inverse agonists, neuromedin U agonists, MTP / ApoB inhibitors (eg, gastrointestinal selective MTP inhibitors such as dirlotapide), Opioid antagonists, like orexin antagonists.

Preferred anti-obesity agents for use in the combination aspect of the present invention include gastrointestinal selective MTP inhibitors (eg, zirlotapide, mitrapatide and implitapide, R56918 (CAS number 403987), and CAS. No. 913541-47-6), CCKa agonist (eg, N-benzyl-2- [4- (1H-indol-3-ylmethyl) described in PCT Publication No. WO2005 / 116034 or US Publication No. 2005-0267100A1) -5-oxo-1-phenyl-4,5-dihydro-2,3,6,10b-tetraaza-benzo [e] azulen-6-yl] -N-isopropyl-acetamide), 5HT2c agonist (e.g. lorcase Emissions), MCR4 agonist (e.g., compounds described in US6,818,658), lipase inhibitor (e.g., _cetilistat), the _{PYY 3-36} (herein, _{"PYY 3-36"} refers Beg of PYY _3-36 (including analogs such as those described in US Publication No. 2006/0178501), opioid antagonists (eg, naltrexone), oleoyl-estrone (CAS number 180003-17-2), obinetide ( obineptide (TM30338), pramlintide (Symlin (registered trademark)), tesofensin (NS2330), leptin, liraglutide, bromocriptine, orlistat, exenatide (Byetta (registered trademark)), AOD-9604 (CAS number 221231-10-) ), And sibutramine and the like. The compounds of the invention and combination therapies are preferably administered in conjunction with exercise and a sensible diet.

  All US patents and publications cited above are hereby incorporated by reference.

Pharmaceutical formulations The present invention also provides a pharmaceutical composition comprising a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof admixed with at least one pharmaceutically acceptable excipient. The pharmaceutical compositions include compositions in a form adapted for oral, topical, or parenteral use and can be used to treat diabetes and related conditions as described above.

  The pharmaceutical composition can be formulated for administration by any route known in the art, including subcutaneous, inhalation, oral, topical, parenteral and the like. The pharmaceutical composition can be any form known in the art including, but not limited to, tablets, capsules, powders, granules, lozenges, or liquid formulations such as oral or sterile parenteral solutions or suspensions. But you can.

  Tablets and capsules for oral administration can be in unit dosage form and are combined with conventional excipients such as syrup, acacia, gelatin, sorbitol, tragacanth, polyvinylpyrrolidone; lactose, sugar, corn starch Contains fillers such as calcium phosphate, sorbitol, glycine; tableting lubricants such as magnesium stearate, talc, polyethylene glycol, silica; disintegrants such as potato starch; or acceptable wetting agents such as sodium lauryl sulfate It's okay. The tablets may be coated according to methods well known in standard pharmaceutical practice.

  Oral liquid formulations can be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups, or elixirs, or dry products that are reconstituted with water or other appropriate vehicle before use. It can also take the form of Such liquid preparations contain conventional additives such as suspending agents such as sorbitol, methylcellulose, glucose syrup, gelatin, hydroxyethylcellulose, carboxymethylcellulose, aluminum stearate gel, hydrogenated edible fat; lecithin, monooleic acid Emulsifiers such as sorbitan and acacia; non-aqueous vehicles such as tonsil oil and glycerin, propylene glycol and ethyl alcohol (may include edible oils); methyl or propyl p-hydroxybenzoate, and sorbic acid Preservatives and, if desired, conventional flavoring or coloring agents may be included.

  For parenteral administration, fluid unit dosage forms are prepared utilizing the compound and a sterile vehicle, water being preferred. The compound can be suspended or dissolved in a vehicle or other suitable solvent, depending on the vehicle and concentration used. In preparing solutions, the compound can be dissolved in water for injection and filter sterilized before filling into a suitable vial or ampoule and sealing. For convenience, drugs such as local anesthetics, preservatives, buffering agents can be dissolved in the vehicle. To increase stability, the composition can be frozen after filling into the vial and the water removed in vacuo. The lyophilized dry powder can then be sealed in a vial and supplied with an attached vial of water for injection to reform the liquid prior to use. Parenteral suspensions are prepared in substantially the same manner except that the compound is suspended in the vehicle instead of being dissolved and that sterilization cannot be accomplished by filtration. The compound can be sterilized by exposure to ethylene oxide before suspending in the sterile vehicle. Advantageously, a surfactant or wetting agent is incorporated into the composition to facilitate uniform distribution of the compound.

  The composition may contain, for example, from about 0.1% to about 99% by weight of active material, depending on the method of administration. When the composition comprises dosage units, each unit will contain, for example, from about 0.1 to 900 mg, more typically from 1 mg to 250 mg of active ingredient.

  The compounds of the present invention can be formulated for administration in any convenient manner for use in human or veterinary medicine by analogy with other antidiabetic agents. Such methods are known in the art and are outlined above. For a more detailed discussion on the preparation of such formulations, please turn to Remington's Pharmaceutical Sciences, 21st edition, by the University of the Sciences in Philadelphia.

  The following examples illustrate embodiments of the invention. However, it should be understood that embodiments of the present invention do not limit the details of the examples, and therefore other variations thereof will be known to those skilled in the art or will be apparent in light of this disclosure. I want to be.

(Example)
Unless otherwise specified, the starting materials are generally from Aldrich Chemicals Co. (Milwaukee, Wis.), Lancaster Synthesis, Inc. (Windham, New Hampshire), Acros Organics (Fair Lawn, New Jersey), Maybridge Chemical Company, Ltd. Available from commercial sources such as (Cornwall, UK), Tyger Scientific (Princeton, NJ), AstraZeneca Pharmaceuticals (London, UK), Mallinckrodt Baker (Philipsburg, NJ), EMD (Gibstown, NJ), etc.

General Experimental Procedures For proton analysis, NMR spectra were obtained at room temperature using a Varian Unity ™ 400 (DG400-5 probe) or 500 (DG500-5 probe) (both available from Varian Inc., Palo Alto, Calif.). Recorded at 400 MHz or 500 MHz, respectively. Chemical shifts are expressed in parts per million (δ) based on residual solvent as an internal standard. The peak shape is expressed as follows. That is, s: single line, d: double line, dd: double double line, t: triple line, q: quadruple line, m: multiple line, bs: broad single line, 2s: two single lines .

  Atmospheric pressure chemical ionization mass spectrum (APCI) was measured using a Waters ™ spectrometer (Micromass ZMD, carrier gas: nitrogen) (available from Waters Corp., Milford, Mass., USA) at a flow rate of 0.3 mL / min. And obtained using a 50:50 water / acetonitrile eluent system. Electrospray ionization mass spectra (ES) were obtained using a Waters ™ (Micromass ZQ or ZMD instrument (carrier gas: nitrogen) (Waters Corp., Milford, Mass.) Liquid chromatography mass spectrometer for each solvent. Acquired using a 95: 5 to 0: 100 gradient water acetonitrile solution with 0.01% formic acid, these instruments include 1 mL / min for 3.75 min or 2 mL / min for 1.95 min A Varian Polaris 5 C18-A 20 × 2.0 mm column (Varian Inc., Palo Alto, Calif.) Was used at a flow rate of

  Column chromatography uses either a Flash 40 Biotage ™ column (ISC, Inc., Shelton, Conn.) Or a Biotage ™ SNAP cartridge KPsil or Redisep Rf silica (from Teledyne Isco Inc), using silica gel. And carried out under nitrogen pressure. Preparative HPLC was performed using a Waters FractionLynx system equipped with a photodiode array (Waters 2996) and a mass spectrometer (Waters / Micromass ZQ) detection scheme. Analytical HPLC work was performed using a Waters 2795 Alliance HPLC or Waters ACQUITY UPLC equipped with a photodiode array, single focusing quadrupole mass detection and evaporative light scattering detection scheme.

  Concentration in vacuo refers to evaporating the solvent under reduced pressure using a rotary evaporator.

  Unless otherwise stated, chemical reactions were performed at room temperature (about 23 degrees Celsius). Also, unless otherwise stated, the chemical reactions were carried out in a nitrogen atmosphere.

Pharmacological Data The practice of the invention to treat diseases modulated by agonist activation of the G protein-coupled receptor GPR119 by a compound of the invention can be demonstrated by activity in one or more of the functional assays described below. . The supplier is shown in parentheses.

In-vitro functional assay β-lactamase:
The assay for GPR119 agonists utilizes a cell-based (hGPR119 HEK293-CRE β-lactamase) reporter construct that combines agonist activation of human GPR119 with β-lactamase production by a cyclic AMP response element (CRE). To do. GPR119 activity is measured using CCF4-AM (Live Blaze FRET-B / G Loading kit, Invitrogen catalog number K1027), which is a β-lactamase substrate that enables FRET. Specifically, hGPR119-HEK-CRE-β-lactamase cells (Invitrogen 2.5 × 10 ⁷ / mL) are removed from a liquid nitrogen reservoir and plated medium (Dulbecco's modified Eagle medium high glucose (DMEM, Gibco catalog number 11995). -065) 10% heat inactivated fetal bovine serum (HIFBS, Sigma catalog number F4135), 1 × MEM nonessential amino acids (Gibco catalog number 15630-080), 25 mM HEPES pH 7.0 (Gibco catalog number 15630-080) ), Diluted in 200 nM potassium clavulanate (Sigma catalog number P3494.) Cell plating medium was used to adjust the cell concentration and 50 μL of this cell suspension (12.5 × 10 ⁴ viable cells) Poly-d- In addition to each well of a thin coated black clear bottom 384 well plate (Greiner Bio-One Cat # 781946), it was incubated at 37 ° C. in a humidified environment containing 5% carbon dioxide. The medium was removed and replaced with 40 μL of assay medium (the assay medium is a plating medium that does not contain potassium clavulanate and HIFBS). The cells were incubated for 16 hours at 37 ° C. in a humidified environment containing 5% carbon dioxide (DMSO ≦ 0.5%) and the plates were removed from the incubator and allowed to equilibrate to room temperature for approximately 15 minutes. 10 uL of 6 × CCF4 / AM working dye solution (Live lazer FRET-B / G Loading kit (prepared according to instructions contained in Invitrogen catalog number K1027) was added per well and incubated for 2 hours at room temperature in the dark EnVision Fluorometric Plate Reader (Excitation 405 nm, luminescence) Fluorescence was measured at 460 nm / 535 nm) EC ₅₀ was determined from agonist response curves analyzed with a curve fitting program using a four parameter logistic dose response equation.

cAMP:
GPR119 agonist activity was also determined in a cellular assay utilizing an HTRF (homogeneous time-resolved fluorescence) cAMP detection kit (cAMP dynamic 2 assay kit Cis Bio catalog number 62AM4PEC) that measures cAMP levels in cells. This method is a competitive immunoassay between natural cAMP produced by cells and cAMP labeled with the dye d2. Tracer binding is visualized with Mab anti-cAMP labeled with cryptate. The specific signal (ie energy transfer) is inversely proportional to the concentration of cAMP in the standard or sample.

Specifically, hGPR119 HEK-CRE β-lactamase cells (Invitrogen 2.5 × 10 ⁷ / mL, the same cell line used in the β-lactamase assay described above) were removed from cryopreservation and grown in growth medium (Dulbecco's modified Eagle medium high Glucose (DMEM, Gibco catalog number 119905-065), 1% charcoal dextran treated fetal calf serum (CD serum, HyClone catalog number SH30068.03), 1 × MEM non-essential amino acids (Gibco catalog number 15630-080), and 25 mM Dilute in HEPES pH 7.0 (Gibco catalog number 15630-080)). The cell concentration was adjusted to 1.5 × 10 ⁵ cells / mL and 30 mL of this suspension was added to a T-175 flask and incubated at 37 ° C. in a humidified environment of 5% carbon dioxide. After 16 hours (overnight), cells were removed from the T-175 flask (by tapping the sides of the flask), centrifuged at 800 × g, and then assay medium (1 × HBSS + CaCl ₂ + MgCl ₂ (Gibco catalog number 14025− 092) and 25 mM HEPES pH 7.0 (Gibco catalog number 15630-080)). Adjust the cell concentration to 6.25 × 10 ⁵ cells / mL using assay medium, and add 8 μl (5000 cells) of this cell suspension to each of the Greiner 384 well white small volume assay plates (VWR catalog number 82051-458). Added to wells.

  Different concentrations of each compound to be tested were diluted in assay buffer containing 3-isobutyl-1-methylxanthine (IBMX, Sigma catalog number I5879) and added to the assay plate wells in a 2 μL volume (final IBMX concentration). Was 400 μM, and the final DMSO concentration was 0.58%). Following a 30 minute incubation at room temperature, 5 μL of labeled d2cAMP and 5 μL of anti-cAMP antibody (both diluted 1:20 in cell lysis buffer, as described in the manufacturer's assay protocol) were added to the assay plate. Added to each well. Plates were then incubated at room temperature and after 60 minutes, changes in the HTRF signal were read on an Envision 2104 multilabel plate reader using excitation wavelength 330 nm, emission wavelengths 615 nm and 665 nm. From the agonist response curve, the raw data was converted to nM cAMP by interpolation from a cAMP calibration curve (as described in the manufacturer's assay protocol) and analyzed with a curve fitting program using a four parameter logistic dose response equation. EC50 was determined.

  It has been observed that the cAMP reaction due to activation of GPR119 can also occur in cells other than the specific cell line used here.

β-arrestin:
GPR119 agonist activity was also determined in a cell assay utilizing the DiscoverX PathHunter β-arrestin cell assay technology and its U2OS hGPR119β-arrestin cell line (DiscoverX catalog number 93-0356C3). In this assay, agonist activation is determined by measuring the agonist-induced interaction between β-arrestin and activated GPR119. A small 42-amino acid enzyme fragment called ProLink was added to the C-terminus of GPR119. Arrestin was fused to a larger enzyme fragment called EA (enzyme acceptor). When GPR119 is activated, arrestin binding is stimulated and the complementation of the two enzyme fragments is derived, resulting in the production of a functional β-galactosidase enzyme that can hydrolyze the substrate and generate a chemiluminescent signal.

Specifically, U2OS hGPR119β-arrestin cells (DiscoverX 1 × 10 ⁷ / mL) were removed from cryopreservation and grown in growth medium (minimum essential medium (MEM, Gibco catalog number 11095-080), 10% heat-inactivated fetal bovine serum ( HIFBS, Sigma catalog number F4135-100), 100 mM sodium pyruvate (Sigma catalog number S8636), 500 μg / mL G418 (Sigma catalog number G8168), and 250 μg / mL hygromycin B (Invitrogen catalog number 10687-010) diluted in. the cell concentration was adjusted to 1.66 × 10 ⁵ cells / mL, was added and the suspension 30mL in T-175 flasks and incubated at 37 ° C. in a humidified environment of 5% CO After 24 hours, cells were removed from the T-175 flask using enzyme-free cell dissociation buffer (Gibco catalog number 13151-014), centrifuged at 800 × g, and then plated medium (Opti-MEM I ( Invitrogen / BRL catalog number 31985-070) and 2% charcoal dextran-treated fetal calf serum (CD serum, HyClone catalog number SH30068.03)). Adjust to ⁵ cells / mL and add 20 microliters (5000 cells) of this cell suspension to each well of a Greiner 384 well white small volume assay plate (VWR catalog number 82051-458) and place the plate in 5% carbon dioxide. 37 ° C in a humidified environment And incubated.

After 16 hours (overnight), the assay plate was removed from the incubator and tested at various concentrations of each compound (assay buffer (1 × HBSS + CaCl ₂ + MgCl ₂ (Gibco catalog number 14025-092), 20 mM HEPES pH7. 0 (Gibco catalog number 15630-080), and 0.1% BSA (diluted in Sigma catalog number A9576) was added to the assay plate wells in a volume of 5 microliters (final DMSO concentration 0.5). After incubation for 90 minutes at 37 ° C. in a humidified environment of 5% carbon dioxide, 12 microliters of Galacton Starβ-galactosidase substrate (PathHunter Detection Kit (DiscoverRx catalog) No. 93-0001), prepared as described in the manufacturer's assay protocol) was added to each well of the assay plate, and the plate was incubated at room temperature and after 60 minutes, using an Envision 2104 multilabel plate reader The change in luminescence was read at 0.1 seconds EC50 was determined from the agonist response curve analyzed with a curve fitting program using a 4-parameter logistic dose response equation.

GPR119 Expression and GPR119 Binding Assay Using BacMam Wild-type human GPR119 by polymerase chain reaction (PCR) (Pfu Turbo Mater Mix, Stratagene, La Jolla, Calif.) Using pIRES-puro-hGPR119 as template and the following primers: (FIG. 1) was amplified.
hGPR119 BamH1, upstream 5'-TAAATTGGATCCACCCATGGAATCATTTTTCTCATTTGGAG-3 '
(Insert a BamHI site at the 5 'end)
hGPR119 EcoRI, downstream 5'-TAAATTGAATTCTTATCAGCCATCAAACTCTGAGC-3 '
(Insert EcoRI site at 3 'end)

  The amplification product was purified (Qiaquick Kit, Qiagen, Valencia, Calif.) And digested with BamH1 and EcoRI (New England BioLabs, Ipswich, Mass.) According to the manufacturer's protocol. The vector pFB-VSVG-CMV-poly (FIG. 2) was digested with BamHI and EcoRI (New England BioLabs, Ipswich, Mass.). Digested DNA was separated by electrophoresis on a 1% agarose gel and fragments were excised from the gel and purified (Qiaquick Kit, Qiagen, Valencia, Calif.). The vector and gene fragment were ligated (Rapid Ligase Kit, Roche, Pleasanton, Calif.) And transformed into OneShot DH5αT1R cells (Invitrogen, Carlsbad, Calif.). Eight ampicillin resistant colonies (“clone 1-8”) were grown for minipreps (Qiagen Miniprep Kit, Qiagen, Valencia, Calif.) And sequenced to confirm identity and correct orientation of insertion.

  The pFB-VSVG-CMV-poly-hGPR119 construct (clone # 1) was transformed into OneShot DH10Bac cells (Invitrogen, Carlsbad, CA) according to the manufacturer's protocol. Eight positive (ie white) colonies were re-streaked to be identified as “positive” and subsequently grown for bacmid isolation. Recombinant hGPR119 bacmid was isolated by a modified alkaline lysis procedure using a buffer of Qiagen Miniprep Kit (Qiagen, Valencia, CA). Briefly, pelleted cells were dissolved in buffer P1, neutralized in buffer P2, and precipitated with buffer N3. The precipitate was pelleted by centrifugation (17,900 × g for 10 minutes) and the supernatant was combined with isopropanol to precipitate the DNA.

  The DNA was pelleted by centrifugation (17,900 × g for 30 minutes), washed once with 70% ethanol and resuspended in 50 microliters of buffer EB (Tris-HCL, pH 8.5). Polymerase chain reaction (PCR) using commercially available primers (M13F, M13R, Invitrogen, Carlsbad, CA) was used to confirm the presence of the hGPR119 insert in the bacmid.

Production of hGPR119 Recombinant Baculovirus Generation of P0 Virus Stock Suspension-adapted Sf9 cells grown in Sf900II medium (Invitrogen, Carlsbad, Calif.) were subjected to the manufacturer's protocol (Cellfectin, Invitrogen, Carls. CA). 10 μL of hGPR119 bacmid DNA was transfected according to After 5 days of incubation, conditioned medium (ie, “P0” virus stock) was centrifuged and filtered through a 0.22 μm filter (Steriflip, Millipore, Billerica, Mass.).

Preparation of Frozen Virus (BIIC) Stocks In preparation for long-term virus storage and production (ie, “P1”) virus stock production, frozen BIIC (insect cells infected with baculovirus) stocks were prepared as follows. Suspension adapted Sf9 cells were grown in Sf900II medium (Invitrogen, Carlsbad, Calif.) And infected with hGPR119 P0 virus stock. After growing for 24 hours, the infected cells are gently centrifuged (approximately 100 × g) and resuspended in freezing medium (Sf900II medium containing 10% DMSO, 1% albumin) to a final density. Was 1 × 10 ⁷ cells / mL and frozen in aliquots of 1 mL according to standard freezing protocols.

Preparation of working (“P1”) virus stock Suspension-adapted Sf9 cells grown in Sf900II medium (Invitrogen, Carlsbad, Calif.) Were infected with a 1: 100 dilution of thawed hGPR119 BIIC stock. Incubated for several days (27 ° C. with shaking). When cell viability reached 70%, conditioned media was collected by centrifugation and virus titer determined by ELISA (BaculoElisa Kit, Clontech, Mountain View, CA).

Overexpression of hGPR119 in HEK 293FT cells adapted to suspension In shake flasks, grow HEK293FT cells (Invitrogen, Carlsbad, CA) in 293 Freestyle medium (Invitrogen) supplemented with 50 μg / mL neomycin and 10 mM HEPES. (37C, 8% carbon dioxide, shaking). Cells are gently centrifuged (approximately 500 × g, 10 minutes) and the pellet is resuspended in a mixture of Dulbecco's PBS (Mg ++ / − Ca ++ no) and P1 virus supplemented with 18% fetal calf serum (Sigma Aldrich). The multiplicity of infection (MOI) was 10 and the final cell density was 1.3 × 10 ⁶ / mL (total volume 2.5 liters). Cells were transferred to 5 liters of Wave Bioreactor Wavebag (Wave Technologies, Mass.) And incubated for 4 hours at 27 ° C (17 rocks / min, platform angle 7 °), at the end of the incubation period 30 mM butyric acid An equal volume (2.5 liters) of 293 Freestyle medium supplemented with sodium (Sigma Aldrich) was added (final concentration = 15 mM) and the cells were grown for 20 hours (37 ° C., 8% CO 2 [0.2 liters / min}). , 25 rocks / minute, platform angle 7 °). Cells were collected by centrifugation (3,000 × g, 10 minutes), washed once with DPBS (Ca ++ / Mg ++ not), 0.25 M sucrose, 25 mM HEPES, 0.5 mM EDTA, pH 7.4. And frozen at −80 ° C.

Membrane preparation for radioligand binding assay Frozen cells were thawed on ice and centrifuged at 700 × g (1400 rpm) for 10 minutes at 4 ° C. The cell pellet was resuspended in 20 mL phosphate buffer solution and centrifuged at 1400 rpm for 10 minutes. The cell pellet is then homogenized buffer (10 mM HEPES (Gibco # 15630), pH 7.5, 1 mM EDTA (BioSolutions, # BIO260-15), 1 mM EGTA (Sigma, # E-4378), 0.01 mg / mL Benzamidine (Sigma # B6506), 0.01 mg / mL bacitracin (Sigma # B0125), 0.005 mg / mL leupeptin (Sigma # L8511), 0.005 mg / mL aprotinin (Sigma # A1153)) Turbid and incubated on ice for 10 minutes. The cells were then lysed with 15 gentle strokes in a tight fit glass Dounce homogenizer. The homogenate was centrifuged at 1000 × g (2200 rpm) for 10 minutes at 4 ° C. The supernatant was transferred to a new centrifuge tube on ice. The cell pellet was resuspended in homogenization buffer and centrifuged again at 1000 × g (2200 rpm) for 10 minutes at 4 ° C., after which the supernatant was removed and the pellet was resuspended in homogenization buffer. This process was repeated a third time, after which the supernatants were combined and Benzonase (Novagen # 71206) and MgCl ₂ (Fluka # 63020) were added to a final concentration of 1 U / mL and 6 mM, respectively, and incubated on ice for 1 hour. The solution was then centrifuged at 25,000 × g (15000 rpm) for 20 minutes at 4 ° C., the supernatant was discarded, and the pellet was resuspended in fresh homogenization buffer (no Benzonase and MgCl ₂ ). After repeating the centrifugation step at 25,000 × g, the final membrane pellet was resuspended in homogenization buffer and frozen at −80 ° C. The protein concentration was determined using the Pierce BCA protein assay kit (Pierce Reagent A # 23223 and B # 23224).

Synthesis and purification of [ ³ H] -Compound A

化合物Ａ（４−（１−（４−（メチルスルホニル）フェニル）−３ａ，７ａ−ジヒドロ−１Ｈ−ピラゾロ［３，４−ｄ］ピリミジン−４−イルオキシ）ピペリジン−１−カルボン酸イソプロピル、上で示したとおり）（４ｍｇ、０．００９ｍｍｏｌ）を０．５ｍＬのジクロロメタンに溶解させ、得られる溶液を（１，５−シクロオクタジエン）（ピリジン）（トリシクロヘキシルホスフィン）−イリジウム（Ｉ）ヘキサフルオロホスフェート（Ｊ．Ｏｒｇａｎｏｍｅｔａｌ．Ｃｈｅｍ．１９７９、１６８、１８３）（５ｍｇ、０．００６ｍｍｏｌ）で処理した。反応容器を密封し、溶液をトリチウムガス雰囲気中で１７時間撹拌した。減圧下で反応溶媒を除去し、得られる残渣をエタノールに溶解させた。未精製の［^３Ｈ］−化合物Ａの精製を、以下の条件を使用する分取ＨＰＬＣによって実施した。
カラム：Ａｔｌａｎｔｉｓ、４．６×１５０ｍｍ、５μｍ
移動相Ａ：水／アセトニトリル／ギ酸（９８／２／０．１）
移動相Ｂ：アセトニトリル
勾配： 時間 ％Ｂ
０．００ ３０．０
１．００ ３０．０
１３．００ ８０．０
分析時間：１６分
ポストタイム：５分
流量：１．５ｍＬ／分
注入体積：２０〜５０μＬ
注入溶媒：ＤＭＳＯ
検出：２１０ｎｍおよび２４５ｎｍでのＵＶ

Compound A (4- (1- (4- (methylsulfonyl) phenyl) -3a, 7a-dihydro-1H-pyrazolo [3,4-d] pyrimidin-4-yloxy) piperidine-1-carboxylate, on (As indicated) (4 mg, 0.009 mmol) was dissolved in 0.5 mL dichloromethane and the resulting solution was (1,5-cyclooctadiene) (pyridine) (tricyclohexylphosphine) -iridium (I) hexafluorophosphate. Treated with (J. Organometal. Chem. 1979, 168, 183) (5 mg, 0.006 mmol). The reaction vessel was sealed and the solution was stirred in a tritium gas atmosphere for 17 hours. The reaction solvent was removed under reduced pressure, and the resulting residue was dissolved in ethanol. Purification of the crude [ ³ H] -Compound A was performed by preparative HPLC using the following conditions.
Column: Atlantis, 4.6 × 150 mm, 5 μm
Mobile phase A: water / acetonitrile / formic acid (98/2 / 0.1)
Mobile phase B: acetonitrile gradient: time% B
0.00 30.0
1.00 30.0
13.00 80.0
Analysis time: 16 minutes Post time: 5 minutes Flow rate: 1.5 mL / min Injection volume: 20-50 μL
Injection solvent: DMSO
Detection: UV at 210 nm and 245 nm

The specific activity of purified [ ³ H] -Compound A was determined to be 70 Ci / mmol by mass spectrometry.

Alternatively, binding assays may be performed with [< ³ > H] -Compound B.

Synthesis and purification of [ ³ H] -Compound B

化合物Ｂ（４−（１−（４−（メチルスルホニル）フェニル）−１Ｈ−ピラゾロ［３，４−ｄ］ピリミジン−４−イルオキシ）ピペリジン−１−カルボン酸ｔｅｒｔ−ブチル、上で示したとおり）（５ｍｇ、１０．６μｍｏｌ）を１．０ｍＬのジクロロメタンに溶解させ、得られる溶液をＣｒａｂｔｒｅｅ触媒（５ｍｇ、６．２μｍｏｌ）で処理した。反応容器を密封し、溶液をトリチウムガス雰囲気中で１７時間撹拌した。減圧下で反応溶媒を除去し、得られる残渣をエタノールに溶解させた。未精製の［^３Ｈ］−化合物Ｂの精製を、７０％のヘキサン／３０％の酢酸エチルを溶離液とするシリカゲルフラッシュカラムクロマトグラフィーに続いて、６０％の石油エーテル／４０％の酢酸エチルを溶離液とするシリカゲルフラッシュカラムクロマトグラフィーによって実施した。

Compound B (tert-butyl 4- (1- (4- (methylsulfonyl) phenyl) -1H-pyrazolo [3,4-d] pyrimidin-4-yloxy) piperidine-1-carboxylate, as indicated above) (5 mg, 10.6 μmol) was dissolved in 1.0 mL of dichloromethane and the resulting solution was treated with a Crabtree catalyst (5 mg, 6.2 μmol). The reaction vessel was sealed and the solution was stirred in a tritium gas atmosphere for 17 hours. The reaction solvent was removed under reduced pressure, and the resulting residue was dissolved in ethanol. Purification of the crude [ ³ H] -Compound B was followed by silica gel flash column chromatography eluting with 70% hexane / 30% ethyl acetate followed by 60% petroleum ether / 40% ethyl acetate. It was performed by silica gel flash column chromatography as eluent.

The specific activity of purified [ ³ H] -Compound B was determined to be 57.8 Ci / mmol by mass spectrometry.

GPR119 radioligand binding assay Test compounds were serially diluted in 100% DMSO (JT Baker # 922401). 2 μL of each dilution was added to the appropriate wells of a 96 well plate (in triplicate concentrations). Unlabeled Compound A (or Compound B) was used at a final concentration of 10 μM to measure nonspecific binding.

[ ³ H] -Compound A (or [ ³ H] -Compound B) is bound to binding buffer (50 mM Tris-HCl, pH 7.5 (Sigma # T7443), 10 mM MgCl ₂ (Fluka 63020), 1 mM EDTA ( BioSolutions # BIO260-15), 0.15% bovine serum albumin (Sigma # A7511), 0.01 mg / mL benzamidine (Sigma # B6506), 0.01 mg / mL bacitracin (Sigma # B0125), 0.005 mg Dilute in / mL leupeptin (Sigma # L8511), 0.005 mg / mL aprotinin (Sigma # A1153) to a concentration of 60 nM and add 100 μL to all wells of a 96-well plate (Nalge Nunc # 267245) The added.

  Membranes expressing GPR119 were thawed and diluted in binding buffer to a final concentration of 20 μg / 100 μL per well, and 100 μL of diluted membrane was added to each well of a 96 well plate.

  The plate was incubated for 60 minutes at room temperature (about 25 ° C.) with shaking. The assay was terminated by vacuum filtration on GF / C filter plates (Packard # 600005174) presoaked in 0.3% polyethyleneamine using a Packard harvester. The filter was then washed 6 times using wash buffer (50 mM Tris-HCl, pH 7.5, kept at 4 ° C.). The filter plate was then air dried overnight at room temperature. 30 μιχpoλιτερ scintillation fluid (Ready Safe, Beckman Coulter # 141349) was added to each well, the plates were sealed, and the radioactivity associated with each filter was measured using a Wallac Trilux MicroBeta plate-based scintillation counter.

^[3 H] - Compound A (or ^[3 H] - Compound B) Kd of was obtained by carrying out the saturation binding experiments with data analysis by non-linear regression to fit the one-site hyperbola (Graph Pad Prism). IC ₅₀ was determined from competition curves analyzed using a proprietary curve fitting program (SIGHTS) and a four parameter logistic dose response equation. Ki values were calculated from IC ₅₀ values using the Cheng-Prusoff equation.

  The following results were obtained for the above assay.

In vivo pharmacology All in vivo protocols were approved by Pfizer's Animal Protection Committee. Untreated male Wistar rats (weighing 225-250 g when received) were obtained from Harlan Laboratories (Indianapolis, IN) and raised in a hanging plastic cage with sawdust Sani-chips as a floor covering. Purina 5001 chow was given without restriction. Rats were housed under controlled temperature and humidity conditions under a controlled lighting cycle (lights from 6 am to 6 pm). Rats were acclimated to equipment for at least one week prior to the study.

Compound Preparation Example 17 was formulated in 0.5% methylcellulose. The maximum dose (30 mg / kg) is formulated at 6 mg / mL for administration at 5 mL / kg, the required bulk is added to the mortar and ground with a pestle with a small amount of 0.5% methylcellulose to make a smooth paste, Additional 0.5% methylcellulose was added until the mixture became fluid and when transferred to a stirred vessel, the mortar was rinsed several times with the remaining amount of 0.5% methylcellulose and covered with a lid to prevent evaporation. The suspension was stirred continuously with a magnetic stir bar overnight before the study, and smaller doses were diluted from a 6 mg / mL suspension using an appropriate volume of 0.5% methylcellulose. All dosing suspensions were stirred throughout the dosing procedure.

Oral Glucose Tolerance Test (OGTT) Protocol Rats (n = 8 / group) were either vehicle (0.5% methylcellulose) or 3 dose groups (1 mg / kg, 5 mg / kg, or 30 mg / kg) according to day 1 body weight. It was divided into one to ensure that the group average body weight values of each group were equal. Prior to the oral glucose tolerance test, rats were fasted overnight (about 15 hours) in a clean cage. Body weight was recorded on the morning of study day (after fasting) for dose volume calculation. Blood samples were collected from all rats before vehicle or test compound was administered by oral gavage (5 mL / kg). After 30 minutes, blood was collected from the rats and an oral dose of glucose (2 g / kg) was immediately administered. Blood was collected from the rats again at 15, 30, 60, and 120 minutes after glucose loading. Blood samples (approximately 250 μL / 1 time point) were collected in EDTA tubes containing aprotinin / DPPIVi (0.6 TIU / 20 μL per mL of whole blood). Immediately after collection, the blood tube was inverted several times, placed on ice and then spun at 14,000 rpm for 5 minutes in a refrigerated centrifuge. The glucose level of the plasma sample is analyzed using a Roche 912 clinical chemistry analyzer, the plasma insulin concentration is determined using the Alpco Ultra-Sensitive Insulin Rat ELISA, and the total amide GLP-1 concentration using the MSD ELISA kit It was determined.

  Results are presented as mean +/- SEM (standard error of the mean) unless otherwise stated. Statistical evaluation of the data is performed using one-way analysis of variance (ANOVA) with appropriate post hoc analysis of the vehicle and treatment groups. Dunnett's T-test was used to consider a difference of p> 0.05 compared to vehicle to be statistically significant.

Intraperitoneal glucose tolerance test (IPGTT) protocol Rats (n = 8 / group) were assigned to vehicle or one of three dose groups (1 mg / kg or 10 mg / kg) according to body weight on day 1 to ensure that each group Group average body weight values were made equal. Prior to the intraperitoneal glucose tolerance test, rats were fasted overnight (approximately 15 hours) in a clean cage. Body weight was recorded on the morning of study day (after fasting) for dose volume calculation. Blood samples were taken from all rats and then vehicle (0.5% methylcellulose) or test compound was administered by oral gavage (5 mL / kg). Sixty minutes later, blood was collected from the rats and an IP dose of glucose (2 g / kg) was immediately administered. Blood was collected from the rats again at 15, 30, 60, and 120 minutes after glucose loading. To determine plasma glucose, insulin, and total amide GLP-1 concentrations, blood samples (approximately 250 μL / 1 time point) were collected in EDTA tubes containing aprotinin / DPPIVi (0.6 TIU / 20 μL per mL of whole blood). . Immediately after collection, the blood tube was inverted several times, placed on ice and then spun at 14,000 rpm for 5 minutes in a refrigerated centrifuge. Plasma samples were analyzed for glucose levels using a Roche 912 clinical chemistry analyzer, and plasma insulin concentrations were determined using Alpco Ultra-Sensitive Insulin Rat Elisa.

  Results are presented as mean +/- SEM (standard error of the mean) unless otherwise stated. Statistical evaluation of the data is performed using one-way analysis of variance (ANOVA) with appropriate post hoc analysis of the vehicle and treatment groups. Dunnett's T-test was used to consider a difference of p <0.05 compared to vehicle to be statistically significant.

  Example 3 prepared as described above (administered as a 0.5% methylcellulose suspension) or amorphous dispersion using hydroxypropylmethylcellulose-acetate succinate (25% active) The IPGTT study was performed as prepared (administered as a 0.5% methylcellulose / 0.1% polysorbate 80 suspension). Table 2 shows the group means, and the results are expressed as a percentage of the vehicle response. Statistical significance is based on comparison with the vehicle group.

Preparation of Starting Materials Preparative Example 1: Scheme A illustrates the preparation of syn and anti-9-hydroxy-3-oxa-7-azabicyclo [3.3.1] nonane-7-carboxylates of syn and anti. Details of the experiment are detailed below.

Preparation Example 1: -9-Hydroxy-3-oxa-7-azabicyclo [3.3.1] nonane-7-carboxylate (mixture of syn and anti isomers)

Step A of Scheme A. Synthesis of 7-benzyl-3-oxa-7-azabicyclo [3.3.1] nonan-9-one-hydrochloride (2):
Tetrahydro-4H-pyran-4-one 1 (60.0 g, 0.60 mol), benzylamine (63.4 g, 0.60 mol), and glacial acetic acid (35.9 g, 0.60 mol) were added to anhydrous methanol (1. 2 L) was added to a stirred suspension of paraformaldehyde (39.6 g, 1.3 mol) in anhydrous methanol (1.2 L) at 65 ° C. over 75 minutes. A second portion of paraformaldehyde (39.6 g, 1.3 mol) was added and the mixture was stirred at 65 ° C. for 1 hour. The reaction was quenched with water (1.2 L) and 1M aqueous potassium hydroxide (600 mL). The mixture was extracted with ethyl acetate (3 L × 3). The organic layers were combined, dried over sodium sulfate, filtered, and the filtrate was concentrated to dryness in vacuo. The residue was purified by column chromatography (petroleum ether / ethyl acetate = 20: 1 to 2: 1) to give a brown oil. The residue was diluted with 6M anhydrous hydrochloric acid 1,4 dioxane solution (500 mL) and the mixture was stirred for 30 minutes. The solvent was removed in vacuo and acetone (500 mL) was added. The resulting mixture was sonicated for 30 minutes to produce a white precipitate. The mixture was filtered and the solid was washed with acetone and then dried in vacuo to give the desired product as a white solid (21 g, 13%). ¹ H NMR (400 MHz, deuterium oxide) δ 7.43-7.42 (m, 5H), 4.66 (s, 2H), 3.95
-3.90 (m, 4H), 3.54-3.47 (m, 4H); 1.96 (bs, 2H); LCMS (ES +): 232.0 (M + 1).

Step B of Scheme A. Synthesis of 7-benzyl-3-oxa-7-azabicyclo [3.3.1] nonan-9-ol (mixture of syn and anti isomers) (3):
7-Benzyl-3-oxa-7-azabicyclo [3.3.1] nonan-9-one hydrochloride (4.40 g, 16.9 mmol) was suspended in ethanol (40 mL) and anhydrous tetrahydrofuran (40 mL). . The mixture was cooled in an ice bath and sodium borohydride (1.5 g, 37.3 mmol) was added in one portion. The mixture was slowly warmed to room temperature over 4 hours. The reaction was then concentrated in vacuo to remove most of the ethanol and tetrahydrofuran. The mixture was partitioned between methyl tert-butyl ether and 1.0 M aqueous sodium hydroxide. After stirring the solution for 30 minutes, the two layers were separated. The aqueous layer was extracted with methyl tert-butyl ether. The organic extracts were combined, washed with brine and dried over sodium sulfate. The mixture was filtered and the filtrate was concentrated in vacuo to give a clear oil that solidified partially upon standing to an oily white solid (3.71 g, 94%). This mixture of syn and anti 7-benzyl-3-oxa-7-azabicyclo [3.3.1] nonan-9-ol isomers was used in the next step without further purification. LCMS (ES +): 234.1 (M + 1).

An alternative procedure was performed as follows.
A 20 L reactor equipped with a reflux condenser was charged with methanol (8.00 L, 6.33 kg), benzylamine (4.00 mol, 428.12 g), tetrahydro-4H-pyran-4-one (400 g, 4.3 g). 00 mol), and acetic acid (4.00 mol, 239.93 g) were added. The jacket temperature was kept at 15-25 ° C. during the addition. The reaction mixture was heated to reflux (66 ° C.).

  An aqueous formaldehyde solution (7.99 mol, 600.42 mL, 648.46 g) was combined with methanol (2 L). The resulting solution was added to the reaction solution over 1 hour, during which time the reaction solution was subsequently refluxed. After the addition of formaldehyde, the reaction was heated at reflux for 10 minutes and cooled to 10-20 ° C. Sodium bicarbonate (4.00 mol, 335.63 g) was added. The reaction was cooled to 10 ° C. and sodium borohydride (4.20 mol, 158.71 g) was added in small portions (using sodium borohydride tablets, approximately 1 g of each tablet). After the addition of sodium borohydride was complete, the reaction was stirred at 15-25 ° C. for 40 minutes. To the reaction mixture was added diatomaceous earth (400 g) followed by water (2 L) and 1N sodium hydroxide solution (4.00 L). The reaction mixture was stirred at 15-25 ° C. for 1 hour and filtered. The filter cake was rinsed with methanol / water (1: 1 mixture, 800 mL). The filtrate was concentrated in vacuo at 40-45 ° C. to remove most of the methanol. The resulting aqueous mixture was extracted with 2-methyltetrahydrofuran (1 × 6.00 L). The 2-methyltetrahydrofuran layer was washed with brine (2.00 L, 2.38 kg) and concentrated under partial vacuum at a pot temperature of 40-45 ° C. to give an oil that was collected in a 5 L container (Naljug). . The reactor was rinsed with 1 L of acetonitrile and the rinse was combined with the crude oily product. After 12 hours of standing at 10-15 ° C., crystallization occurred in Naljug. The mixture was filtered to give the syn-diastereoisomer (193 g, 98% de). After the filtrate is purified by silica gel chromatography (mobile phase: toluene / heptane / diethylamine 70/30/5, isocomposition), ChiralPak AD (mobile phase: isopropanol / heptane / diethylamine 5/95 / 0.2) is used. Purification by another chromatography gave an additional portion of the syn-diastereoisomer (86.3 g) and the anti-diastereoisomer (145 g).

An alternative enzymatic reduction procedure was also performed as follows.
Enzymatic procedure A
In a reaction vial, 75 microliters of a solution of nicotinamide adenine dinucleotide phosphate (NADH) (53 mg / mL, 0.1 M potassium phosphate buffer, pH 7), 20 microliters Codexis KRED-NADH101 (Codexis, Inc.). , 200 Penobscot Drive, Redwood City, Calif. 94063) (50 mg / mL, 0.1 M potassium phosphate buffer, pH 7), and 5 microliters of 7-benzyl-3-oxa-7-azabicyclo [3. 3.1] A solution of nonan-9-one (200 mg / mL, DMSO solution) was added. The resulting mixture was stirred at 30 ° C. for 20 hours. The reaction was diluted with ethyl acetate (900 microliters), mixed and centrifuged. The organic layer (600 microliters) was collected, evaporated to dryness and resuspended in methanol (600 microliters) for analysis by supercritical fluid chromatography (SFC). SFC analysis showed only the formation of the anti-7-benzyl-3-oxa-7-azabicyclo [3.3.1] nonan-9-ol isomer with a conversion yield of 97%. No evidence of syn isomer was found.

Enzymatic procedure B
In a reaction vial, 75 microliters of NADH solution (53 mg / mL, 0.1 M potassium phosphate buffer, pH 7), 20 microliters of DAICEL-E002 (Daicel Corporation, CPI Company, Japan, 108-8230 Tokyo, Japan) 2-18-1 Konan, Minato-ku, JR Shinagawa East Building) (50 mg / mL, 0.1 M potassium phosphate buffer, pH 7), and 5 microliters of 7-benzyl-3-oxa-7-azabicyclo [ 3.3.1] A solution of nonan-9-one (200 mg / mL, DMSO solution) was added. The resulting mixture was stirred at 30 ° C. for 20 hours. The reaction was diluted with ethyl acetate (900 microliters), mixed and centrifuged. The organic layer (600 microliters) was collected, evaporated to dryness, resuspended in methanol (600 microliters) and prepared for SFC analysis. SFC analysis showed only the formation of the syn-7-benzyl-3-oxa-7-azabicyclo [3.3.1] nonan-9-ol isomer with a conversion yield of 99%. No evidence of anti isomers was found.

Step C of Scheme A. Synthesis of 3-oxa-7-azabicyclo [3.3.1] nonan-9-ol (mixture of syn and anti isomers) (4):
A starting mixture of syn and anti 7-benzyl-3-oxa-7-azabicyclo [3.3.1] nonane-9-ol isomers (3.71 g, 15.9 mmol) was dissolved in ethanol (120 mL), Pd (OH) ₂ (450 mg) was added. The mixture was shaken in 50 psi hydrogen for 2.5 hours on a Parr shaker. The mixture was filtered through diatomaceous earth and the collected solid was washed 3 times with methanol. The filtrate was concentrated in vacuo to give an oily solid. This oily solid was dissolved in ethyl acetate and heptane was added. Concentration of the solution in vacuo gave a syn and anti isomer mixture of 3-oxa-7-azabicyclo [3.3.1] nonan-9-ol as a white solid (2.08 g, 91%). . This material was used in the next step without further purification. LCMS (ES +): 144.1 (M + 1).

Step D of Scheme A. Synthesis of isopropyl 9-hydroxy-3-oxa-7-azabicyclo [3.3.1] nonane-7-carboxylate (mixture of syn and anti isomers) (5):
Syn and anti isomer mixture of 3-oxa-7-azabicyclo [3.3.1] nonane-9-ol (2.08 g, 14.5 mmol) and N, N diisopropylethylamine (2.80 mL, 16.0 mmol) Of chlorochloroformate (14.2 mL, 14.2 mmol, 1.0 M toluene solution) was added dropwise to a 0 ° C. dichloromethane solution (15 mL). The reaction mixture was warmed to room temperature over 14 hours. Subsequently, the reaction liquid was diluted with 1M hydrochloric acid aqueous solution (50 mL), and the aqueous layer was separated. The organic layer was washed sequentially with water (50 mL) and brine (50 mL) and dried over sodium sulfate. The mixture was filtered and the filtrate was concentrated in vacuo to give a colorless oil. This oil was dissolved in ethyl acetate, heptane was added and the mixture was concentrated. The resulting oil was dried in vacuo to give a mixture of syn and anti isomers of isopropyl 9-hydroxy-3-oxa-7-azabicyclo [3.3.1] nonane-7-carboxylate as a clear oil ( 2.74 g, 82%). LCMS (ES +): 230.1 (M + 1).

Step E. Separation of syn and anti isomers of isopropyl 9-hydroxy-3-oxa-7-azabicyclo [3.3.1] nonane-7-carboxylate:
By preparative high pressure liquid chromatography using a Chiralpak AD-H column (21 × 250 mm) with 85:15 carbon dioxide and methanol each at a flow rate of 65 mL / min as the mobile phase, 9-hydroxy-3-oxa- A syn and anti isomer mixture of isopropyl 7-azabicyclo [3.3.1] nonane-7-carboxylate (5.04 g, 35.1 mmol) was isolated. The wavelength for monitoring separation was 210 nm. By analytical high-pressure chromatography using a Chiralpak AD-H (4.6 mm × 25 cm) column with 85:15 carbon dioxide and methanol each at a flow rate of 2.5 mL / min as mobile phases. The purity of each isomer was determined. The wavelength for monitoring the peak was 210 nm. The following two isomers were obtained.
-9-Syn-hydroxy-3-oxa-7-azabicyclo [3.3.1] nonane-7-carboxylate isopropyl (6) (1.34 g): a clear oil that solidified on standing did. Retention time (R _t ) = 2.3 min, ¹ H NMR (400 MHz, deuterated-DMSO): δ 5.12 (d, 1H, J = 2.8 Hz), 4.76-4.71
(m, 1H), 4.20 (d, 1H, J = 13Hz), 4.16 (d, 1H, J = 13Hz), 3.96-3.92 (m, 2H), 3.79
(d, 1H, J = 3Hz), 3.55 (s, 1H), 3.52 (S, 1H), 3.08 (d, 1H, J = 13Hz), 2.98 (d, 1H,
J = 13Hz), 1.47 (m, 2H) 1.16 (d, 3H, J = 3Hz), 1.15 (d, 3H, J = 3Hz); LCMS (ES +):
230.2 (M + 1).
-9-Anti-hydroxy-3-oxa-7-azabicyclo [3.3.1] nonane-7-carboxylate isopropyl (7) (1.70 g): amber oil, R _t = 3.08 min , ¹ H NMR (400 MHz, DMSO-d ₆ ): δ 5.11 (d, 1H, J = 2.8Hz), 4.74-4.67 (m, 1H), 3.89 (d, 1H, J = 13Hz),
3.84-3.78 (m, 2H, J = 11Hz), 3.80 (d, 1H, J = 6Hz), 3.78 (d, 1H, J = 3Hz), 3.52-
3.47 (m, 2H), 3.35-3.30 (m, 1H), 3.24-3.20 (m, 1H), 1.53 (s, 1H), 1.51 (s,
1H), 1.13 (d, 3H, J = 1Hz), 1.16 (d, 3H, J = 1Hz); LCMS (ES +): 230.2 (M + 1)

Alternatively, Steps A and B of Reaction Scheme A above are combined as described below to produce 7-benzyl-3-oxa-7-azabicyclo [3.3.1] nonan-9-ol (syn and anti-isomerism). Body mixtures) can also be synthesized.
Benzylamine (21.35 g, 199.27 mmol), tetrahydro-4H-pyran-4-one (1) (19.95 g, 199.27 mmol), and acetic acid (11.97 g, 199.27 mmol) in methanol (400 mL) Dissolved in. The mixture was heated to reflux. To the reaction mixture, an aqueous formaldehyde solution (37%, 32.34 g, 398.53 mmol) and methanol (100 mL) were added over 60 minutes while the reaction solution was refluxed. The reaction was cooled to room temperature. Then sodium bicarbonate (16.74 g, 199.27 mmol) was added in small portions. Subsequently, sodium borohydride (7.92 g 209.23 mmol) was added in small portions while keeping the reaction temperature below 25 ° C. The mixture was stirred at ambient temperature for 30 minutes. After adding diatomaceous earth (20 g), water (100 mL) and 1N aqueous sodium hydroxide solution (100 mL) were added. After stirring for 1 hour, the mixture was filtered and the filter cake was rinsed sequentially with methanol and water (20 mL each). The filtrate was concentrated in vacuo to remove most of the methanol. The resulting aqueous mixture was extracted with 2-methyltetrahydrofuran (300 mL). The organic phase was washed with brine solution (100 mL), dried over anhydrous magnesium sulfate and concentrated in vacuo to give syn and anti-7-benzyl-3-oxa-7-azabicyclo [3.3.1] nonane- A mixture of 9-ol isomers was obtained as an oil that solidified on standing at room temperature (22.0 g, 47.3%).

Preparation Example 2: 9-hydroxy-3-oxa-7-azabicyclo [3.3.1] nonane-7-carboxylate tert-butyl (mixture of syn and anti isomers)

３−オキサ−７−アザビシクロ［３．３．１］ノナン−９−オール（シンおよびアンチ異性体の混合物）（３．７８ｇ、２６．４ｍｍｏｌ）を水（３０ｍＬ）およびテトラヒドロフラン（３０ｍＬ）に溶かした０℃の溶液に、二炭酸ジ−ｔｅｒｔ−ブチル（５．７６ｇ、２６．４ｍｍｏｌ）のテトラヒドロフラン（２０ｍＬ）溶液を滴下した。溶液を徐々に室温に温めながら約１５時間撹拌した。反応液をジクロロメタンおよび水で希釈した。層を分離し、水層をジクロロメタンで抽出した。有機層を合わせ、硫酸ナトリウムで乾燥させた。混合物を濾過し、濾液を減圧下で濃縮すると、表題化合物が透明な油状物（６．５５ｇ）として現れ、これをそれ以上精製せずに使用した。

3-Oxa-7-azabicyclo [3.3.1] nonane-9-ol (mixture of syn and anti isomers) (3.78 g, 26.4 mmol) was dissolved in water (30 mL) and tetrahydrofuran (30 mL). To a solution at 0 ° C., a solution of di-tert-butyl dicarbonate (5.76 g, 26.4 mmol) in tetrahydrofuran (20 mL) was added dropwise. The solution was stirred for about 15 hours while gradually warming to room temperature. The reaction was diluted with dichloromethane and water. The layers were separated and the aqueous layer was extracted with dichloromethane. The organic layers were combined and dried over sodium sulfate. The mixture was filtered and the filtrate was concentrated under reduced pressure to reveal the title compound as a clear oil (6.55 g) that was used without further purification.

Preparation Example 3: Separation of syn and anti isomers of tert-butyl 9-hydroxy-3-oxa-7-azabicyclo [3.3.1] nonane-7-carboxylate

９−ヒドロキシ−３−オキサ−７−アザビシクロ［３．３．１］ノナン−７−カルボン酸ｔｅｒｔ−ブチル（５．０４ｇ、３５．１ｍｍｏｌ）のシンおよびアンチ異性体の混合物を、それぞれ８５：１５の二酸化炭素およびメタノールを移動相とし、流量を６５ｍＬ／分としたＣｈｉｒａｌｐａｋ ＡＤ−Ｈカラム（２１×２５０ｍｍ）を利用する分取高圧液体クロマトグラフィーによって分離した。分離をモニターする波長は２１０ｎｍとした。各異性体の純度分析値は、それぞれ８５：１５の二酸化炭素およびメタノールを移動相とし、流量を２．５ｍＬ／分としたＣｈｉｒａｌｐａｋ ＡＤ−Ｈ（４．６ｍｍ×２５ｃｍ）カラムを使用する分析高速クロマトグラフィーを使用して求めた。ピークをモニターする波長は２１０ｎｍとした。以下の２種の異性体が得られた。
９−アンチ−ヒドロキシ−３−オキサ−７−アザビシクロ［３．３．１］ノナン−７−カルボン酸ｔｅｒｔ−ブチル：（１．３０ｇ、１００％ｄｅ）、静置すると白色の固体に凝固した透明な油状物、保持時間（Ｒ_ｔ）＝３．１５分。1H NMR (400 MHz, 重水素化クロロホルム) δ 1.44 (s, 9 H),
1.66 (d, J=16.79 Hz, 2 H), 1.84 (d, J=2.93 Hz, 1 H), 3.30 - 3.52 (m, 2 H), 3.64
(t, J=11.03 Hz, 2 H), 3.93 - 4.21 (m, 5 H).
９−シン−ヒドロキシ−３−オキサ−７−アザビシクロ［３．３．１］ノナン−７−カルボン酸ｔｅｒｔ−ブチル：（１．６４ｇ、８９％ｄｅ）、静置すると白色の固体に凝固した透明な油状物、Ｒ_ｔ＝３．５５分。1H NMR (400 MHz, 重水素化クロロホルム) δ 1.47 (s, 9 H),
1.64 (d, J=13.47 Hz, 2 H), 2.12 (d, J=3.32 Hz, 1 H), 2.92 - 3.22 (m, 2 H), 3.71
- 3.83 (m, 2 H), 3.99 (d, J=3.32 Hz, 1 H), 4.09 - 4.19 (m, 2 H), 4.32 (d,
J=13.66 Hz, 1 H), 4.48 (d, J=13.66 Hz, 1 H).

A mixture of the syn and anti isomers of tert-butyl 9-hydroxy-3-oxa-7-azabicyclo [3.3.1] nonane-7-carboxylate (5.04 g, 35.1 mmol), respectively, 85:15 Were separated by preparative high pressure liquid chromatography using a Chiralpak AD-H column (21 × 250 mm) with a mobile phase of carbon dioxide and methanol as the mobile phase and a flow rate of 65 mL / min. The wavelength for monitoring separation was 210 nm. The purity analysis value of each isomer was analytical high-speed chromatography using a Chiralpak AD-H (4.6 mm × 25 cm) column with carbon dioxide and methanol of 85:15 as mobile phases and a flow rate of 2.5 mL / min. Determined using graphy. The wavelength for monitoring the peak was 210 nm. The following two isomers were obtained.
9-anti-hydroxy-3-oxa-7-azabicyclo [3.3.1] nonane-7-carboxylate tert-butyl: (1.30 g, 100% de), clear to solidify on white solid upon standing such oil, retention time _(R t) = 3.15 min. 1H NMR (400 MHz, deuterated chloroform) δ 1.44 (s, 9 H),
1.66 (d, J = 16.79 Hz, 2 H), 1.84 (d, J = 2.93 Hz, 1 H), 3.30-3.52 (m, 2 H), 3.64
(t, J = 11.03 Hz, 2 H), 3.93-4.21 (m, 5 H).
Tert-butyl 9-syn-hydroxy-3-oxa-7-azabicyclo [3.3.1] nonane-7-carboxylate: (1.64 g, 89% de), clear to solidify on white solid upon standing Oil, R _t = 3.55 min. 1H NMR (400 MHz, deuterated chloroform) δ 1.47 (s, 9 H),
1.64 (d, J = 13.47 Hz, 2 H), 2.12 (d, J = 3.32 Hz, 1 H), 2.92-3.22 (m, 2 H), 3.71
-3.83 (m, 2 H), 3.99 (d, J = 3.32 Hz, 1 H), 4.09-4.19 (m, 2 H), 4.32 (d,
J = 13.66 Hz, 1 H), 4.48 (d, J = 13.66 Hz, 1 H).

Preparation Example 1: 1- (6-Chloropyrimidin-4-yl) -5- (methylthio) indoline:

４，６−ジクロロピリミジン（８．６０ｇ、５７．７ｍｍｏｌ）をｎ−プロパノール（１１０ｍＬ）に溶かした１０７℃の撹拌した溶液に、５−（メチルチオ）インドリン（ＷＯ１９９５０１９７６）（８．８１ｇ）のｎ−プロパノール（６０ｍＬ）溶液を速やかに加えた。反応混合物を１０７℃で４５分間加熱した。これを室温に冷却した後、混合物をメチルｔｅｒｔ−ブチルエーテル（１２５ｍＬ）で希釈した。得られる固体を濾過によって収集し、フィルターケーキをメチルｔｅｒｔ−ブチルエーテルで洗浄した。濾液を廃棄し、フィルターケーキを飽和炭酸水素ナトリウム水溶液（２００ｍＬ）とクロロホルム（５００ｍＬ）とに分配した。二相性混合物を４０℃の水浴で加熱して、残存するすべての固体を溶解させた。次いで有機溶液を分離し、硫酸マグネシウムで乾燥させた。混合物を濾過し、濾液を減圧下で濃縮して、１−（６−クロロピリミジン−４−イル）−５−（メチルチオ）インドリンを黄色の固体（１４．８ｇ、８４％）として得た。¹H NMR (400 MHz, 重水素化クロロホルム) δ 2.49 (s, 3 H) 3.27 (t, J=8.5 Hz ,2 H), 4.02 (t, J=8.5 Hz, 2 H),
6.59 (s, 1H), 7.17 - 7.20 (m, 2 H), 8.35 (d, J=8.7 Hz, 1H), 8.58 (s, 1H); LCMS
(ES+): 278.4 (M+1).

To a stirred solution of 4,6-dichloropyrimidine (8.60 g, 57.7 mmol) in n-propanol (110 mL) at 107 ° C., 5- (methylthio) indoline (WO199501976) (8.81 g) n- Propanol (60 mL) solution was added quickly. The reaction mixture was heated at 107 ° C. for 45 minutes. After cooling to room temperature, the mixture was diluted with methyl tert-butyl ether (125 mL). The resulting solid was collected by filtration and the filter cake was washed with methyl tert-butyl ether. The filtrate was discarded and the filter cake was partitioned between saturated aqueous sodium bicarbonate (200 mL) and chloroform (500 mL). The biphasic mixture was heated in a 40 ° C. water bath to dissolve any remaining solids. The organic solution was then separated and dried over magnesium sulfate. The mixture was filtered and the filtrate was concentrated under reduced pressure to give 1- (6-chloropyrimidin-4-yl) -5- (methylthio) indoline as a yellow solid (14.8 g, 84%). ¹ H NMR (400 MHz, deuterated chloroform) δ 2.49 (s, 3 H) 3.27 (t, J = 8.5 Hz, 2 H), 4.02 (t, J = 8.5 Hz, 2 H),
6.59 (s, 1H), 7.17-7.20 (m, 2 H), 8.35 (d, J = 8.7 Hz, 1H), 8.58 (s, 1H); LCMS
(ES +): 278.4 (M + 1).

Preparation Example 5: 1- (6-Chloropyrimidin-4-yl) -5- (methylsulfonyl) indoline

１−（６−クロロピリミジン−４−イル）−５−（メチルチオ）インドリン（１２．４ｇ、４４．５ｍｍｏｌ）をクロロホルム（３００ｍＬ）に溶かした５０℃の撹拌した溶液に、ｍｅｔａ−クロロペルオキシ安息香酸（２７．４ｇ、１１１ｍｍｏｌ）をクロロホルム（１５０ｍＬ）に溶かした無水溶液（温クロロホルムに溶解させ、分離した水層を廃棄することにより調製）を加えた。１時間後、反応混合物をジメチルスルフィド（１．７ｍＬ）で失活させ、１０分間撹拌し、次いで１０％炭酸ナトリウム水溶液（１５０ｍＬ）中に注いだ。水層を分離し、有機層を１０％炭酸ナトリウム水溶液（１００ｍＬ）で洗浄し、硫酸マグネシウムで乾燥させた。混合物を濾過し、濾液を減圧下で濃縮した。得られる残渣を熱アセトニトリルに溶解させた。冷却すると、１−（６−クロロピリミジン−４−イル）−５−（メチルスルホニル）インドリンが白色の固体（１３．８ｇ、８５％）として沈殿した。¹H NMR (400 MHz, 重水素化クロロホルム) δ 3.05 (s, 3 H), 3.36 (t, J=8.7 Hz, 2 H), 4.12 (t, J=8.7 Hz, 2 H),
6.68 (s, 1 H), 7.74 - 7.85 (m, 1H), 7.81 (d, J=8.4 Hz 1H), 8.66 (s, 1H), 8.63
(d, J=8.4 Hz, 1H); LCMS (ES+) 310.4 (M+1).

To a stirred solution of 1- (6-chloropyrimidin-4-yl) -5- (methylthio) indoline (12.4 g, 44.5 mmol) in chloroform (300 mL) at 50 ° C. was added meta-chloroperoxybenzoic acid. An aqueous solution (27.4 g, 111 mmol) dissolved in chloroform (150 mL) (dissolved in warm chloroform and prepared by discarding the separated aqueous layer) was added. After 1 hour, the reaction mixture was quenched with dimethyl sulfide (1.7 mL), stirred for 10 minutes, and then poured into 10% aqueous sodium carbonate (150 mL). The aqueous layer was separated, and the organic layer was washed with 10% aqueous sodium carbonate solution (100 mL) and dried over magnesium sulfate. The mixture was filtered and the filtrate was concentrated under reduced pressure. The resulting residue was dissolved in hot acetonitrile. Upon cooling, 1- (6-chloropyrimidin-4-yl) -5- (methylsulfonyl) indoline precipitated as a white solid (13.8 g, 85%). ¹ H NMR (400 MHz, deuterated chloroform) δ 3.05 (s, 3 H), 3.36 (t, J = 8.7 Hz, 2 H), 4.12 (t, J = 8.7 Hz, 2 H),
6.68 (s, 1 H), 7.74-7.85 (m, 1H), 7.81 (d, J = 8.4 Hz 1H), 8.66 (s, 1H), 8.63
(d, J = 8.4 Hz, 1H); LCMS (ES +) 310.4 (M + 1).

Preparation 6: 4-Chloro-6- [5- (methylthio) -2,3-dihydro-1H-indol-1-yl] pyrimidine-5-carbonitrile

５−（メチルチオ）インドリン（５０ｍｇ、０．３０ｍｍｏｌ）を含有するアセトニトリル（１ｍＬ）を８０℃で２分間加熱し、次いで室温に冷却した。反応混合物に４，６−ジクロロピリミジン−５−カルボニトリル（ＷＯ２００６１１８７４９）（５３ｍｇ、０．３０ｍｍｏｌ）およびジイソプロピルエチルアミン（０．１０ｍＬ、０．４５ｍｍｏｌ）を加え、次いでこれを３時間撹拌した。反応混合物を減圧下で濃縮し、残渣をヘプタンで摩砕した。混合物を濾過して、４−クロロ−６−［５−（メチルチオ）−２，３−ジヒドロ−１Ｈ−インドール−１−イル］ピリミジン−５−カルボニトリルを白色の固体（４０ｍｇ、４３％）として得た。¹H NMR (400 MHz, 重水素化-DMSO) δ 8.63 (s, 1 H), 8.09 (d, 1 H, J=8.8 Hz,), 7.24 (s, 1 H), 7.12 (d, 1
H, J=8.4 Hz), 4.49 (t, 2 H, J=8.2 Hz), 3.21 (t, 2 H, J=8.0Hz), 2.45 (s, 3 H).

Acetonitrile (1 mL) containing 5- (methylthio) indoline (50 mg, 0.30 mmol) was heated at 80 ° C. for 2 minutes and then cooled to room temperature. To the reaction mixture was added 4,6-dichloropyrimidine-5-carbonitrile (WO2006118749) (53 mg, 0.30 mmol) and diisopropylethylamine (0.10 mL, 0.45 mmol), which was then stirred for 3 hours. The reaction mixture was concentrated under reduced pressure and the residue was triturated with heptane. The mixture was filtered to give 4-chloro-6- [5- (methylthio) -2,3-dihydro-1H-indol-1-yl] pyrimidine-5-carbonitrile as a white solid (40 mg, 43%). Obtained. ¹ H NMR (400 MHz, deuterated DMSO) δ 8.63 (s, 1 H), 8.09 (d, 1 H, J = 8.8 Hz,), 7.24 (s, 1 H), 7.12 (d, 1
H, J = 8.4 Hz), 4.49 (t, 2 H, J = 8.2 Hz), 3.21 (t, 2 H, J = 8.0 Hz), 2.45 (s, 3 H).

Preparation Example 7: Isopropyl 4-[(6-chloro-5-methoxypyrimidin-4-yl) oxy] piperidine-1-carboxylate

４，６−ジクロロ−５−メトキシピリミジン（２４０ｍｇ、１．３４ｍｍｏｌ）および４−ヒドロキシピペリジン−１−カルボン酸イソプロピル（３２６ｍｇ、１．７４ｍｍｏｌ）を無水１，４−ジオキサン（３ｍＬ）に溶かした１００℃の溶液に、１Ｍのナトリウムビス（トリメチルシリル）アミドテトラヒドロフラン溶液（１．３４ｍＬ、１．３４ｍｍｏｌ、１．０Ｍ）を加えた。反応混合物を１０時間加熱し、次いで室温に冷ました。次いで反応を水（３ｍＬ）で失活させ、酢酸エチル（２０ｍＬ）で希釈した。次いで溶液を飽和炭酸水素ナトリウム水溶液（１０ｍＬ）およびブライン（１０ｍＬ）で順次洗浄した後、硫酸ナトリウムで乾燥させた。混合物を濾過し、濾液を減圧下で濃縮した。未精製残渣を、カラムクロマトグラフィー（０〜１００％の酢酸エチルヘプタン溶液）によって精製して、４−［（６−クロロ−５−メトキシピリミジン−４−イル）オキシ］ピペリジン−１−カルボン酸イソプロピルを油状物（２６０ｍｇ、５９％）として得た。¹H NMR (400 MHz, 重水素化クロロホルム) δ 8.25 (1 H, s) 5.29 - 5.44 (1 H, m) 4.84 - 5.01 (1 H, m) 3.90 (3 H,
s) 3.72 - 3.82 (2 H, m) 3.31 - 3.47 (2 H, m) 1.93 - 2.10 (2 H, m) 1.72 - 1.89
(2 H, m) 1.25 (6 H, d, J=6.24 Hz); LCMS (ES+): 329.0 (M+1).

4,6-dichloro-5-methoxypyrimidine (240 mg, 1.34 mmol) and isopropyl 4-hydroxypiperidine-1-carboxylate (326 mg, 1.74 mmol) were dissolved in anhydrous 1,4-dioxane (3 mL) at 100 ° C. To the solution was added 1M sodium bis (trimethylsilyl) amide tetrahydrofuran solution (1.34 mL, 1.34 mmol, 1.0 M). The reaction mixture was heated for 10 hours and then cooled to room temperature. The reaction was then quenched with water (3 mL) and diluted with ethyl acetate (20 mL). The solution was then washed sequentially with saturated aqueous sodium bicarbonate (10 mL) and brine (10 mL) and then dried over sodium sulfate. The mixture was filtered and the filtrate was concentrated under reduced pressure. The crude residue was purified by column chromatography (0-100% ethyl acetate heptane solution) to give isopropyl 4-[(6-chloro-5-methoxypyrimidin-4-yl) oxy] piperidine-1-carboxylate. As an oil (260 mg, 59%). ¹ H NMR (400 MHz, deuterated chloroform) δ 8.25 (1 H, s) 5.29-5.44 (1 H, m) 4.84-5.01 (1 H, m) 3.90 (3 H,
s) 3.72-3.82 (2 H, m) 3.31-3.47 (2 H, m) 1.93-2.10 (2 H, m) 1.72-1.89
(2 H, m) 1.25 (6 H, d, J = 6.24 Hz); LCMS (ES +): 329.0 (M + 1).

Preparation Example 8: Isopropyl 4-[(6-chloro-5-methylpyrimidin-4-yl) oxy] piperidine-1-carboxylate

４，６−ジクロロ−５−メチル−ピリミジン（３．０ｇ、１８．４ｍｍｏｌ）および４−ヒドロキシピペリジン−１−カルボン酸イソプロピル（３．７９ｇ、２０．２ｍｍｏｌ）を無水テトラヒドロフラン（１００ｍＬ）に溶かした０℃の溶液に、１Ｍのカリウムｔｅｒｔ−ブトキシドテトラヒドロフラン溶液（３．１ｇ、２７．６ｍｍｏｌ）を加えた。反応液を撹拌しながら１８時間かけて室温に温めた。次いで水で反応を失活させ、酢酸エチルで４回抽出した。有機抽出物を合わせ、硫酸ナトリウムで乾燥させた。混合物を濾過し、濾液を減圧下で濃縮した。得られる材料をカラムクロマトグラフィー（０〜５０％の酢酸エチルヘプタン溶液）によって精製して、４−［（６−クロロ−５−メチルピリミジン−４−イル）オキシ］ピペリジン−１−カルボン酸イソプロピルを白色の固体（４．４ｇ、７６％）として得た。¹H NMR (400 MHz, 重水素化クロロホルム) δ 1.23 (d, J=6.4 Hz, 6 H) 1.70 - 1.79 (m, 2 H) 1.91 - 2.01 (m, 2 H)
2.20 (s, 3 H) 3.34 - 3.42 (m, 2 H) 3.67 - 3.77 (m, 2 H) 4.86 - 4.95 (m, 1 H)
5.29 - 5.35 (m, 1 H) 8.36 (s, 1 H); LCMS (ES+): 314.2 (M+1).

4,6-Dichloro-5-methyl-pyrimidine (3.0 g, 18.4 mmol) and isopropyl 4-hydroxypiperidine-1-carboxylate (3.79 g, 20.2 mmol) were dissolved in anhydrous tetrahydrofuran (100 mL). To the solution at 0 ° C. was added 1M potassium tert-butoxide tetrahydrofuran solution (3.1 g, 27.6 mmol). The reaction was allowed to warm to room temperature over 18 hours with stirring. The reaction was then quenched with water and extracted four times with ethyl acetate. The organic extracts were combined and dried over sodium sulfate. The mixture was filtered and the filtrate was concentrated under reduced pressure. The resulting material was purified by column chromatography (0-50% ethyl acetate heptane solution) to give isopropyl 4-[(6-chloro-5-methylpyrimidin-4-yl) oxy] piperidine-1-carboxylate. Obtained as a white solid (4.4 g, 76%). ¹ H NMR (400 MHz, deuterated chloroform) δ 1.23 (d, J = 6.4 Hz, 6 H) 1.70-1.79 (m, 2 H) 1.91-2.01 (m, 2 H)
2.20 (s, 3 H) 3.34-3.42 (m, 2 H) 3.67-3.77 (m, 2 H) 4.86-4.95 (m, 1 H)
5.29-5.35 (m, 1 H) 8.36 (s, 1 H); LCMS (ES +): 314.2 (M + 1).

Preparation Example 9: Isopropyl 4-[(6-chloro-pyrimidin-4-yl) oxy] piperidine-1-carboxylate

４−ヒドロキシピペリジン−１−カルボン酸イソプロピル（６６０ｍｇ、３．５２ｍｍｏｌ）および４，６−ジクロロピリミジン（５００ｍｇ、３．３６ｍｍｏｌ）をテトラヒドロフラン（１５ｍＬ）に溶かした溶液に、１Ｍのカリウムｔｅｒｔ−ブトキシドテトラヒドロフラン溶液（５．０３ｍＬ、５．０３ｍｍｏｌ）を０℃で加えた。反応混合物を一晩かけてゆっくりと室温に温めた。１８時間後、反応混合物を水で希釈し、酢酸エチルで３回抽出した。有機層を合わせて硫酸ナトリウムで乾燥させ、次いで濾過し、濾液を減圧下で濃縮した。未精製残渣をカラムクロマトグラフィー（０〜５０％の酢酸エチルヘプタン溶液）によって精製して、４−［（６−クロロ−ピリミジン−４−イル）オキシ］ピペリジン−１−カルボン酸イソプロピル（７００ｍｇ、６９．６％）を無色の油状物として得た。¹H NMR (400 MHz, 重水素化クロロホルム) δ 1.25 (d, J=6.25 Hz, 6 H) 1.68 - 1.79 (m, 2 H) 1.94 - 2.03 (m, 2 H)
3.29 - 3.37 (m, 2 H) 3.75 - 3.83 (m, 2 H) 4.88 - 4.97 (m, 1 H) 5.28 - 5.36 (m,
1 H) 6.75 (d, J=0.78 Hz, 1 H) 8.55 (d, J=0.98 Hz, 1 H). LCMS (ES+): 300.3
(M+1).

To a solution of isopropyl 4-hydroxypiperidine-1-carboxylate (660 mg, 3.52 mmol) and 4,6-dichloropyrimidine (500 mg, 3.36 mmol) in tetrahydrofuran (15 mL), 1 M potassium tert-butoxide tetrahydrofuran solution (5.03 mL, 5.03 mmol) was added at 0 ° C. The reaction mixture was slowly warmed to room temperature overnight. After 18 hours, the reaction mixture was diluted with water and extracted three times with ethyl acetate. The combined organic layers were dried over sodium sulfate and then filtered and the filtrate was concentrated under reduced pressure. The crude residue was purified by column chromatography (0-50% ethyl acetate heptane solution) to give isopropyl 4-[(6-chloro-pyrimidin-4-yl) oxy] piperidine-1-carboxylate (700 mg, 69 .6%) as a colorless oil. ¹ H NMR (400 MHz, deuterated chloroform) δ 1.25 (d, J = 6.25 Hz, 6 H) 1.68-1.79 (m, 2 H) 1.94-2.03 (m, 2 H)
3.29-3.37 (m, 2 H) 3.75-3.83 (m, 2 H) 4.88-4.97 (m, 1 H) 5.28-5.36 (m,
1 H) 6.75 (d, J = 0.78 Hz, 1 H) 8.55 (d, J = 0.98 Hz, 1 H). LCMS (ES +): 300.3
(M + 1).

Preparation Example 10: 1- (6-Chloro-pyrimidin-4-yl) -2,3-dihydro-1H-indole-5-carboxylic acid methyl ester

４，６−ジクロロピリミジン（８１５ｍｇ、４．６０ｍｍｏｌ）のｎ−プロパノール（１２．０ｍＬ）溶液に、２，３−ジヒドロ−１Ｈ−インドール−５−カルボン酸メチルエステル（Ｂｉｏｏｒｇ．Ｍｅｄ．Ｃｈｅｍ．Ｌｅｔｔ．２００８、１８、５６８４〜８）（７５４ｍｇ、５．０６ｍｍｏｌ）を加えた。得られる黄色の溶液を２時間加熱還流した。反応液を室温に冷ました後、反応混合物をメチルｔｅｒｔ−ブチルエーテルで希釈し、次いで濾過した。収集した固体をクロロホルムと飽和炭酸水素ナトリウム水溶液とに分配した。分離した有機相を硫酸マグネシウムで乾燥させ、濾過し、濾液を減圧下で濃縮して、１−（６−クロロ−ピリミジン−４−イル）−２，３−ジヒドロ−１Ｈ−インドール−５−カルボン酸メチルエステル（９２９ｍｇ、６９．７％）をオフホワイトの固体として得た。¹H NMR (400 MHz, 重水素化クロロホルム) δ 3.32 (t, J=8.49 Hz, 2 H) 3.91 (s, 3 H) 4.08 (t, J=8.69 Hz, 2 H)
6.67 (s, 1 H) 7.90 (d, J=0.98 Hz, 1 H) 7.96 (dd, J=8.49, 1.46 Hz, 1 H) 8.46 (d,
J=8.59 Hz, 1 H) 8.65 (s, 1 H).

To a solution of 4,6-dichloropyrimidine (815 mg, 4.60 mmol) in n-propanol (12.0 mL) was added 2,3-dihydro-1H-indole-5-carboxylic acid methyl ester (Bioorg. Med. Chem. Lett. 2008, 18, 5684-8) (754 mg, 5.06 mmol) was added. The resulting yellow solution was heated to reflux for 2 hours. After cooling the reaction to room temperature, the reaction mixture was diluted with methyl tert-butyl ether and then filtered. The collected solid was partitioned between chloroform and saturated aqueous sodium bicarbonate. The separated organic phase is dried over magnesium sulfate, filtered, and the filtrate is concentrated under reduced pressure to give 1- (6-chloro-pyrimidin-4-yl) -2,3-dihydro-1H-indole-5-carbon. The acid methyl ester (929 mg, 69.7%) was obtained as an off-white solid. ¹ H NMR (400 MHz, deuterated chloroform) δ 3.32 (t, J = 8.49 Hz, 2 H) 3.91 (s, 3 H) 4.08 (t, J = 8.69 Hz, 2 H)
6.67 (s, 1 H) 7.90 (d, J = 0.98 Hz, 1 H) 7.96 (dd, J = 8.49, 1.46 Hz, 1 H) 8.46 (d,
J = 8.59 Hz, 1 H) 8.65 (s, 1 H).

Preparation Example 11: 1- (6-Chloro-pyrimidin-4-yl) -2,3-dihydro-1H-indole-5-carboxylic acid

１−（６−クロロ−ピリミジン−４−イル）−２，３−ジヒドロ−１Ｈ−インドール−５−カルボン酸メチルエステル（１００ｍｇ、０．３４５ｍｍｏｌ）をテトラヒドロフラン（３ｍＬ）と水（１ｍＬ）からなる溶液に溶かした溶液に、水酸化リチウム一水和物（１６．８ｍｇ、０．３８０ｍｍｏｌ）を加えた。反応混合物を６０℃に加熱した。４時間後、反応混合物を室温に冷まし、溶液中に沈殿を生じさせた。混合物を濾過し、収集した固体を減圧下で乾燥させて、１−（６−クロロ−ピリミジン−４−イル）−２，３−ジヒドロ−１Ｈ−インドール−５−カルボン酸（６７ｍｇ、７０％）を白色の固体として得た。¹H NMR (400 MHz, 重水素化-DMSO) δ 3.24 (t, J=8.78 Hz, 2 H) 4.10 (t, J=8.69 Hz, 2 H) 7.02 (s, 1 H)
7.77 (d, J=1.17 Hz, 1 H) 7.81 (dd, J=8.49, 1.85 Hz, 1 H) 8.44 (d, J=8.59 Hz, 1
H) 8.62 (s, 1 H) 12.60 (広幅. s.,
1 H). LCMS (ES+): 276.5 m/z (M+1).

1- (6-Chloro-pyrimidin-4-yl) -2,3-dihydro-1H-indole-5-carboxylic acid methyl ester (100 mg, 0.345 mmol) in tetrahydrofuran (3 mL) and water (1 mL) To the solution dissolved in lithium hydroxide monohydrate (16.8 mg, 0.380 mmol) was added. The reaction mixture was heated to 60 ° C. After 4 hours, the reaction mixture was cooled to room temperature, causing precipitation in the solution. The mixture was filtered and the collected solid was dried under reduced pressure to give 1- (6-chloro-pyrimidin-4-yl) -2,3-dihydro-1H-indole-5-carboxylic acid (67 mg, 70%). Was obtained as a white solid. ¹ H NMR (400 MHz, deuterated-DMSO) δ 3.24 (t, J = 8.78 Hz, 2 H) 4.10 (t, J = 8.69 Hz, 2 H) 7.02 (s, 1 H)
7.77 (d, J = 1.17 Hz, 1 H) 7.81 (dd, J = 8.49, 1.85 Hz, 1 H) 8.44 (d, J = 8.59 Hz, 1
H) 8.62 (s, 1 H) 12.60 (wide.s.,
1 H). LCMS (ES +): 276.5 m / z (M + 1).

Preparation Example 12: Methyl 1- (6-chloro-5-methylpyrimidin-4-yl) indoline-5-carboxylate

４，６−ジクロロ−５−メチルピリミジン（１０１ｍｇ、０．６２ｍｍｏｌ）をｎ−プロパノール（２．０ｍＬ）に溶かした撹拌した溶液に、２，３−ジヒドロ−１Ｈ−インドール−５−カルボン酸メチルエステル（Ｂｉｏｏｒｇ．Ｍｅｄ．Ｃｈｅｍ．Ｌｅｔｔ．２００８、１８、５６８４〜８）（１００ｍｇ、０．５６ｍｍｏｌ）を加えた。得られる黄色の溶液を還流加熱（１００℃）した。還流させながら４時間経過後、反応混合物を室温に冷却し、真空中で濃縮した。残渣を、ヘプタンに対して１０〜４０％の酢酸エチルからなる勾配混合物を溶離液とするフラッシュクロマトグラフィーによって精製して、１−（６−クロロ−５−メチルピリミジン−４−イル）インドリン−５−カルボン酸メチルを白色の固体（６０ｍｇ）として得た。

To a stirred solution of 4,6-dichloro-5-methylpyrimidine (101 mg, 0.62 mmol) in n-propanol (2.0 mL) was added 2,3-dihydro-1H-indole-5-carboxylic acid methyl ester. (Bioorg. Med. Chem. Lett. 2008, 18, 5684-8) (100 mg, 0.56 mmol) was added. The resulting yellow solution was heated to reflux (100 ° C.). After 4 hours at reflux, the reaction mixture was cooled to room temperature and concentrated in vacuo. The residue was purified by flash chromatography eluting with a gradient mixture consisting of 10-40% ethyl acetate to heptane to give 1- (6-chloro-5-methylpyrimidin-4-yl) indoline-5. -Methyl carboxylate was obtained as a white solid (60 mg).

Preparation Example 13: tert-Butyl 5-[(2-hydroxyethyl) thio] indoline-1-carboxylate

５−ブロモ−２，３−ジヒドロ−インドール−１−カルボン酸ｔｅｒｔ−ブチルエステル（９３３ｍｇ、３．１３ｍｍｏｌ）、ジイソプロピルエチルアミン（１．１ｍＬ、６．２６ｍｍｏｌ）を無水１，４−ジオキサン（２０ｍＬ）に溶かした溶液を、窒素流で１０分間パージした。次いで４，５−ビス（ジフェニルホスフィノ）−９，９−ジメチルキサンテン（２０１．４ｍｇ、０．３４ｍｍｏｌ）、トリス（ジベンジリデンアセトン）ジパラジウム（１４８．４ｍｇ、０．１６２ｍｍｏｌ）、および２−メルカプトエタノール（０．２２０ｍＬ．３．１３ｍｍｏｌ）を順次加え、反応混合物を１１０℃で２４時間加熱した。反応混合物を室温に冷却し、珪藻土パッドで濾過した。次いで濾液を水（５０ｍＬ）で２回洗浄した。有機層を合わせて硫酸マグネシウムで乾燥させ、濾過し、濾液を減圧下で濃縮して、未精製の黄色の油状物を得、これをカラムクロマトグラフィーによって精製して、５−［（２−ヒドロキシエチル）チオ］インドリン−１−カルボン酸ｔｅｒｔ−ブチル（８９８ｍｇ、９７％）を濃厚な黄色の油状物として得た。¹H NMR (500 MHz, 重水素化クロロホルム) δ 1.57 (s, 9 H) 3.02 (t, 2 H) 3.08 (t, 2 H) 3.69 (br. s., 2 H) 3.96 -
4.03 (m, 2 H) 7.25 (s, 1 H) 7.26 (s, 1 H) 7.28 (s, 1 H) 7.79 (広幅 s, 1 H).

5-Bromo-2,3-dihydro-indole-1-carboxylic acid tert-butyl ester (933 mg, 3.13 mmol), diisopropylethylamine (1.1 mL, 6.26 mmol) in anhydrous 1,4-dioxane (20 mL). The dissolved solution was purged with a stream of nitrogen for 10 minutes. 4,5-bis (diphenylphosphino) -9,9-dimethylxanthene (201.4 mg, 0.34 mmol), tris (dibenzylideneacetone) dipalladium (148.4 mg, 0.162 mmol), and 2-mercapto Ethanol (0.220 mL. 3.13 mmol) was added sequentially and the reaction mixture was heated at 110 ° C. for 24 hours. The reaction mixture was cooled to room temperature and filtered through a diatomaceous earth pad. The filtrate was then washed twice with water (50 mL). The combined organic layers were dried over magnesium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give a crude yellow oil that was purified by column chromatography to give 5-[(2-hydroxy Ethyl) thio] indoline-1-carboxylate tert-butyl (898 mg, 97%) was obtained as a thick yellow oil. ¹ H NMR (500 MHz, deuterated chloroform) δ 1.57 (s, 9 H) 3.02 (t, 2 H) 3.08 (t, 2 H) 3.69 (br. S., 2 H) 3.96-
4.03 (m, 2 H) 7.25 (s, 1 H) 7.26 (s, 1 H) 7.28 (s, 1 H) 7.79 (wide s, 1 H).

Preparation Example 14: 2- (2,3-Dihydro-1H-indol-5-ylthio) ethanol

５−［（２−ヒドロキシエチル）チオ］インドリン−１−カルボン酸ｔｅｒｔ−ブチル（８９０ｍｇ、３．０１ｍｍｏｌ）の１，４−ジオキサン（８．０ｍＬ）溶液に、４Ｍの塩酸１，４−ジオキサン溶液（２．０ｍＬ）を加えた。反応液を１５分間撹拌した後、２０分間５０℃に、次いで３０分間７５℃に順次加熱した。反応液を室温に冷まし、固体を濾過して、２−（２，３−ジヒドロ−１Ｈ−インドール−５−イルチオ）エタノール（３７６ｍｇ、６４％）を淡褐色がかった橙色の固体として得た。¹H NMR (400 MHz, 重水素化メタノール) δ 3.11 (t, 2 H)
3.30 - 3.33 (m, 2 H) 3.69 (t, 2 H) 3.84 (t, 2 H) 7.38 - 7.39 (m, 2 H) 7.48 -
7.50 (m, 1 H).

To a solution of tert-butyl 5-[(2-hydroxyethyl) thio] indoline-1-carboxylate (890 mg, 3.01 mmol) in 1,4-dioxane (8.0 mL), 4M hydrochloric acid 1,4-dioxane solution (2.0 mL) was added. The reaction was stirred for 15 minutes and then heated sequentially to 50 ° C. for 20 minutes and then to 75 ° C. for 30 minutes. The reaction was cooled to room temperature and the solid was filtered to give 2- (2,3-dihydro-1H-indol-5-ylthio) ethanol (376 mg, 64%) as a light brownish orange solid. ¹ H NMR (400 MHz, deuterated methanol) δ 3.11 (t, 2 H)
3.30-3.33 (m, 2 H) 3.69 (t, 2 H) 3.84 (t, 2 H) 7.38-7.39 (m, 2 H) 7.48-
7.50 (m, 1 H).

Preparation Example 15: 5-[(2-{[tert-Butyl (dimethyl) silyl] oxy} ethyl) thio] indoline

２−（２，３−ジヒドロ−１Ｈ−インドール−５−イルチオ）エタノールのジクロロメタン（８ｍＬ）懸濁液に、トリエチルアミン（０．６ｍＬ、４．０ｍｍｏｌ）、４−ジメチルアミノピリジン（２１．８ｍｇ、０．１８ｍｍｏｌ）、および塩化ｔｅｒｔ−ブチルジメチルシリル（２４４ｍｇ、１．６２ｍｍｏｌ）を順次加えた。反応液を３時間撹拌し、減圧下で濃縮した。残渣を酢酸エチル（２０ｍＬ）で希釈した。混合物を濾過し、濾液を濃縮して、未精製の橙色の油状物を得、これをカラムクロマトグラフィーによって精製して、５−［（２−｛［ｔｅｒｔ−ブチル（ジメチル）シリル］−オキシ｝エチル）−チオ］インドリン（１４５ｍｇ．３４％）を油状物として得た。¹H NMR (400 MHz, 重水素化クロロホルム) δ 0.01 (s, 6 H) 0.85 (s, 9 H) 2.83 - 2.90 (m, 2 H) 2.99 (t, J=8.39
Hz, 2 H) 3.55 (t, J=8.49 Hz, 2 H) 3.67 - 3.75 (m, 2 H) 6.52 (d, J=8.00 Hz, 1 H)
7.10 (dd, J=8.00, 1.95 Hz, 1 H) 7.19 (d, J=1.37 Hz, 1 H).

To a suspension of 2- (2,3-dihydro-1H-indol-5-ylthio) ethanol in dichloromethane (8 mL) was added triethylamine (0.6 mL, 4.0 mmol), 4-dimethylaminopyridine (21.8 mg, 0 .18 mmol) and tert-butyldimethylsilyl chloride (244 mg, 1.62 mmol) were added sequentially. The reaction was stirred for 3 hours and concentrated under reduced pressure. The residue was diluted with ethyl acetate (20 mL). The mixture was filtered and the filtrate was concentrated to give a crude orange oil which was purified by column chromatography to give 5-[(2-{[tert-butyl (dimethyl) silyl] -oxy}. Ethyl) -thio] indoline (145 mg. 34%) was obtained as an oil. ¹ H NMR (400 MHz, deuterated chloroform) δ 0.01 (s, 6 H) 0.85 (s, 9 H) 2.83-2.90 (m, 2 H) 2.99 (t, J = 8.39
Hz, 2 H) 3.55 (t, J = 8.49 Hz, 2 H) 3.67-3.75 (m, 2 H) 6.52 (d, J = 8.00 Hz, 1 H)
7.10 (dd, J = 8.00, 1.95 Hz, 1 H) 7.19 (d, J = 1.37 Hz, 1 H).

Preparation Example 16: 2,3-Dihydro-1H-pyrrolo [3,2-b] pyridine

ステップＡ：１Ｈ−ピロロ［３，２−ｂ］ピリジン−１−カルボン酸ｔｅｒｔ−ブチル

Step A: tert-Butyl 1H-pyrrolo [3,2-b] pyridine-1-carboxylate

赤色の固体としての４−アザインドール（５０．０５ｇ、４２６ｍｍｏｌ）をテトラヒドロフラン（３８０ｍＬ）に溶解させて、濃赤色の溶液を得た。ジ−ｔｅｒｔブチルカーボネート（９５．２４ｇ、４３０ｍｍｏｌ）をテトラヒドロフラン（５０ｍＬ）に溶解させ、アザインドールの溶液に、添加漏斗で７５分かけてゆっくりと滴下した。流量は約２ｍＬ／分とした。時間をかけた滴下を用いて、二酸化炭素の発生を調節した。滴下によって、反応混合物の色がより淡く橙色の色目に変わった。混合物を室温で１６時間撹拌した後、反応液を真空中で濃縮乾燥した。橙色の残渣が凝固して、９３．８４ｇの黄褐色の固体（MS ES+:163.2[M-tBu]）が得られた。この材料をそれ以上精製せずに後続のステップで使用した。

4-Azaindole (50.05 g, 426 mmol) as a red solid was dissolved in tetrahydrofuran (380 mL) to give a dark red solution. Di-tertbutyl carbonate (95.24 g, 430 mmol) was dissolved in tetrahydrofuran (50 mL) and slowly added dropwise to the azaindole solution over 75 minutes with an addition funnel. The flow rate was about 2 mL / min. The evolution of carbon dioxide was controlled using dripping over time. Upon dropwise addition, the color of the reaction mixture changed to a lighter orange color. After the mixture was stirred at room temperature for 16 hours, the reaction was concentrated to dryness in vacuo. The orange residue solidified to give 93.84 g of a tan solid (MS ES +: 163.2 [M-tBu]). This material was used in subsequent steps without further purification.

Step B: tert-butyl 2,3-dihydro-1H-pyrrolo [3,2-b] pyridine-1-carboxylate

最小限のエタノールで湿らせた水酸化パラジウム（３．２２ｇ、約１３ｍｏｌ％のパラジウム、Ａｌｄｒｉｃｈ、３３００９４）を、窒素雰囲気中で５００ｍＬのＰａｒｒボトルに加えた。これに、固体としての未精製の１Ｈ−ピロロ［３，２−ｂ］ピリジン−１−カルボン酸ｔｅｒｔ−ブチル（１０．０ｇ）を加えた。エタノール（１６０ｍＬ）を加え、混合物を２０ｐｓｉの水素雰囲気中で振盪した。混合物を６０℃で加熱し、水素圧を５０ｐｓｉに上げた。熱い混合物を５０ｐｓｉの水素雰囲気中で３０時間振盪した後、混合物を室温に冷却し、Ｐａｌｌ ＧＨＰ膜（０．４５マイクロメートル）で濾過し、エタノールですすいだ。濾液を真空中で濃縮して、９．９５ｇの２，３−ジヒドロ−１Ｈ−ピロロ［３，２−ｂ］ピリジン−１−カルボン酸ｔｅｒｔ−ブチルを黄色の油状物として得、これをそれ以上精製せずに後続のステップで使用した。

Palladium hydroxide moistened with minimal ethanol (3.22 g, ˜13 mol% palladium, Aldrich, 330094) was added to a 500 mL Parr bottle in a nitrogen atmosphere. To this was added crude tert-butyl 1H-pyrrolo [3,2-b] pyridine-1-carboxylate (10.0 g) as a solid. Ethanol (160 mL) was added and the mixture was shaken in a 20 psi hydrogen atmosphere. The mixture was heated at 60 ° C. and the hydrogen pressure was increased to 50 psi. After the hot mixture was shaken in a 50 psi hydrogen atmosphere for 30 hours, the mixture was cooled to room temperature, filtered through a Pall GHP membrane (0.45 micrometers) and rinsed with ethanol. The filtrate was concentrated in vacuo to give 9.95 g of tert-butyl 2,3-dihydro-1H-pyrrolo [3,2-b] pyridine-1-carboxylate as a yellow oil, which was further Used in subsequent steps without purification.

Step C: 2,3-Dihydro-1H-pyrrolo [3,2-b] pyridine

２，３−ジヒドロ−１Ｈ−ピロロ［３，２−ｂ］ピリジン−１−カルボン酸ｔｅｒｔ−ブチル（９．９５ｇ）を４５ｍＬのメタノールに溶かした撹拌した溶液に、室温で塩化水素（４５．２ｍＬ、４Ｎジオキサン溶液）を加えた。混合物を１時間６０℃に加熱した。混合物を室温に冷却し、ジエチルエーテルで希釈し、固体沈殿を濾過によって収集した。収集した固体を真空中で乾燥させると、塩酸塩が黄褐色の固体として得られた。この塩１．０ｇを１０ｍＬのメタノールに溶解させた。混合物を０℃に冷却し、水酸化カリウム水溶液（０．９７ｍＬ、１１．８Ｍ、１１．４５ｍｍｏｌ、２．２当量）を加えた。塩基を加えたなら、冷浴を取り外し、反応混合物を室温で５分間撹拌した。混合物を真空中で濃縮してほぼ乾燥させた後、２０ｍＬのジクロロメタンを加えた。混合物を硫酸ナトリウムで乾燥させ、目の粗いフリットガラス漏斗で濾過し、固体をジクロロメタンですすいだ。濾液を真空中で濃縮乾燥して、２，３−ジヒドロ−１Ｈ−ピロロ［３，２−ｂ］ピリジンを橙色の油状物として得たが、放置するとこれが凝固して、０．６ｇ、９６％が得られた。¹H NMR (500 MHz, 重水素化クロロホルム) δ 3.16 (t, 2 H) 3.65 (td, J=8.66, 1.71 Hz, 2 H) 3.78 (br. s., 1 H)
6.79 - 6.84 (m, 1 H) 6.89 (dd, J=7.56, 5.37 Hz, 1 H) 7.87 (dd, J=5.00, 1.10 Hz,
1 H)

To a stirred solution of tert-butyl 2,3-dihydro-1H-pyrrolo [3,2-b] pyridine-1-carboxylate (9.95 g) in 45 mL of methanol was added hydrogen chloride (45.2 mL) at room temperature. 4N dioxane solution) was added. The mixture was heated to 60 ° C. for 1 hour. The mixture was cooled to room temperature, diluted with diethyl ether and the solid precipitate was collected by filtration. The collected solid was dried in vacuo to give the hydrochloride salt as a tan solid. 1.0 g of this salt was dissolved in 10 mL of methanol. The mixture was cooled to 0 ° C. and aqueous potassium hydroxide (0.97 mL, 11.8 M, 11.45 mmol, 2.2 eq) was added. Once the base was added, the cold bath was removed and the reaction mixture was stirred at room temperature for 5 minutes. After the mixture was concentrated to near dryness in vacuo, 20 mL of dichloromethane was added. The mixture was dried over sodium sulfate, filtered through a coarse fritted glass funnel and the solid rinsed with dichloromethane. The filtrate was concentrated to dryness in vacuo to give 2,3-dihydro-1H-pyrrolo [3,2-b] pyridine as an orange oil that solidified on standing to give 0.6 g, 96% was gotten. ¹ H NMR (500 MHz, deuterated chloroform) δ 3.16 (t, 2 H) 3.65 (td, J = 8.66, 1.71 Hz, 2 H) 3.78 (br. S., 1 H)
6.79-6.84 (m, 1 H) 6.89 (dd, J = 7.56, 5.37 Hz, 1 H) 7.87 (dd, J = 5.00, 1.10 Hz,
1 H)

Preparation Example 17: 1- (6-Chloropyrimidin-4-yl) -2,3-dihydro-1H-pyrrolo [3,2-b] pyridine

２，３−ジヒドロ−１Ｈ−ピロロ［３，２−ｂ］ピリジン（２００ｍｇ、１．６６ｍｍｏｌ）（Ｊ．Ｍｅｄ．Ｃｈｅｍ．、１９９８、４１、１５９８）と１−プロパノール（６ｍＬ）の混合物を１１０℃で加熱して、溶液を生成した。溶液を室温に冷まし、４，６−ジクロロピリミジン（２４８ｍｇ、１．６６ｍｍｏｌ）を加え、反応液を１１５℃で３時間加熱し、次いで室温に冷ました。反応液を酢酸エチルおよび水で希釈し、水相を酢酸エチルで２回抽出した。抽出物を合わせて水、次いでブラインで順次洗浄した後、硫酸ナトリウムで乾燥させた。混合物を濾過し、濾液を減圧下で濃縮して固体とし、これをカラムクロマトグラフィー（５％メタノール／０．５％トリエチルアミンのジクロロメタン溶液）によって精製して、１−（６−クロロピリミジン−４−イル）−２，３−ジヒドロ−１Ｈ−ピロロ［３，２−ｂ］ピリジン（１００ｍｇ、２６％）を泡沫として得た。¹H NMR (400 MHz, クロロホルム-d) δ 8.64 ppm (d, J=8.31 Hz, 1 H) 8.60 ppm (s, 1 H) 8.15 ppm (d, J=4.98
Hz, 1H) 7.15 ppm (d, J=8.31 Hz, 1 H) 6.62 ppm (s, 1 H) 4.04 ppm (t, 2 H) 3.42
ppm (t, 2 H). LCMS (ES+): 233 (M+1)

A mixture of 2,3-dihydro-1H-pyrrolo [3,2-b] pyridine (200 mg, 1.66 mmol) (J. Med. Chem., 1998, 41, 1598) and 1-propanol (6 mL) was added at 110 ° C. To produce a solution. The solution was cooled to room temperature, 4,6-dichloropyrimidine (248 mg, 1.66 mmol) was added and the reaction was heated at 115 ° C. for 3 hours and then cooled to room temperature. The reaction solution was diluted with ethyl acetate and water, and the aqueous phase was extracted twice with ethyl acetate. The extracts were combined, washed sequentially with water and then with brine, and then dried over sodium sulfate. The mixture was filtered and the filtrate was concentrated under reduced pressure to a solid which was purified by column chromatography (5% methanol / 0.5% triethylamine in dichloromethane) to give 1- (6-chloropyrimidine-4- Yl) -2,3-dihydro-1H-pyrrolo [3,2-b] pyridine (100 mg, 26%) was obtained as a foam. ¹ H NMR (400 MHz, chloroform-d) δ 8.64 ppm (d, J = 8.31 Hz, 1 H) 8.60 ppm (s, 1 H) 8.15 ppm (d, J = 4.98
Hz, 1H) 7.15 ppm (d, J = 8.31 Hz, 1 H) 6.62 ppm (s, 1 H) 4.04 ppm (t, 2 H) 3.42
ppm (t, 2 H). LCMS (ES +): 233 (M + 1)

Preparation Example 18: 1- (6-Chloro-5-methylpyrimidin-4-yl) -2,3-dihydro-1H-pyrrolo [3,2-b] pyridine

この化合物は、２，３−ジヒドロ−１Ｈ−ピロロ［３，２−ｂ］ピリジンと４，６−ジクロロ−５−メチルピリミジンから、調製例１７の手順と類似した手順を使用して調製した。１−（６−クロロ−５−メチルピリミジン−４−イル）−２，３−ジヒドロ−１Ｈ−ピロロ［３，２−ｂ］ピリジン（１００ｍｇ、２６％）を黄褐色の固体として単離した。¹H NMR (400 MHz, 重水素化クロロホルム) δ 8.49 (s, 1H), 8.09 (d, J=4.98 Hz, 1H), 7.21 (d, J=7.89 Hz, 1H), 7.05
(d, J=7.89 Hz, 1H), 4.20 (t, 2 H), 3.31 (t, 2 H), 2.29 (s, 3 H). LCMS (ES+):
247 (M+1).

This compound was prepared from 2,3-dihydro-1H-pyrrolo [3,2-b] pyridine and 4,6-dichloro-5-methylpyrimidine using a procedure similar to that of Preparative Example 17. 1- (6-Chloro-5-methylpyrimidin-4-yl) -2,3-dihydro-1H-pyrrolo [3,2-b] pyridine (100 mg, 26%) was isolated as a tan solid. ¹ H NMR (400 MHz, deuterated chloroform) δ 8.49 (s, 1H), 8.09 (d, J = 4.98 Hz, 1H), 7.21 (d, J = 7.89 Hz, 1H), 7.05
(d, J = 7.89 Hz, 1H), 4.20 (t, 2 H), 3.31 (t, 2 H), 2.29 (s, 3 H). LCMS (ES +):
247 (M + 1).

An alternative procedure is as follows.
2,3-dihydro-1H-pyrrolo [3,2-b] pyridine (9.05 g, 75.3 mmol) and dichloropyrimidine (12.3 g, 75.3 mmol) in tert-butanol (90 mL) and toluene (90 mL) To the solution dissolved in cesium carbonate (37.6 g) was added. The mixture was degassed with a stream of nitrogen gas. Bis (triphenylphosphine) palladium (II) dichloride (1.59 g) was added and the mixture was degassed again with nitrogen for several minutes. The resulting mixture was heated to reflux (115 ° C.) for 18 hours. The mixture was cooled to room temperature, diluted with ethyl acetate and the mixture was filtered through diatomaceous earth. The filtrate was concentrated in vacuo to an oil. This oil was dissolved in 2-methyltetrahydrofuran (400 mL), and 300 mL of 1N aqueous hydrochloric acid was added. The aqueous layer was separated and extracted twice with 2-methyltetrahydrofuran. The organic extracts were combined and washed with water. The aqueous layers were combined and cooled in an ice bath, and triethylamine was added slowly until the pH was adjusted to 8-9. Precipitates formed and the solids were collected by filtration. The aqueous filtrate was extracted twice with 2-methyltetrahydrofuran. The organic extracts were combined, washed with brine, dried over sodium sulfate, filtered, and the filtrate was concentrated in vacuo. The residue was combined with the previously collected solid, dissolved in 2-methyltetrahydrofuran and concentrated in vacuo. The residue was purified by flash chromatography using 330 g of silica gel and eluting with a gradient mixture of heptane and ethyl acetate (50-100% over 30 minutes, then 100% ethyl acetate for 30 minutes). 1- (6-Chloro-5-methylpyrimidin-4-yl) -2,3-dihydro-1H-pyrrolo [3,2-b] pyridine was obtained as an off-white solid (25.5 g). ¹ H NMR (400 MHz, deuterated chloroform) δ 2.27 (s, 3 H) 3.29 (t, J = 8.39 Hz, 2 H) 4.18 (t, J = 8.39 Hz, 2 H)
7.03 (dd, J = 8.10, 4.98 Hz, 1 H) 7.20 (dd, J = 8.10, 1.27 Hz, 1 H) 8.07 (dd, J = 5.08,
1.37 Hz, 1 H) 8.47 (s, 1 H)

Preparation Example 19 2,3-dihydro-1H-pyrrolo [2,3-b] pyridine

７−アザインドール（３．０１ｇ、２５．５ｍｍｏｌ）、ｐ−トルエンスルホン酸一水和物（４．８６ｇ、２５．５ｍｍｏｌ）、およびギ酸（９５％溶液１４ｍＬ）を３０ｍＬの１−プロパノールに溶解させた。反応混合物を撹拌しながら、予熱した１２５℃の浴に浸した。ラネーニッケル（６ｍＬの２８００活性触媒懸濁液、Ａｌｄｒｉｃｈ）を加え、混合物を１２５℃で１時間加熱し続けた。次いで混合物を２５℃に冷まし、珪藻土で濾過した。固体を１−プロパノールで洗浄して、透明な淡緑色の濾液を得た。エチレンジアミン四酢酸二ナトリウム（ＥＤＴＡ）二水和物（２．５ｇ）を濾液に溶解させた後、６Ｍ水酸化ナトリウム水溶液（５０ｍＬ）を加えた。混合物を２０分間還流加熱し、室温に冷却し、１−プロパノール相を分離し、減圧下で濃縮した。残存する塩基性の水相を５０ｍＬのメチルｔｅｒｔ−ブチルエーテルで抽出し、分離した。１−プロパノール相からの濃縮された残渣を５０ｍＬのメチルｔｅｒｔ−ブチルエーテルおよび１０ｍＬの水に溶かした。層を分離し、２つのメチルｔｅｒｔ−ブチルエーテル相を合わせ、１０ｍＬの２回分の水、１０ｍＬの１回分のブラインで洗浄し、硫酸マグネシウムで乾燥させた。混合物を濾過し、濾液を減圧下で濃縮して、白色の固体を得た。これを１０ｍＬのヘキサンから再結晶させて、２，３−ジヒドロ−１Ｈ−ピロロ［２，３−ｂ］ピリジン（１．８７ｇ、６１％）を淡い黄褐色の固体として得た。¹H NMR (400 MHz, 重水素化クロロホルム) δ 3.06 (t, J=8.4 Hz, 2 H), 3.61 (t, J=8.3 Hz, 2 H), 4.51 (広幅 s., 1 H), 6.50 (dd, J=7.0, 5.3 Hz, 1 H),
7.24 (dd, J=7.0, 1.4 Hz, 1 H), 7.82 (d, J=5.3 Hz, 1 H). LCMS (ES): 121 (M+1).

7-azaindole (3.01 g, 25.5 mmol), p-toluenesulfonic acid monohydrate (4.86 g, 25.5 mmol), and formic acid (95% solution 14 mL) were dissolved in 30 mL 1-propanol. It was. The reaction mixture was immersed in a preheated 125 ° C. bath with stirring. Raney nickel (6 mL of 2800 active catalyst suspension, Aldrich) was added and the mixture continued to heat at 125 ° C. for 1 hour. The mixture was then cooled to 25 ° C. and filtered through diatomaceous earth. The solid was washed with 1-propanol to obtain a clear light green filtrate. Ethylenediaminetetraacetic acid disodium (EDTA) dihydrate (2.5 g) was dissolved in the filtrate, and 6 M aqueous sodium hydroxide solution (50 mL) was added. The mixture was heated at reflux for 20 minutes, cooled to room temperature, the 1-propanol phase was separated and concentrated under reduced pressure. The remaining basic aqueous phase was extracted with 50 mL methyl tert-butyl ether and separated. The concentrated residue from the 1-propanol phase was dissolved in 50 mL methyl tert-butyl ether and 10 mL water. The layers were separated and the two methyl tert-butyl ether phases were combined, washed with 10 mL of 2 portions of water, 10 mL of 1 portion of brine, and dried over magnesium sulfate. The mixture was filtered and the filtrate was concentrated under reduced pressure to give a white solid. This was recrystallized from 10 mL of hexane to give 2,3-dihydro-1H-pyrrolo [2,3-b] pyridine (1.87 g, 61%) as a light tan solid. ¹ H NMR (400 MHz, deuterated chloroform) δ 3.06 (t, J = 8.4 Hz, 2 H), 3.61 (t, J = 8.3 Hz, 2 H), 4.51 (wide s., 1 H), 6.50 (dd, J = 7.0, 5.3 Hz, 1 H),
7.24 (dd, J = 7.0, 1.4 Hz, 1 H), 7.82 (d, J = 5.3 Hz, 1 H). LCMS (ES): 121 (M + 1).

Preparation Example 20: 5- (Methylthio) -2,3-dihydro-1H-pyrrolo [2,3-b] pyridine

この化合物は、２，３−ジヒドロ−１Ｈ−ピロロ［２，３−ｂ］ピリジンを出発材料として利用し、５−（メチルチオ）インドリン（ＷＯ１９９５０１９７６）と同様にして合成した。¹H NMR (500 MHz, 重水素化クロロホルム) δ 2.37 (s, 3 H), 3.06 (t, J=8.4 Hz, 2 H), 3.64 (td, J=8.4, 1.3 Hz, 2
H), 4.60 (br. s., 1 H), 7.33 (s, 1 H), 7.90 (s, 1 H). LCMS (ES+): 167 (M+1).

This compound was synthesized in the same manner as 5- (methylthio) indoline (WO199501976) using 2,3-dihydro-1H-pyrrolo [2,3-b] pyridine as a starting material. ¹ H NMR (500 MHz, deuterated chloroform) δ 2.37 (s, 3 H), 3.06 (t, J = 8.4 Hz, 2 H), 3.64 (td, J = 8.4, 1.3 Hz, 2
H), 4.60 (br. S., 1 H), 7.33 (s, 1 H), 7.90 (s, 1 H). LCMS (ES +): 167 (M + 1).

Preparation Example 21: 1- (6-Chloropyrimidin-4-yl) -5- (methylthio) -2,3-dihydro-1H-pyrrolo [2,3-b] pyridine

５−（メチルチオ）−２，３−ジヒドロ−１Ｈ−ピロロ［２，３−ｂ］ピリジン（３５６ｍｇ、２．１ｍｍｏｌ）および４，６−ジクロロピリミジン（３５４ｍｇ、２．４ｍｍｏｌ）を４ｍＬの無水１，４−ジオキサンに溶解させ、混合物を、予熱した１００℃の油浴に浸した。１Ｍのナトリウムビス（トリメチルシリル）アミドテトラヒドロフラン溶液（２．１ｍＬ）を速やかに滴下して加え、黒ずんだ混合物を速やかに生成させた。混合物を３０分間加熱し、室温に冷まし、減圧下で濃縮した。残渣を酢酸エチルと水とに分配した。有機層を分離し、水で２回、次いでブラインで順次洗浄した後、硫酸マグネシウムで乾燥させた。混合物を濾過し、濾液を減圧下で濃縮して赤色の固体を得、これをカラムクロマトグラフィー（ヘプタン−酢酸エチル勾配）によって精製して、１−（６−クロロピリミジン−４−イル）−５−（メチルチオ）−２，３−ジヒドロ−１Ｈ−ピロロ［２，３−ｂ］ピリジンをオフホワイトの固体（３６３ｍｇ、６１％）として得た。¹H NMR (400 MHz, 重水素化クロロホルム) δ 2.49 (s, 3 H), 3.18 (t, J=8.6 Hz, 2 H), 4.30 - 4.36 (m, 2 H), 7.49
(d, J=2.1 Hz, 1 H), 8.15 (d, J=2.1 Hz, 1 H), 8.61 (d, J=0.8 Hz, 1 H), 8.80 (d,
J=1.0 Hz, 1 H). LCMS (ES+): 279 (M+1).

5- (Methylthio) -2,3-dihydro-1H-pyrrolo [2,3-b] pyridine (356 mg, 2.1 mmol) and 4,6-dichloropyrimidine (354 mg, 2.4 mmol) in 4 mL of anhydrous 1, Dissolved in 4-dioxane and the mixture was immersed in a preheated 100 ° C. oil bath. A 1M sodium bis (trimethylsilyl) amide tetrahydrofuran solution (2.1 mL) was quickly added dropwise to quickly form a dark mixture. The mixture was heated for 30 minutes, cooled to room temperature and concentrated under reduced pressure. The residue was partitioned between ethyl acetate and water. The organic layer was separated, washed sequentially with water twice, then with brine, and then dried over magnesium sulfate. The mixture was filtered and the filtrate was concentrated under reduced pressure to give a red solid, which was purified by column chromatography (heptane-ethyl acetate gradient) to give 1- (6-chloropyrimidin-4-yl) -5. -(Methylthio) -2,3-dihydro-1H-pyrrolo [2,3-b] pyridine was obtained as an off-white solid (363 mg, 61%). ¹ H NMR (400 MHz, deuterated chloroform) δ 2.49 (s, 3 H), 3.18 (t, J = 8.6 Hz, 2 H), 4.30-4.36 (m, 2 H), 7.49
(d, J = 2.1 Hz, 1 H), 8.15 (d, J = 2.1 Hz, 1 H), 8.61 (d, J = 0.8 Hz, 1 H), 8.80 (d,
J = 1.0 Hz, 1 H). LCMS (ES +): 279 (M + 1).

Preparation Example 22: 1- (6-Chloropyrimidin-4-yl) -5- (methylsulfonyl) -2,3-dihydro-1H-pyrrolo [2,3-b] pyridine

３−クロロ過安息香酸（７０％、８５１ｍｇ、３．５ｍｍｏｌ）を４ｍＬのクロロホルムに溶解させ、分離した水を除去した。有機溶液を、１−（６−クロロピリミジン−４−イル）−５−（メチルチオ）−２，３−ジヒドロ−１Ｈ−ピロロ［２，３−ｂ］ピリジン（３６３ｍｇ、１．３ｍｍｏｌ）を８ｍＬのクロロホルムに溶かした撹拌状態の溶液に１回で加えた。１時間後、ジメチルスルフィドを加えて、反応液中の過剰の３−クロロ過安息香酸を失活させた。混合物を５分間撹拌し、次いで０．５Ｍ水酸化ナトリウム（２０ｍＬ）で洗浄した。クロロホルム層を分離し、水で再び洗浄し、硫酸マグネシウムで乾燥させた。混合物を濾過し、濾液を減圧下で濃縮して、１−（６−クロロピリミジン−４−イル）−５−（メチルスルホニル）−２，３−ジヒドロ−１Ｈ−ピロロ［２，３−ｂ］ピリジン（３６６ｍｇ、９０％）を白色の粉末として得た。¹H NMR (400 MHz, 重水素化クロロホルム): 3.11 (s, 3 H), 3.29 (t, J=8.6
Hz, 2 H), 4.40 - 4.49 (m, 2 H), 7.92 (d, J=2.1 Hz, 1 H), 8.70 (d, J=1.0 Hz, 1
H), 8.75 (d, J=2.1 Hz, 1 H), 8.86 (d, J=0.8 Hz, 1 H). LCMS (ES+): 311 (M+1).

3-chloroperbenzoic acid (70%, 851 mg, 3.5 mmol) was dissolved in 4 mL of chloroform and the separated water was removed. The organic solution was mixed with 1- (6-chloropyrimidin-4-yl) -5- (methylthio) -2,3-dihydro-1H-pyrrolo [2,3-b] pyridine (363 mg, 1.3 mmol) in 8 mL. It was added once to a stirred solution in chloroform. After 1 hour, dimethyl sulfide was added to inactivate excess 3-chloroperbenzoic acid in the reaction solution. The mixture was stirred for 5 minutes and then washed with 0.5M sodium hydroxide (20 mL). The chloroform layer was separated, washed again with water and dried over magnesium sulfate. The mixture was filtered and the filtrate was concentrated under reduced pressure to give 1- (6-chloropyrimidin-4-yl) -5- (methylsulfonyl) -2,3-dihydro-1H-pyrrolo [2,3-b]. Pyridine (366 mg, 90%) was obtained as a white powder. ¹ H NMR (400 MHz, deuterated chloroform): 3.11 (s, 3 H), 3.29 (t, J = 8.6
Hz, 2 H), 4.40-4.49 (m, 2 H), 7.92 (d, J = 2.1 Hz, 1 H), 8.70 (d, J = 1.0 Hz, 1
H), 8.75 (d, J = 2.1 Hz, 1 H), 8.86 (d, J = 0.8 Hz, 1 H). LCMS (ES +): 311 (M + 1).

Preparation Example 23: Isomer (4 and 5) of tert-butyl 3-fluoro-4-hydroxypiperidine-1-carboxylate. Details of the experiment are detailed in Scheme B below.

Step A. 4-[(Trimethylsilyl) oxy] -3,6-dihydropyridine-1 (2H) -carboxylate tert-butyl (2)

Ｎ−ｔｅｒｔ−ブトキシカルボニル−４−ピペリドン（３０．０ｇ、０．１５ｍｏｌ）を無水Ｎ，Ｎ−ジメチルホルムアミド（３００ｍＬ）に溶かした室温の溶液に、塩化トリメチルシリル（２２．９ｍＬ、０．１８ｍｏｌ）およびトリエチルアミン（５０．４ｍＬ、０．３６ｍｏｌ）を添加漏斗で連続的に加えた。得られる溶液を８０℃で終夜加熱し、次いで室温に冷却した。反応混合物を水およびヘプタンで希釈した。層を分離し、水層をヘプタンで抽出した。ヘプタン層を合わせて水およびブラインで順次洗浄し、次いで硫酸マグネシウムで乾燥させた。混合物を濾過し、濾液を減圧下で濃縮して、粗生成物を黄色の油状物として得た。油状物を９０：１０のヘプタン／酢酸エチルの溶液としてシリカゲル充填物に通すことにより精製して、表題化合物を無色の油状物（３３．６ｇ、８２％）として得た。¹H NMR (400 MHz, 重水素化クロロホルム) δ 4.78 (br s, 1H), 3.86 (br s, 2 H), 3.51 (t, 2 H), 2.09 (br s, 2 H),
1.45 (s, 9 H), 0.18 (s, 9 H).

To a room temperature solution of N-tert-butoxycarbonyl-4-piperidone (30.0 g, 0.15 mol) in anhydrous N, N-dimethylformamide (300 mL) was added trimethylsilyl chloride (22.9 mL, 0.18 mol) and Triethylamine (50.4 mL, 0.36 mol) was added continuously with an addition funnel. The resulting solution was heated at 80 ° C. overnight and then cooled to room temperature. The reaction mixture was diluted with water and heptane. The layers were separated and the aqueous layer was extracted with heptane. The heptane layers were combined and washed sequentially with water and brine and then dried over magnesium sulfate. The mixture was filtered and the filtrate was concentrated under reduced pressure to give the crude product as a yellow oil. The oil was purified by passing through a plug of silica gel as a 90:10 heptane / ethyl acetate solution to give the title compound as a colorless oil (33.6 g, 82%). ¹ H NMR (400 MHz, deuterated chloroform) δ 4.78 (br s, 1H), 3.86 (br s, 2 H), 3.51 (t, 2 H), 2.09 (br s, 2 H),
1.45 (s, 9 H), 0.18 (s, 9 H).

Step B. Tert-Butyl 3-fluoro-4-oxopiperidine-1-carboxylate (3)

４−［（トリメチルシリル）オキシ］−３，６−ジヒドロピリジン−１（２Ｈ）−カルボン酸ｔｅｒｔ−ブチル（２８．８ｇ、０．１１ｍｏｌ）をアセトニトリル（３００ｍＬ）に溶かした室温の撹拌した溶液に、Ｓｅｌｅｃｔｆｌｕｏｒ（商標）（４１．４ｇ、０．１２ｍｏｌ）を加えた。得られる淡黄色の懸濁液を室温で１．５時間撹拌した。飽和炭酸水素ナトリウム水溶液（３００ｍＬ）および酢酸エチル（３００ｍＬ）を加え、層を分離した。水層を酢酸エチルで２回抽出し、すべての有機層を合わせ、飽和炭酸水素ナトリウム水溶液およびブラインで順次洗浄し、次いで硫酸マグネシウムで乾燥させた。混合物を濾過し、濾液を減圧下で濃縮して、粗生成物を淡黄色の油状物として得た。この材料を、ヘプタン／酢酸エチルの勾配（２：１〜１：１）をかけたシリカゲルでのカラムクロマトグラフィーに繰り返しかけて精製すると、表題化合物が白色の固体（１５．５ｇ、６７％）として得られた。¹H NMR (400 MHz, 重水素化クロロホルム): δ 4.88 (dd, 0.5 H), 4.77 (dd, 0.5 H), 4.47 (br s, 1H), 4.17 (ddd,
1H), 3.25 (br s, 1H), 3.23 (ddd, 1H), 2.58 (m, 1H), 2.51 (m, 1H), 1.49 (s, 9
H).

To a stirred solution at room temperature of tert-butyl 4-[(trimethylsilyl) oxy] -3,6-dihydropyridine-1 (2H) -carboxylate (28.8 g, 0.11 mol) in acetonitrile (300 mL) was added SelectFluor. (Trademark) (41.4 g, 0.12 mol) was added. The resulting pale yellow suspension was stirred at room temperature for 1.5 hours. Saturated aqueous sodium bicarbonate (300 mL) and ethyl acetate (300 mL) were added and the layers were separated. The aqueous layer was extracted twice with ethyl acetate and all organic layers were combined, washed sequentially with saturated aqueous sodium bicarbonate and brine, then dried over magnesium sulfate. The mixture was filtered and the filtrate was concentrated under reduced pressure to give the crude product as a pale yellow oil. This material was purified by repeated column chromatography on silica gel with a heptane / ethyl acetate gradient (2: 1 to 1: 1) to give the title compound as a white solid (15.5 g, 67%). Obtained. ¹ H NMR (400 MHz, deuterated chloroform): δ 4.88 (dd, 0.5 H), 4.77 (dd, 0.5 H), 4.47 (br s, 1H), 4.17 (ddd,
1H), 3.25 (br s, 1H), 3.23 (ddd, 1H), 2.58 (m, 1H), 2.51 (m, 1H), 1.49 (s, 9
H).

Step B was performed by isolating the ketone hydrate as follows.
To a stirred solution at room temperature of tert-butyl 4-[(trimethylsilyl) oxy] -3,6-dihydropyridine-1 (2H) -carboxylate (41.3 g, 0.15 mol) in acetonitrile (500 mL) was added SelectFluor. (Trademark) (56.9 g, 0.16 mol) was added. The resulting pale yellow suspension was stirred at room temperature for 4 hours and 10 minutes. Saturated aqueous sodium bicarbonate and ethyl acetate were added and the layers were separated. The aqueous layer was extracted twice with ethyl acetate and all organic layers were combined, washed sequentially with saturated aqueous sodium bicarbonate and brine, then dried over magnesium sulfate. The mixture was filtered and the filtrate was concentrated under reduced pressure to give tert-butyl crude 3-fluoro-4-oxopiperidine-1-carboxylate as a white solid. Crude tert-butyl 3-fluoro-4-oxopiperidine-1-carboxylate was suspended in tetrahydrofuran (120 mL), and water (120 mL) was added. The resulting solution was stirred at room temperature for 5.5 hours and then concentrated under reduced pressure. The residue was dried in high vacuum, transferred to an Erlenmeyer flask and suspended in dichloromethane (250 mL). The resulting suspension was stirred for 5 minutes and the solid was collected by filtration using a sintered glass funnel. The resulting filter cake was washed thoroughly with dichloromethane (200 mL), a 1: 1 mixture of dichloromethane (200 mL) and heptane (100 mL). The solid was then dried in high vacuum to give tert-butyl 3-fluoro-4,4-dihydroxypiperidine-1-carboxylate (26.4 g). ¹ H NMR (500 MHz, deuterated dimethyl sulfoxide) δ 1.38 (s, 9 H), 1.49-1.52 (m, 1H), 1.63-1.68 (m, 1 H), 2.82 -3.20
(m, 2 H) 3.75 (br, 1 H), 3.97 (br, 1 H), 4.12 (d, J = 45, 1 H), 5.92 (s, 1 H),
5.97 (s, 1 H).

Step C. (R ^* )-3- (S) -Fluoro-4- (R) -hydroxypiperidine-1-carboxylate tert-butyl isomers (4 and 5) (racemate)

３−フルオロ−４−オキソピペリジン−１−カルボン酸ｔｅｒｔ−ブチル（１５．５ｇ、７１．３ｍｍｏｌ）をメタノール（１５０ｍＬ）に溶かした０℃の溶液に、水素化ホウ素ナトリウム（３．５１ｇ、９３．７ｍｍｏｌ）を加えた。得られる混合物を０℃で２時間撹拌し、次いで室温に温めた。飽和塩化アンモニウム水溶液（２００ｍＬ）を加え、混合物を酢酸エチルで３回抽出した。抽出物を合わせてブラインで洗浄し、硫酸マグネシウムで乾燥させた。混合物を濾過し、濾液を減圧下で濃縮して粗生成物の混合物を得、これを、ヘプタン−酢酸エチル（３：２〜１：１）を溶離液とするシリカゲルでのカラムクロマトグラフィーによって精製して、第一の溶出生成物である（３，４−トランス）−３−フルオロ−４−ヒドロキシピペリジン−１−カルボン酸ｔｅｒｔ−ブチル（３．８１ｇ、２４％）を淡黄色の油状物として得たが、油状物は静置すると白色の固体に凝固した。¹H NMR (400 MHz, 重水素化クロロホルム) δ 4.35 (ddd, 0.5 H), 4.18 (ddd, 0.5 H), 4.15 (br s, 1H), 3.89-3.74
(m, 2 H), 2.97 (br s, 1H), 2.93 (ddd, 1H), 2.47 (s, 1H), 2.05-1.92 (m, 1H),
1.58-1.46 (m, 1H), 1.44 (s, 9 H).

To a solution of tert-butyl 3-fluoro-4-oxopiperidine-1-carboxylate (15.5 g, 71.3 mmol) in methanol (150 mL) at 0 ° C. was added sodium borohydride (3.51 g, 93. 7 mmol) was added. The resulting mixture was stirred at 0 ° C. for 2 hours and then warmed to room temperature. Saturated aqueous ammonium chloride solution (200 mL) was added and the mixture was extracted three times with ethyl acetate. The extracts were combined, washed with brine and dried over magnesium sulfate. The mixture is filtered and the filtrate is concentrated under reduced pressure to give a crude product mixture which is purified by column chromatography on silica gel eluting with heptane-ethyl acetate (3: 2 to 1: 1). The first elution product, tert-butyl (3,4-trans) -3-fluoro-4-hydroxypiperidine-1-carboxylate (3.81 g, 24%) as a pale yellow oil Obtained but the oil solidified to a white solid upon standing. ¹ H NMR (400 MHz, deuterated chloroform) δ 4.35 (ddd, 0.5 H), 4.18 (ddd, 0.5 H), 4.15 (br s, 1H), 3.89-3.74
(m, 2 H), 2.97 (br s, 1H), 2.93 (ddd, 1H), 2.47 (s, 1H), 2.05-1.92 (m, 1H),
1.58-1.46 (m, 1H), 1.44 (s, 9 H).

The second eluting compound, tert-butyl (3,4-cis) -3-fluoro-4-hydroxy-piperidine-1-carboxylate (10.57 g, 68%) was then isolated as a white solid. . ¹ H NMR (400 MHz, deuterated chloroform) δ 4.69-4.65 (m, 0.5 H), 4.53-4.49 (m, 0.5 H), 3.92-3.86 (m, 2 H),
3.69 (br s, 1H), 3.39 (br s, 1H), 3.16 (br s, 1H), 2.13 (s, 1H), 1.88-1.73
(m, 2 H), 1.44 (s, 9 H).

  Step C was also carried out starting from the hydrate 3-fluoro-4,4-dihydroxypiperidine-1-carboxylate tert-butyl as follows.

  To a stirred solution at −35 ° C. of tert-butyl 3-fluoro-4,4-dihydroxypiperidine-1-carboxylate (20.0 g, 85 mmol) in tetrahydrofuran (500 mL) was added a tetrahydrofuran solution of L-selectride (170 mL). 1M, 170 mmol) was added dropwise over 30 minutes. The reaction mixture was warmed to 0 ° C. over 1.5 hours. The reaction mixture was quenched with saturated aqueous ammonium chloride (150 mL) and stirred vigorously for 15 minutes. After adding a pH 7 phosphate buffer solution (150 mL) to the 0 ° C. mixture, 35% aqueous hydrogen peroxide solution (150 mL) was added dropwise. The resulting mixture was stirred for 30 minutes and diluted with ethyl acetate. The organic layer was separated and washed sequentially with water, saturated aqueous sodium thiosulfate, and brine. The organic layer is then dried over anhydrous magnesium sulfate, filtered, and the filtrate is concentrated under reduced pressure to give a crude product mixture that is silica gel eluting with heptane-ethyl acetate (10-60% gradient). Purification by column chromatography on [combiflash ISCO 330 g column] gave tert-butyl (3,4-cis) -3-fluoro-4-hydroxypiperidine-1-carboxylate (13.9 g).

Step D. Enantiomer of tert-butyl (3,4-cis) -3-fluoro-4-hydroxy-piperidine-1-carboxylate Racemic (3,4-cis) -3-fluoro-4-hydroxy-piperidine- A 1 gram sample of tert-butyl 1-carboxylate was fractionated using a Chiralpak AD-H column (10 × 250 mm) with 90:10 carbon dioxide and ethanol as mobile phases and a flow rate of 10 mL / min, respectively. Purified to its enantiomer by high pressure liquid chromatography. The wavelength for monitoring separation was 210 nm. The purity analysis value of each enantiomer was a Chiralpak AD-H (4.6 mm × 25 cm) column using a constant composition mobile phase consisting of 90:10 carbon dioxide and ethanol, respectively, and a flow rate of 2.5 mL / min. Determined using the analytical high performance chromatography used. The wavelength for monitoring the peak was 210 nm. The following two isomers were obtained.
Tert-Butyl (3S, 4R) -3-fluoro-4-hydroxypiperidine-1-carboxylate, enantiomer 1 (363 mg): R _t = 2.67 min (100% ee) (rotation in dichloromethane = + 21.2 °)

（３Ｒ，４Ｓ）−３−フルオロ−４−ヒドロキシピペリジン−１−カルボン酸ｔｅｒｔ−ブチル、鏡像異性体２（４０３ｍｇ）：Ｒ_ｔ＝２．９９分（８８％ｅｅ）

Tert-Butyl (3R, 4S) -3-fluoro-4-hydroxypiperidine-1-carboxylate, enantiomer 2 (403 mg): R _t = 2.99 min (88% ee)

  The absolute stereochemistry of the tert-butyl isomer of (3,4-cis) -3-fluoro-4-hydroxy-piperidine-1-carboxylic acid was determined using 5- (6- ( (3S, 4R) -3-fluoropiperidin-4-yloxy) -5-methylpyrimidin-4-yl) -1-methyl-1,4,5,6-tetrahydropyrrolo [3,4-c] pyrazole ( 1S)-(+)-camphor camphorsulfonate (determined by analogy with preparation in racemic form below).

5- (6-{[(3,4-cis) -3-fluoropiperidin-4-yl] oxy} -5-methylpyrimidin-4-yl) -1-methyl-1,4,5,6-tetrahydro Preparation of pyrrolo [3,4-c] pyrazole (racemate) a. Preparation of 5- (6-chloro-5-methylpyrimidin-4-yl) -1-methyl-1,4,5,6-tetrahydropyrrolo [3,4-c] pyrazole

１−メチル−１，４，５，６−テトラヒドロピロロ［３，４−ｃ］ピラゾール二塩酸塩（２．００ｇ、１０．２ｍｍｏｌ）および４，６−ジクロロ−５−メチルピリミジン（１．６６ｇ、１０．２ｍｍｏｌ）を室温でテトラヒドロフラン（５１ｍＬ）に懸濁させた。これにトリエチルアミン（４．４１ｍＬ、３１．６ｍｍｏｌ）を加えると、混合物が濁り、フラスコの壁面に褐色の固体が固着した。この混合物を室温で４時間撹拌し、次いでさらに１９時間５０℃に加熱した。反応混合物を室温に冷却し、水（１００ｍＬ）で希釈した。この混合物を酢酸エチル（３×１００ｍＬ）で抽出した。有機抽出物をプールし、ブラインで洗浄し、硫酸ナトリウムで乾燥させ、濾過した。真空中で濾液を乾燥状態まで減少させて、表題化合物を淡褐色の固体（１．９５ｇ、７８％）として得、これをそれ以上精製せずに次のステップで使用した。¹H NMR (500 MHz, 重水素化クロロホルム) δ 2.54 (s, 3 H) 3.88 (s, 3 H) 4.90 (見かけd, J=3.66 Hz, 4 H) 7.28 (s, 1 H) 8.29 (s, 1 H).

1-methyl-1,4,5,6-tetrahydropyrrolo [3,4-c] pyrazole dihydrochloride (2.00 g, 10.2 mmol) and 4,6-dichloro-5-methylpyrimidine (1.66 g, 10.2 mmol) was suspended in tetrahydrofuran (51 mL) at room temperature. When triethylamine (4.41 mL, 31.6 mmol) was added thereto, the mixture became cloudy, and a brown solid adhered to the wall of the flask. The mixture was stirred at room temperature for 4 hours and then heated to 50 ° C. for an additional 19 hours. The reaction mixture was cooled to room temperature and diluted with water (100 mL). This mixture was extracted with ethyl acetate (3 × 100 mL). The organic extracts were pooled, washed with brine, dried over sodium sulfate and filtered. The filtrate was reduced to dryness in vacuo to give the title compound as a light brown solid (1.95 g, 78%), which was used in the next step without further purification. ¹ H NMR (500 MHz, deuterated chloroform) δ 2.54 (s, 3 H) 3.88 (s, 3 H) 4.90 (apparent d, J = 3.66 Hz, 4 H) 7.28 (s, 1 H) 8.29 (s , 1 H).

b. (3,4-cis) -3-fluoro-4-{[5-methyl-6- (1-methyl-4,6-dihydropyrrolo [3,4-c] pyrazol-5 (1H) -yl) pyrimidine Preparation of tert-butyl (racemate) of -4-yl] oxy} piperidine-1-carboxylate

（３，４−シス）−３−フルオロ−４−ヒドロキシピペリジン−１−カルボン酸ｔｅｒｔ−ブチル（１．６７ｇ、７．６２ｍｍｏｌ）と上で調製した５−（６−クロロ−５−メチルピリミジン−４−イル）−１−メチル−１，４，５，６−テトラヒドロピロロ［３，４−ｃ］ピラゾール（９００ｍｇ、３．６０ｍｍｏｌ）の混合物を１，４−ジオキサン（２０ｍＬ）に溶解させ、１０５℃に加熱した。１０分間加熱した後、すべての材料が溶液になり、ナトリウムビス（トリメチルシリル）アミド（４．３ｍＬ、４．３ｍｍｏｌ、１Ｍトルエン溶液）を混合物に速やかに加えると、濁った黄色の混合物が得られ、次いでこれを１０５℃で２時間撹拌した。次いで反応液を室温に冷却し、水と飽和炭酸水素ナトリウム水溶液の等体積混合物を加えて失活させた。混合物を酢酸エチル（３×１５ｍＬ）で抽出した。有機抽出物を合わせてブラインで洗浄し、硫酸ナトリウムで乾燥させ、濾過した。濾液を真空中で濃縮して黄色の残渣を得、これを、６０〜１００％の酢酸エチルヘプタン溶液を溶離液とするシリカゲルでのカラムクロマトグラフィーによって精製した。表題化合物と出発材料の５−（６−クロロ−５−メチルピリミジン−４−イル）−１−メチル−１，４，５，６−テトラヒドロピロロ［３，４−ｃ］ピラゾールの混合物を白色の固体（１．２０ｇ）として単離し、それ以上精製せずに後続の反応で使用した。

Tert-Butyl (3,4-cis) -3-fluoro-4-hydroxypiperidine-1-carboxylate (1.67 g, 7.62 mmol) and 5- (6-chloro-5-methylpyrimidine- prepared above 4-yl) -1-methyl-1,4,5,6-tetrahydropyrrolo [3,4-c] pyrazole (900 mg, 3.60 mmol) was dissolved in 1,4-dioxane (20 mL) and 105 Heated to ° C. After heating for 10 minutes, all the material goes into solution and sodium bis (trimethylsilyl) amide (4.3 mL, 4.3 mmol, 1 M toluene solution) is quickly added to the mixture to give a cloudy yellow mixture, This was then stirred at 105 ° C. for 2 hours. The reaction was then cooled to room temperature and quenched by the addition of an equal volume mixture of water and saturated aqueous sodium bicarbonate. The mixture was extracted with ethyl acetate (3 × 15 mL). The combined organic extracts were washed with brine, dried over sodium sulfate and filtered. The filtrate was concentrated in vacuo to give a yellow residue which was purified by column chromatography on silica gel eluting with 60-100% ethyl acetate heptane solution. A mixture of the title compound and the starting material 5- (6-chloro-5-methylpyrimidin-4-yl) -1-methyl-1,4,5,6-tetrahydropyrrolo [3,4-c] pyrazole Isolated as a solid (1.20 g) and used in subsequent reactions without further purification.

One batch of crude (3,4-cis) -3-fluoro-4-{[5-methyl-6- (1-methyl-4,6-dihydropyrrolo [ Tert-Butyl 3,4-c] pyrazol-5 (1H) -yl) pyrimidin-4-yl] oxy} piperidine-1-carboxylate was purified by HPLC. A crude sample (9.5 mg) was dissolved in dimethyl sulfoxide (1 mL) and 80% water / acetonitrile (0.03%) by preparative reverse phase HPLC on a Waters XBridge C ₁₈ 19 × 100 mm, 0.005 mm column. Purification with a linear gradient from 8.5% ammonium hydroxide modifier to 0% water / acetonitrile in 8.5 minutes followed by elution with 0% water / acetonitrile for 1.5 minutes at a flow rate of 25 mL / min. did. There was thus obtained the title compound (5 mg). Analytical LCMS: Retention time 2.81 minutes (Waters XBridge C ₁₈ 4.6 × 50 mm, 0.005 mm column, linear gradient from 90% water / acetonitrile to 5% water / acetonitrile over 4.0 minutes, followed by 5% water / acetonitrile for 1 minute, 0.03% ammonium hydroxide modifier, flow rate: 2.0 mL / min), LCMS (ES +) 433.2 (M + 1).

c. 5- (6-{[(3,4-cis) -3-fluoropiperidin-4-yl] oxy} -5-methylpyrimidin-4-yl) -1-methyl-1,4,5,6-tetrahydro Pyrrolo [3,4-c] pyrazole (racemic)

上で調整した未精製の（３，４−シス）−３−フルオロ−４−｛［５−メチル−６−（１−メチル−４，６−ジヒドロピロロ［３，４−ｃ］ピラゾール−５（１Ｈ）−イル）ピリミジン−４−イル］オキシ｝ピペリジン−１−カルボン酸ｔｅｒｔ−ブチル（１．２０ｇ）をジクロロメタン（１２ｍＬ）に溶解させ、この溶液にトリフルオロ酢酸（５ｍＬ）を加えた。反応液を室温で１時間撹拌した。真空中で溶媒を除去し、残渣を水（５０ｍＬ）および１Ｎ塩酸水溶液（１０ｍＬ）に溶解させた。混合物をジクロロメタン（１０×３０ｍＬ）で抽出した。次いで１Ｎ水酸化ナトリウム水溶液（２０ｍＬ）を加えて水層がｐＨ１２になるようにし、ジクロロメタン（４０ｍＬ）で３回抽出した。有機抽出物を合わせてブラインで洗浄し、硫酸ナトリウムで乾燥させ、濾過した。濾液を減圧下で濃縮して、５−（６−｛［（３，４−シス）−３−フルオロピペリジン−４−イル］オキシ｝−５−メチルピリミジン−４−イル）−１−メチル−１，４，５，６−テトラヒドロピロロ［３，４−ｃ］ピラゾール（０．７２ｇ、２ステップで６０％）を白色の固体として得、これをさらに精製することなく使用した。
¹H NMR (500 MHz, 重水素化クロロホルム) δ 1.84 - 2.08 (m,
2 H) 2.33 (s, 3 H) 2.69 - 2.84 (m, 1 H) 2.83 - 3.01 (m, 1 H) 3.16 (d, J=13.66
Hz, 1 H) 3.27 - 3.44 (m, 1 H) 3.86 (s, 3 H) 4.78-4.91 (m, 1 H) 4.86 (d, J=1.95
Hz, 2 H) 4.88 (d, J=1.95 Hz, 2 H) 5.21 - 5.32 (m, 1 H) 7.26 (s, 1 H) 8.18 (s, 1
H); LCMS (ES+) 333.4 (M+1).

Crude (3,4-cis) -3-fluoro-4-{[5-methyl-6- (1-methyl-4,6-dihydropyrrolo [3,4-c] pyrazole-5 prepared as above. (1H) -yl) pyrimidin-4-yl] oxy} piperidine-1-carboxylate tert-butyl (1.20 g) was dissolved in dichloromethane (12 mL) and trifluoroacetic acid (5 mL) was added to this solution. The reaction was stirred at room temperature for 1 hour. The solvent was removed in vacuo and the residue was dissolved in water (50 mL) and 1N aqueous hydrochloric acid (10 mL). The mixture was extracted with dichloromethane (10 × 30 mL). Then, 1N aqueous sodium hydroxide solution (20 mL) was added to adjust the aqueous layer to pH 12, and the mixture was extracted 3 times with dichloromethane (40 mL). The combined organic extracts were washed with brine, dried over sodium sulfate and filtered. The filtrate was concentrated under reduced pressure to give 5- (6-{[(3,4-cis) -3-fluoropiperidin-4-yl] oxy} -5-methylpyrimidin-4-yl) -1-methyl- 1,4,5,6-tetrahydropyrrolo [3,4-c] pyrazole (0.72 g, 60% over 2 steps) was obtained as a white solid, which was used without further purification.
¹ H NMR (500 MHz, deuterated chloroform) δ 1.84-2.08 (m,
2 H) 2.33 (s, 3 H) 2.69-2.84 (m, 1 H) 2.83-3.01 (m, 1 H) 3.16 (d, J = 13.66
Hz, 1 H) 3.27-3.44 (m, 1 H) 3.86 (s, 3 H) 4.78-4.91 (m, 1 H) 4.86 (d, J = 1.95
Hz, 2 H) 4.88 (d, J = 1.95 Hz, 2 H) 5.21-5.32 (m, 1 H) 7.26 (s, 1 H) 8.18 (s, 1
H); LCMS (ES +) 333.4 (M + 1).

Racemic tert-butyl (3,4-cis) -3-fluoro-4-hydroxy-piperidine-1-carboxylate was also prepared as follows.
To the Biotage Atlantis reactor was added 3-fluoropyridin-4-ol (2.0 g, 17.7 mmol), hexamethyldisilazane (3.7 mL, 17.7 mmol), and 20 mL of tetrahydrofuran. The reactor was purged with nitrogen gas (4x), pressurized to 50 psi and then vented. The mixture was stirred at 1000 rpm while heating to 80 ° C. After heating the mixture at 80 ° C. for 1 hour, the mixture was cooled to room temperature. Di-tert-butyl dicarbonate (7.7 g, 35.4 mmol) and ruthenium (400 mg, 5% on carbon, 198 micromol, JM UK-35) were added. The reactor was purged with nitrogen gas (4x) followed by hydrogen gas (4x). The mixture was heated to 105 ° C. and pressurized with hydrogen gas to 200 psi for 24 hours. The mixture was cooled to 30 ° C. and purged with nitrogen gas (4 ×). The mixture was filtered and washed with tetrahydrofuran. The filtrate was subjected to GCMS analysis and showed 89% tert-butyl 3-fluoro-4-hydroxypiperidine-1-carboxylate.

Preparation Example 24: 1-methylcyclopropyl carbonate 4-nitrophenyl carbonate

ステップＡ）１−メチルシクロプロパノール
１Ｌのフラスコに、チタンメトキシド（１００ｇ）、シクロヘキサノール（２３２ｇ）、およびトルエン（４６１ｍＬ）を投入した。フラスコにＤｅａｎ−Ｓｔａｒｋトラップおよび冷却器を備え付けた。メタノールが除去されるまで混合物を１４０℃で加熱した。１８０℃でトルエンを除去した。トルエンをさらに加え、この過程を２回繰り返した。すべてのトルエンを除去した後、フラスコを高真空中で乾燥させた。フラスコにジエチルエーテル（５８０ｍＬ）を加えて、１Ｍジエチルエーテル溶液を調製した。５Ｌの３口フラスコにオーバーヘッド撹拌子、不活性ガス導入口、および均圧添加漏斗を備え付けた。フラスコを窒素ガスでフラッシュし、酢酸メチル（６０．１ｍＬ、７５６ｍｍｏｌ）、チタンシクロヘキシルオキシド（１Ｍエーテル溶液７５．６ｍＬ）、およびジエチルエーテル（１５００ｍＬ）を投入した。反応フラスコを室温の水浴に浸した状態で溶液を撹拌した。添加漏斗に３Ｍの臭化エチルマグネシウム溶液（５５４ｍＬ、１．６６モル）を投入した。グリニャール試薬を室温で３時間かけて滴下した。混合物が淡黄色の溶液になり、次いで徐々に沈殿が生成し、最終的に濃い緑色／褐色／黒色の混合物に変わった。さらに１５分撹拌した後、グリニャールを加えたのに続き、混合物を、１０％濃硫酸を１Ｌの水に混ぜた混合物中に慎重に注いだ。得られる混合物を、すべての固体が溶解するまで撹拌した。水層を分離し、ジエチルエーテル２×５００ｍＬで抽出した。有機抽出物を合わせて水、ブラインで順次洗浄し、炭酸カリウム（５００ｇ）で３０分間乾燥させ、濾過し、濾液を真空中で濃縮して油状物とした。炭酸水素ナトリウム（２００ｍｇ）を加え、未精製材料を蒸留し、１００℃付近で沸騰する画分を収集して、少量の不純物としてメチルエチルケトンおよび２−ブタノールを伴う表題化合物（２３グラム）を得た。¹H NMR (500 MHz, 重水素化クロロホルム) δ 0.45 (見かけt, J=6.59
Hz, 2 H), 0.77 (見かけt, J=5.61
Hz, 2 H), 1.46 (s, 3 H).表題化合物の調製は、ＷＯ０９１０５７１７にも記載されている。

Step A) 1-Methylcyclopropanol A 1 L flask was charged with titanium methoxide (100 g), cyclohexanol (232 g), and toluene (461 mL). The flask was equipped with a Dean-Stark trap and a condenser. The mixture was heated at 140 ° C. until the methanol was removed. Toluene was removed at 180 ° C. Additional toluene was added and the process was repeated twice. After removing all the toluene, the flask was dried in high vacuum. Diethyl ether (580 mL) was added to the flask to prepare a 1M diethyl ether solution. A 5 L 3-neck flask was equipped with an overhead stirrer, an inert gas inlet, and a pressure equalizing addition funnel. The flask was flushed with nitrogen gas and charged with methyl acetate (60.1 mL, 756 mmol), titanium cyclohexyl oxide (75.6 mL of 1M ether solution), and diethyl ether (1500 mL). The solution was stirred while the reaction flask was immersed in a room temperature water bath. The addition funnel was charged with 3M ethylmagnesium bromide solution (554 mL, 1.66 mol). Grignard reagent was added dropwise at room temperature over 3 hours. The mixture became a light yellow solution and then gradually a precipitate formed, eventually turning to a dark green / brown / black mixture. After stirring for an additional 15 minutes, following the addition of Grignard, the mixture was carefully poured into a mixture of 10% concentrated sulfuric acid in 1 L of water. The resulting mixture was stirred until all solids were dissolved. The aqueous layer was separated and extracted with 2 × 500 mL of diethyl ether. The combined organic extracts were washed sequentially with water and brine, dried over potassium carbonate (500 g) for 30 minutes, filtered, and the filtrate was concentrated in vacuo to an oil. Sodium bicarbonate (200 mg) was added, the crude material was distilled and the fraction boiling at around 100 ° C. was collected to give the title compound (23 grams) with methyl ethyl ketone and 2-butanol as minor impurities. ¹ H NMR (500 MHz, deuterated chloroform) δ 0.45 (apparent t, J = 6.59
Hz, 2 H), 0.77 (apparent t, J = 5.61
Hz, 2 H), 1.46 (s, 3 H). The preparation of the title compound is also described in WO09105717.

Step B) 4-Nitrophenyl carbonate 1-methylcyclopropyl 1-methylcyclopropanol (10 g, 137 mmol), 4-nitrofeyl chloroformate (32 g, 152 mmol), and several pieces of crystalline 4-dimethylaminopyridine ( A solution of 150 mg, 1.2 mmol) in dichloromethane (462 mL) was cooled to 0 ° C. Triethylamine (36.5 g, 361 mmol) was added dropwise. After 10 minutes, the ice bath was removed and the reaction was stirred at room temperature for 14 hours. The reaction mixture was washed twice with a saturated aqueous sodium carbonate solution. The aqueous phase was extracted with dichloromethane. The combined organic extracts were washed with water, dried over magnesium sulfate, filtered and the filtrate was concentrated in vacuo. The residue is purified by flash silica gel chromatography eluting with a gradient mixture consisting of ethyl acetate heptane solution (constant composition of 0-5% ethyl acetate then 5% ethyl acetate to heptane in the first 10 minutes). To give 20.8 g of the desired carbonate as a clear oil. The oil solidified on standing.
¹ H NMR
(500 MHz, deuterated chloroform) δ 0.77 (apparent t, J = 6.59 Hz, 2 H), 1.09 (apparent t, J = 7.07 Hz, 2 H), 1.67 (s, 3 H), 7.40 (apparent dt , J = 9.27, 3.17 Hz, 2 H), 8.29 (apparent dt, J = 9.27, 3.17 Hz, 2 H).

Alternatively, 1-methylcyclopropanol can also be prepared as follows.
1-Methylcyclopropanol A 2000 mL 4-neck flask was equipped with a mechanical stirrer, an inert gas inlet, a thermometer, and two pressure equalizing addition funnels. The flask was flushed with nitrogen and charged with 490 mL of diethyl ether, followed by 18.2 mL (30 mmol) of titanium tetra (2-ethylhexyl oxide). One addition funnel was charged with a solution prepared by diluting 28.6 mL (360 mmol) of methyl acetate to 120 mL with ether. The second addition funnel was charged with 200 mL of 3M ethylmagnesium bromide ether solution. The reaction flask was cooled with an ice-water bath to keep the internal temperature below 10 ° C. 40 ml of methyl acetate solution was added to the flask. The Grignard reagent was then added dropwise from the addition funnel at a rate of about 2 drops per second and no more than 2 mL per minute. After the first 40 mL of Grignard reagent was added, another 20 mL portion of acetic acid methyl ether solution was added. After the second 40 mL of Grignard reagent was added, another 20 mL portion of methyl acetate in diethyl ether was added. A third 40 mL Grignard reagent was added followed by another 20 mL portion of acetic acid methyl ether solution. A fourth 40 mL of Grignard reagent was added followed by the final 20 mL portion of acetic acid methyl ether solution. Following completion of the Grignard reagent addition, the mixture was stirred for an additional 15 minutes. The mixture was then poured into a mixture of 660 g ice and 60 mL concentrated sulfuric acid with rapid stirring to dissolve all solids. The phases were separated and the aqueous phase was extracted again with 50 mL diethyl ether. The combined ether extracts were washed with 15 mL of 10% aqueous sodium carbonate, 15 mL brine, and dried with stirring over 30 grams of magnesium sulfate for 1 hour. The ether solution was then filtered. Tri-n-butylamine (14.3 mL, 60 mmol) and mesitylene (10 mL) were added. Most of the diethyl ether was removed by distillation at atmospheric pressure using a 2.5 cm x 30 cm jacketed Vigreux column. The remaining liquid was transferred to a smaller distillation flask using 2 portions of 10 mL hexane for smooth transfer. Distillation at atmospheric pressure was continued using a 2 cm × 20 cm jacketed Vigreux column. The liquid distilled at 98-105 ° C. was collected to give 14 g of the title compound as a colorless liquid. ¹ H NMR (400 MHz, deuterated chloroform) δ 0.42-0.48 (m, 2 H), 0.74-0.80 (m, 2 H), 1.45 (s, 3 H), 1.86
(br. s., 1 H).
Preparation Example 25: 1-methylcyclobutyl 4-nitrophenyl carbonate

ステップＡ：１−メチルシクロブタノール
臭化マグネシウムエーテル錯塩（４．２４ｇ、１６．４ｍｍｏｌ）をジエチルエーテル（７１ｍＬ）に溶かした−７８℃の溶液に、メチルリチウム（９．８１ｍＬ、１５．７ｍｍｏｌ、１．６Ｍジエチルエーテル溶液）を加えた。混合物を１５分間撹拌し、その後シクロブタノン（１．１ｍＬ、１４ｍｍｏｌ）を滴下した。混合物を−７８℃で２時間撹拌した後、１．０Ｍ塩酸水溶液（１６ｍＬ）で反応を失活させた。混合物を１時間かけて室温に温めた後、１．０Ｍ水酸化ナトリウム水溶液でｐＨを弱アルカリ性にした。水層を分離し、ジエチルエーテル（２×４０ｍＬ）で抽出した。有機層を合わせて水（５０ｍＬ）で洗浄し、硫酸ナトリウムで乾燥させ、濾過し、濾液を真空中で濃縮して１−メチルシクロブタノールを得、これを精製せずに後続のステップで使用した。

Step A: 1-methylcyclobutanol Magnesium bromide ether complex (4.24 g, 16.4 mmol) dissolved in diethyl ether (71 mL) was added to a solution of −78 ° C. with methyllithium (9.81 mL, 15.7 mmol, 1 .6M diethyl ether solution) was added. The mixture was stirred for 15 minutes, after which cyclobutanone (1.1 mL, 14 mmol) was added dropwise. The mixture was stirred at −78 ° C. for 2 hours, and then the reaction was quenched with 1.0 M aqueous hydrochloric acid solution (16 mL). The mixture was warmed to room temperature over 1 hour and then made pH weakly alkaline with 1.0 M aqueous sodium hydroxide. The aqueous layer was separated and extracted with diethyl ether (2 × 40 mL). The combined organic layers were washed with water (50 mL), dried over sodium sulfate, filtered, and the filtrate was concentrated in vacuo to give 1-methylcyclobutanol, which was used in the subsequent step without purification. .

Step B: 1-methylcyclobutyl 4-nitrophenyl carbonate Stirred crude 1-methylcyclobutanol (1.20 g, 13.9 mmol) and pyridine (1.34 mL, 16.7 mmol) in dichloromethane (46 mL) To the solution was added 4-nitrophenyl carbonochloride (3.37 g, 16.7 mmol) dropwise at 0 ° C. over 10 minutes. The mixture was warmed to room temperature over 3 hours. The reaction was quenched with water and the aqueous layer was extracted with dichloromethane (3x). The combined organic layers were dried over sodium sulfate, filtered and the filtrate was concentrated in vacuo. The crude residue was purified by ISCO MPLC (0-20% ethyl acetate heptane solution) to give 1-methylcyclobutyl 4-nitrophenyl carbonate (1.67 g, 48% over 2 steps) as a clear oil. It was. ¹ H NMR (500 MHz, deuterated chloroform): δ 8.29 (m, 2 H), 7.40 (m, 2 H), 2.53-2.44 (m, 2 H), 2.26-2.19 (m, 2
H), 1.96-1.86 (m, 1 H), 1.77-1.67 (m, 1 H), 1.67 (s, 3 H).

Preparation Example 26: 4-Nitrophenyl carbonate 1-ethylcyclopropyl carbonate

ステップＡ：１−エチルシクロプロパノール
クロロヨードメタン（１１．６ｇ、６６ｍｍｏｌ）、塩化プロピオニル（２．７８ｇ、３０ｍｍｏｌ）、および臭化リチウム（５．７９ｇ、６６ｍｍｏｌ）をテトラヒドロフラン（１２０ｍＬ）に溶かした撹拌した溶液に、窒素雰囲気中にて、メチルリチウムの溶液（１．６Ｍジエチルエーテル溶液、４１．２ｍＬ、６６ｍｍｏｌ）を−７８℃（浴温度）で２０分かけて加えた。反応混合物を−７８℃で３時間撹拌した。次いでリチウム粉末（５．９３ｇ、２７０ｍｍｏｌ）を慎重に加え、混合物を１６時間撹拌し、温度をゆっくりと室温に上げた。次いで混合物を０℃に冷却し、水（１４５ｍＬ）および濃塩酸（３０ｍＬ）で希釈した。水性混合物をジエチルエーテル（３×２００ｍＬ）で抽出した。有機抽出物を合わせて硫酸マグネシウムで乾燥させ、濾過し、濾液を濃縮して、１−エチルシクロプロパノールを黄色の油状物（２．５ｇ）として得た。この材料をそれ以上精製せずに次のステップで使用した。¹H NMR (500 MHz, 重水素化クロロホルム) δ 0.37 - 0.43 (m, 2 H) 0.65 - 0.73 (m, 2 H) 1.01 (t, J=7.44 Hz, 3 H)
1.56 (q, J=7.48 Hz, 2 H).

Step A: Stir 1-ethylcyclopropanol chloroiodomethane (11.6 g, 66 mmol), propionyl chloride (2.78 g, 30 mmol), and lithium bromide (5.79 g, 66 mmol) in tetrahydrofuran (120 mL). To the solution was added a solution of methyllithium (1.6 M diethyl ether solution, 41.2 mL, 66 mmol) at −78 ° C. (bath temperature) over 20 minutes in a nitrogen atmosphere. The reaction mixture was stirred at −78 ° C. for 3 hours. Lithium powder (5.93 g, 270 mmol) was then added carefully and the mixture was stirred for 16 hours and the temperature was slowly raised to room temperature. The mixture was then cooled to 0 ° C. and diluted with water (145 mL) and concentrated hydrochloric acid (30 mL). The aqueous mixture was extracted with diethyl ether (3 × 200 mL). The combined organic extracts were dried over magnesium sulfate, filtered, and the filtrate was concentrated to give 1-ethylcyclopropanol as a yellow oil (2.5 g). This material was used in the next step without further purification. ¹ H NMR (500 MHz, deuterated chloroform) δ 0.37-0.43 (m, 2 H) 0.65-0.73 (m, 2 H) 1.01 (t, J = 7.44 Hz, 3 H)
1.56 (q, J = 7.48 Hz, 2 H).

Step B: 1-ethylcyclopropyl 4-nitrophenyl carbonate Dichloromethane at 0 ° C. (5 mL) containing crude 1-ethylcyclopropanol (1.0 g, 11.6 mmol) and pyridine (1.12 mL, 13.9 mmol). Chloroformate 4-nitrophenyl (2.81 g, 13.9 mmol) was added dropwise over 10 minutes. The ice bath was warmed and the mixture was stirred at room temperature for 18 hours. The reaction was quenched with water and the mixture was extracted with dichloromethane (3x). The combined organic extracts were dried over magnesium sulfate, filtered and the filtrate was concentrated in vacuo. The residue was purified by chromatography on a 40 g silica gel column eluting with a 5% to 25% gradient mixture of ethyl acetate and heptane to give a yellow oil (1.0 g). This material was further purified by HPLC (conditions: column Chiralpak AD-H, solvent methanol, flow rate 10.0 mL / min, wavelength 210 nm) to give 450 mg of 4-nitrophenyl 1-ethylcyclopropyl carbonate as a pale yellow oil. Got as. ¹ H NMR (500 MHz, deuterated chloroform) δ 0.75-0.81 (m, 2 H) 1.01-1.09 (m, 5 H) 1.92 (q, J = 7.48 Hz, 2 H)
7.36-7.42 (m, 2 H) 8.24-8.30 (m, 2 H).

Preparation Example 27: tert-Butyl 4-[(6-chloro-5-methylpyrimidin-4-yl) oxy] piperidine-1-carboxylate

２０ｍＬのＢｉｏｔａｇｅ（商標）マイクロ波対応管を窒素パージし、４，６−ジクロロ−５−メチルピリミジン（０．６００ｇ、２．９８ｍｍｏｌ）および４−ヒドロキシピペリジン−１−カルボン酸ｔｅｒｔ−ブチル（５３４ｍｇ、３．２８ｍｍｏｌ）を投入した。１，４−ジオキサン（１４．９ｍＬ）を加え、混合物を１００℃に加熱した。混合物にナトリウムビス（トリメチルシリル）アミド（３．５８ｍＬ、３．５８ｍｍｏｌ、１．０Ｍテトラヒドロフラン溶液）を１０分かけて滴下した。混合物を６０分間撹拌し、次いで室温で１２時間撹拌した。水で反応を失活させ、水層を酢酸エチルで３回抽出した。有機抽出物を合わせて硫酸ナトリウムで乾燥させ、濾過し、濾液を真空中で濃縮した。未精製材料をシリカゲルクロマトグラフィー（４０ｇのＳｉＯ_２カラム、０〜５０％の酢酸エチルヘプタン溶液の勾配）によって精製して、表題化合物（８４２ｍｇ、８６％）を得た。

A 20 mL Biotage ™ microwave counterpart tube was purged with nitrogen, and 4,6-dichloro-5-methylpyrimidine (0.600 g, 2.98 mmol) and tert-butyl 4-hydroxypiperidine-1-carboxylate (534 mg, 3.28 mmol) was charged. 1,4-Dioxane (14.9 mL) was added and the mixture was heated to 100 ° C. Sodium bis (trimethylsilyl) amide (3.58 mL, 3.58 mmol, 1.0 M tetrahydrofuran solution) was added dropwise to the mixture over 10 minutes. The mixture was stirred for 60 minutes and then at room temperature for 12 hours. The reaction was quenched with water, and the aqueous layer was extracted 3 times with ethyl acetate. The combined organic extracts were dried over sodium sulfate, filtered and the filtrate was concentrated in vacuo. The crude material was purified by silica gel chromatography (40 g SiO ₂ column, gradient of 0-50% ethyl acetate heptane solution) to give the title compound (842 mg, 86%).

Preparation Example 28: (3R, 4S) -4-[(6-Chloro-5-methylpyrimidin-4-yl) oxy] -3-fluoropiperidine-1-carboxylate tert-butyl (racemate)

（３，４−シス）−３−フルオロ−４−ヒドロキシ−ピペリジン−１−カルボン酸ｔｅｒｔ−ブチル（ラセミ体）（１．０ｇ、４．６ｍｍｏｌ）および４，６−ジクロロ−５−メチルピリミジン（８１８ｍｇ、５．０２ｍｍｏｌ）を無水テトラヒドロフラン（２３ｍＬ）に溶かした溶液に、水素化ナトリウム（２０１ｍｇ、５．０２ｍｍｏｌ、６０％鉱油分散液）を０℃にて２回で加えた。１８時間後、反応混合物を飽和塩化アンモニウム水溶液で失活させ、水で希釈した。得られる混合物を酢酸エチルで３回抽出した。有機層を合わせて硫酸ナトリウムで乾燥させ、濾過し、濾液を減圧下で濃縮して、表題化合物を淡黄色の油状物（１．５６ｇ、９９％）として得た。¹H NMR (400 MHz, 重水素化クロロホルム) δ 1.46 (s, 9 H), 1.84 - 1.91 (m, 1 H), 2.04 - 2.17 (m, 1 H), 2.24 (s,
3 H), 3.09 - 3.22 (m, 1 H), 3.29 - 3.43 (m, 1 H), 3.78 - 4.01 (m, 1 H), 4.09 -
4.20 (m, 1 H), 4.74 - 4.93 (m, 1 H), 5.31 - 5.43 (m, 1 H), 8.36 (s, 1 H). LCMS:
(ES+): 346.4 (M+1).

Tert-Butyl (racemate) (1.0 g, 4.6 mmol) (3,4-cis) -3-fluoro-4-hydroxy-piperidine-1-carboxylate and 4,6-dichloro-5-methylpyrimidine ( To a solution of 818 mg, 5.02 mmol) in anhydrous tetrahydrofuran (23 mL), sodium hydride (201 mg, 5.02 mmol, 60% mineral oil dispersion) was added twice at 0 ° C. After 18 hours, the reaction mixture was quenched with saturated aqueous ammonium chloride and diluted with water. The resulting mixture was extracted with ethyl acetate three times. The combined organic layers were dried over sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give the title compound as a pale yellow oil (1.56 g, 99%). ¹ H NMR (400 MHz, deuterated chloroform) δ 1.46 (s, 9 H), 1.84-1.91 (m, 1 H), 2.04-2.17 (m, 1 H), 2.24 (s,
3 H), 3.09-3.22 (m, 1 H), 3.29-3.43 (m, 1 H), 3.78-4.01 (m, 1 H), 4.09-
4.20 (m, 1 H), 4.74-4.93 (m, 1 H), 5.31-5.43 (m, 1 H), 8.36 (s, 1 H). LCMS:
(ES +): 346.4 (M + 1).

Preparation Example 29: 4-Chloro-6-{[(3R, 4S) -3-fluoropiperidin-4-yl] oxy} -5-methylpyrimidine

（３Ｒ，４Ｓ）−４−［（６−クロロ−５−メチルピリミジン−４−イル）オキシ］−３−フルオロピペリジン−１−カルボン酸ｔｅｒｔ−ブチル（１．４ｇ、４．０ｍｍｏｌ）の無水１，２−ジクロロエタン（２０ｍＬ）溶液に、窒素流を吹きかけながら、トリフルオロ酢酸（４．０ｍＬ、５２．０ｍｍｏｌ）を室温で加えた。２時間後、減圧下で揮発性物質を除去し、加熱して無色の残渣を得た。残渣をジクロロメタンに溶かし、飽和炭酸水素ナトリウム水溶液で塩基性化した。次いで混合物をジクロロメタンで３回抽出した。有機層を合わせて硫酸ナトリウムで乾燥させ、濾過し、減圧下で濃縮して、生成物をオフホワイトの固体（９３０ｍｇ、９３％）として得た。¹H NMR (400 MHz, 重水素化クロロホルム) δ 1.88 - 2.07 (m, 2 H) 2.25 (s, 3 H) 2.73 - 2.82 (m, 1 H) 2.86 - 2.99
(m, 1 H) 3.12 - 3.20 (m, 1 H) 3.31 - 3.39 (m, 1 H) 4.76 - 4.93 (m, 1 H) 5.24 -
5.37 (m, 1 H) 8.36 (s, 1 H) LCMS: (ES+): 246.2 (M+1).

Anhydrous 1 of (3R, 4S) -4-[(6-Chloro-5-methylpyrimidin-4-yl) oxy] -3-fluoropiperidine-1-carboxylate (1.4 g, 4.0 mmol) To a solution of 2,2-dichloroethane (20 mL), trifluoroacetic acid (4.0 mL, 52.0 mmol) was added at room temperature while blowing a stream of nitrogen. After 2 hours, volatiles were removed under reduced pressure and heated to give a colorless residue. The residue was dissolved in dichloromethane and basified with saturated aqueous sodium bicarbonate. The mixture was then extracted 3 times with dichloromethane. The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure to give the product as an off-white solid (930 mg, 93%). ¹ H NMR (400 MHz, deuterated chloroform) δ 1.88-2.07 (m, 2 H) 2.25 (s, 3 H) 2.73-2.82 (m, 1 H) 2.86-2.99
(m, 1 H) 3.12-3.20 (m, 1 H) 3.31-3.39 (m, 1 H) 4.76-4.93 (m, 1 H) 5.24-
5.37 (m, 1 H) 8.36 (s, 1 H) LCMS: (ES +): 246.2 (M + 1).

Preparation 30: (3R, 4S) -4-[(6-Chloro-5-methylpyrimidin-4-yl) oxy] -3-fluoropiperidine-1-carboxylic acid 1-methylcyclopropyl

４−クロロ−６−｛［（３Ｒ，４Ｓ）−３−フルオロピペリジン−４−イル］オキシ｝−５−メチルピリミジン（９２５ｍｇ、３．７６ｍｍｏｌ）およびトリエチルアミン（１．５７ｍＬ、１１．３ｍｍｏｌ）をジクロロメタン（２０．０ｍＬ）に溶かした溶液に、４−ニトロフェニル炭酸１−メチルシクロプロピル（１．７９ｍｇ、７．５３ｍｍｏｌ）を室温で加えた。７２時間後、水で反応を失活させ、ジクロロメタンで３回抽出した。有機層を合わせて飽和炭酸水素ナトリウム水溶液で黄色が消えるまで継続的に洗浄した。次いで有機層を硫酸ナトリウムで乾燥させ、濾過し、減圧下で濃縮した。得られる未精製残渣をフラッシュクロマトグラフィー（シリカ：１０〜５０％の酢酸エチル：ヘプタン）によって精製して、８３０ｍｇ（６４％）の所望の生成物を白色の固体として得た。¹H NMR (500 MHz, 重水素化クロロホルム) δ 0.63 - 0.68 (m, 2 H), 0.87 - 0.94 (m, 2 H), 1.60 (s, 3 H), 1.86 -
1.97 (m, 1 H), 2.08 - 2.19 (m, 1 H), 2.27 (s, 3 H), 3.11 - 3.27 (m, 1 H) 3.27 -
3.49 (m, 1 H), 3.78 - 4.11 (m, 1 H), 4.11 - 4.27 (m, 1 H), 4.77 - 4.96 (m, 1
H), 5.33 - 5.46 (m, 1 H), 8.40 (s, 1 H) LCMS: (ES+): 344.4 (M+1).

4-Chloro-6-{[(3R, 4S) -3-fluoropiperidin-4-yl] oxy} -5-methylpyrimidine (925 mg, 3.76 mmol) and triethylamine (1.57 mL, 11.3 mmol) in dichloromethane To a solution dissolved in (20.0 mL), 4-nitrophenyl carbonate 1-methylcyclopropyl carbonate (1.79 mg, 7.53 mmol) was added at room temperature. After 72 hours, the reaction was quenched with water and extracted three times with dichloromethane. The organic layers were combined and washed with saturated aqueous sodium bicarbonate until the yellow color disappeared. The organic layer was then dried over sodium sulfate, filtered and concentrated under reduced pressure. The resulting crude residue was purified by flash chromatography (silica: 10-50% ethyl acetate: heptane) to give 830 mg (64%) of the desired product as a white solid. ¹ H NMR (500 MHz, deuterated chloroform) δ 0.63-0.68 (m, 2 H), 0.87-0.94 (m, 2 H), 1.60 (s, 3 H), 1.86-
1.97 (m, 1 H), 2.08-2.19 (m, 1 H), 2.27 (s, 3 H), 3.11-3.27 (m, 1 H) 3.27-
3.49 (m, 1 H), 3.78-4.11 (m, 1 H), 4.11-4.27 (m, 1 H), 4.77-4.96 (m, 1
H), 5.33-5.46 (m, 1 H), 8.40 (s, 1 H) LCMS: (ES +): 344.4 (M + 1).

Preparation Example 31: 6,7-Dihydro-5H-pyrrolo [3,2-c] pyridazine

ステップＡ：３−オキソ−４，４ａ，６，７−テトラヒドロ−２Ｈ−ピロロ［３，２−ｃ］ピリダジン−５（３Ｈ）−カルボン酸ベンジル
２−（２−エトキシ−２−オキソエチル）−３−オキソピロリジン−１−カルボン酸ベンジル（Ｓｙｎｌｅｔｔ １９９８、１３７８に記載のとおりに調製）（６．４７ｇ、２１．２ｍｍｏｌ）をエタノール（６６ｍＬ）、酢酸（１１ｍＬ）、およびヒドラジン（０．７３ｍＬ、２３．３ｍｍｏｌ）に溶かした溶液を、６時間還流加熱した（１００℃）。混合物を室温に冷却し、真空中で濃縮して、濃褐色の粘稠な油状物８．１３ｇを得た。この未精製材料を、酢酸エチルとヘプタンからなる４０％〜９０％の酢酸エチルの勾配混合物を溶離液とするシリカゲルクロマトグラフィーによって精製して、３−オキソ−４，４ａ，６，７−テトラヒドロ−２Ｈ−ピロロ［３，２−ｃ］ピリダジン−５（３Ｈ）−カルボン酸ベンジル（３．７０ｇ、６４％）を淡い黄褐色の泡沫として得た。¹H NMR (400 MHz, 重水素化クロロホルム) δ 2.29 (t, J=15.34 Hz, 1 H) 2.65 - 2.80 (m, 1 H) 2.80 - 2.97 (m, 1 H)
3.05 - 3.52 (m, 1 H) 3.65 (br. d, J=6.60 Hz, 1 H) 4.04 (br. s., 1 H) 4.49 (br.
s., 1 H) 5.08 - 5.27 (m, 2 H) 7.38 (s, 4 H) 8.27 (br. s., 1 H).

Step A: 3-Oxo-4,4a, 6,7-tetrahydro-2H-pyrrolo [3,2-c] pyridazine-5 (3H) -benzyl carboxylate 2- (2-ethoxy-2-oxoethyl) -3 -Oxopyrrolidine-1-carboxylate (prepared as described in Synlett 1998, 1378) (6.47 g, 21.2 mmol) in ethanol (66 mL), acetic acid (11 mL), and hydrazine (0.73 mL, 23. The solution dissolved in 3 mmol) was heated to reflux (100 ° C.) for 6 hours. The mixture was cooled to room temperature and concentrated in vacuo to give 8.13 g of a dark brown viscous oil. The crude material was purified by silica gel chromatography, eluting with a gradient mixture of 40% to 90% ethyl acetate consisting of ethyl acetate and heptane to give 3-oxo-4,4a, 6,7-tetrahydro- Benzyl 2H-pyrrolo [3,2-c] pyridazine-5 (3H) -carboxylate (3.70 g, 64%) was obtained as a light tan foam. ¹ H NMR (400 MHz, deuterated chloroform) δ 2.29 (t, J = 15.34 Hz, 1 H) 2.65-2.80 (m, 1 H) 2.80-2.97 (m, 1 H)
3.05-3.52 (m, 1 H) 3.65 (br.d, J = 6.60 Hz, 1 H) 4.04 (br. S., 1 H) 4.49 (br.
s., 1 H) 5.08-5.27 (m, 2 H) 7.38 (s, 4 H) 8.27 (br. s., 1 H).

Step B: 3-Oxo-6,7-dihydro-2H-pyrrolo [3,2-c] pyridazine-5 (3H) -carboxylate 3-Oxo-4,4a, 6,7-tetrahydro-2H-pyrrolo [3,2-c] pyridazine-5 (3H) -benzyl carboxylate (3.65 g, 13.3 mmol) and copper (II) chloride (3.59 g, 26.7 mmol) in acetonitrile (53 mL) Was heated to 100 ° C. for 1 hour. The mixture was cooled to room temperature and then poured into 150 mL of water. The aqueous mixture is stirred for 15 minutes and the solid is collected by filtration through a Pall GHP membrane (0.45 micrometers), dried in vacuo to give 3-oxo-6,7-dihydro-2H-pyrrolo [3, 2-c] Pyridazine-5 (3H) -benzyl carboxylate (2.06 g, 57%) was obtained as an off-white solid. This material was used in subsequent steps without purification. ¹ H NMR (400 MHz, deuterated methanol) δ 3.04 (t, J = 8.21 Hz, 2 H) 4.07 (t, J = 8.11 Hz, 2 H) 5.29 (s, 2 H)
6.81 (br. S, 1 H) 7.19-7.60 (m, 5 H).

Step C: 3-Chloro-6,7-dihydro-5H-pyrrolo [3,2-c] pyridazine-5-carboxylic acid benzyl 3-oxo-6,7-dihydro-2H-pyrrolo [3,2-c] A mixture of pyridazine-5 (3H) -benzyl carboxylate (2.06 g, 2.47 mmol) and phosphorus oxychloride (22.5 mL) was heated at 110 ° C. for 20 minutes. Excess phosphorus oxychloride was removed in vacuo and the dark blackish blue residue was diluted with 70 mL water and extracted with dichloromethane (3 × 25 mL). The combined organic extracts were dried (sodium sulfate), filtered and the filtrate was concentrated in vacuo. The residue (2.22 g of dark blue solid) was purified by silica gel chromatography eluting with a gradient mixture of 25% to 70% ethyl acetate consisting of ethyl acetate and heptane to give 3-chloro-6,7- Benzyl dihydro-5H-pyrrolo [3,2-c] pyridazine-5-carboxylate (1.8385 g, 84%) was obtained as a tan solid. MS: ES +: 290.0. ¹ H NMR (400 MHz, deuterated chloroform) δ 3.43 (t, J = 8.79
Hz, 2 H) 4.17 (t, J = 8.70 Hz, 2 H) 5.25-5.40 (m, 2 H) 7.35-7.47 (m, 6 H).

Step D: 6,7-Dihydro-5H-pyrrolo [3,2-c] pyridazine 3-Chloro-6,7-dihydro-5H-pyrrolo [3,2-c] pyridazine-5-carboxylate (320 mg, 1.1 mmol), Pd / C (10 wt%, 59 mg), and ethanol (14 mL) were shaken in a hydrogen atmosphere (50 psi) at room temperature for 16 hours. The Pd / C catalyst was removed by filtration and the filtrate was concentrated in vacuo to give 175 mg of a tan solid. This solid was dissolved in methanol (10 mL) and water (1 mL) and potassium bicarbonate (220 mg, 2.2 mmol) was added. After the mixture was stirred for 1 hour, the solids were removed by filtration and the filtrate was concentrated in vacuo. The residue was dissolved in methanol and stirred with basic alumina (2 g) for 30 minutes and the solvent was removed in vacuo. This solid was placed on top of a column of basic alumina and eluted with a gradient mixture of 0-5% methanol consisting of methanol and dichloromethane to give 112 mg (84%) of 6,7-dihydro-5H-pyrrolo [3 , 2-c] pyridazine was obtained as a yellow solid. ¹ H NMR (400 MHz, deuterated methanol) δ 3.23 (t, J = 8.50 Hz, 2 H) 3.71 (t, J = 8.50 Hz, 2 H) 6.40 (d, J = 5.86
(Hz, 1 H) 8.24 (d, J = 5.86 Hz, 1 H).

Preparation Example 32: 5- (6-Chloro-5-methylpyrimidin-4-yl) -6,7-dihydro-5H-pyrrolo [3,2-c] pyridazine

４，６−ジクロロ−５−メチルピリミジン（１９ｍｇ、０．１２ｍｍｏｌ）、６，７−ジヒドロ−５Ｈ−ピロロ［３，２−ｃ］ピリダジン（１４ｍｇ、０．１２ｍｍｏｌ）、および炭酸セシウム（３８ｍｇ、０．１２ｍｍｏｌ）をＮ，Ｎ−ジメチルホルムアミド（０．２ｍＬ）に混ぜた混合物を室温で４０時間撹拌した。この反応混合物を、４，６−ジクロロ−５−メチルピリミジン（８４ｍｇ、０．５２ｍｍｏｌ）、６，７−ジヒドロ−５Ｈ−ピロロ［３，２−ｃ］ピリダジン（７４ｍｇ、０．４７ｍｍｏｌ）、および炭酸セシウム（１７２ｍｇ、０．５２ｍｍｏｌ）を含有するＮ，Ｎ−ジメチルホルムアミド（１ｍＬ）を使用して実施した実験の反応混合物を室温で１５時間撹拌しておいたものと合わせた。合わせた混合物を水（２５ｍＬ）で希釈し、酢酸エチルで３回抽出した。有機抽出物を合わせてブラインで洗浄し、乾燥させ（硫酸ナトリウム）、濾過し、濾液を真空中で濃縮した。残渣を、メタノールとジクロロメタンからなる０〜５％のメタノールの勾配混合物を溶離液とするシリカゲルクロマトグラフィーによって精製して、７９ｍｇ（５４％）の５−（６−クロロ−５−メチルピリミジン−４−イル）−６，７−ジヒドロ−５Ｈ−ピロロ［３，２−ｃ］ピリダジンを黄褐色の固体として得た。¹H NMR (400 MHz, 重水素化クロロホルム) δ 2.32 (s, 3 H) 3.55 (t, J=8.39 Hz, 2 H) 4.29 (t, J=8.39 Hz, 2 H)
6.72 (d, J=5.66 Hz, 1 H) 8.63 (s, 1 H) 8.77 (d, J=5.66 Hz, 1 H).

4,6-dichloro-5-methylpyrimidine (19 mg, 0.12 mmol), 6,7-dihydro-5H-pyrrolo [3,2-c] pyridazine (14 mg, 0.12 mmol), and cesium carbonate (38 mg, 0 .12 mmol) in N, N-dimethylformamide (0.2 mL) was stirred at room temperature for 40 hours. The reaction mixture was charged with 4,6-dichloro-5-methylpyrimidine (84 mg, 0.52 mmol), 6,7-dihydro-5H-pyrrolo [3,2-c] pyridazine (74 mg, 0.47 mmol), and carbonic acid. The reaction mixture of the experiment performed using N, N-dimethylformamide (1 mL) containing cesium (172 mg, 0.52 mmol) was combined with that which had been stirred at room temperature for 15 hours. The combined mixture was diluted with water (25 mL) and extracted three times with ethyl acetate. The combined organic extracts were washed with brine, dried (sodium sulfate), filtered and the filtrate was concentrated in vacuo. The residue was purified by silica gel chromatography eluting with a gradient mixture of 0-5% methanol consisting of methanol and dichloromethane to give 79 mg (54%) of 5- (6-chloro-5-methylpyrimidine-4- Yl) -6,7-dihydro-5H-pyrrolo [3,2-c] pyridazine was obtained as a tan solid. ¹ H NMR (400 MHz, deuterated chloroform) δ 2.32 (s, 3 H) 3.55 (t, J = 8.39 Hz, 2 H) 4.29 (t, J = 8.39 Hz, 2 H)
6.72 (d, J = 5.66 Hz, 1 H) 8.63 (s, 1 H) 8.77 (d, J = 5.66 Hz, 1 H).

Preparation Example 33: 1-methylcyclopropyl 4- (6-chloropyrimidin-4-yloxy) piperidine-1-carboxylate

４−（６−クロロピリミジン−４−イルオキシ）ピペリジン−１−カルボン酸１−メチルシクロプロピルは、４−［（６−クロロ−ピリミジン−４−イル）オキシ］ピペリジン−１−カルボン酸イソプロピルと同様にして調製した。¹H NMR (500 MHz, 重水素化クロロホルム) δ 0.51 - 0.74 (m, 2 H) 0.77 - 1.00 (m, 2 H) 1.57 (s, 3 H) 1.74 (br.
s., 2 H) 1.98 (br. s., 2 H) 3.31 (br. s., 2 H) 3.78 (br. s, 2 H) 5.28 - 5.37
(m, 1 H) 6.76 (s, 1 H) 8.55 (s, 1 H).

1-methylcyclopropyl 4- (6-chloropyrimidin-4-yloxy) piperidine-1-carboxylate is similar to isopropyl 4-[(6-chloro-pyrimidin-4-yl) oxy] piperidine-1-carboxylate It was prepared as follows. ¹ H NMR (500 MHz, deuterated chloroform) δ 0.51-0.74 (m, 2 H) 0.77-1.00 (m, 2 H) 1.57 (s, 3 H) 1.74 (br.
s., 2 H) 1.98 (br. s., 2 H) 3.31 (br. s., 2 H) 3.78 (br. s, 2 H) 5.28-5.37
(m, 1 H) 6.76 (s, 1 H) 8.55 (s, 1 H).

Preparation Example 34: (3R, 4S) -4- (6-Chloropyrimidin-4-yloxy) -3-fluoropiperidine-1-carboxylic acid 1-methylcyclopropyl (racemate)

（３Ｒ，４Ｓ）−４−（６−クロロピリミジン−４−イルオキシ）−３−フルオロピペリジン−１−カルボン酸１−メチルシクロプロピル（ラセミ体）は、４−［（６−クロロ−ピリミジン−４−イル）オキシ］ピペリジン−１−カルボン酸イソプロピルと同様にして調製した。¹H NMR (重水素化クロロホルム) δ 8.52 (d, J = 0.8
Hz, 1H), 6.83 (d, J = 0.8 Hz, 1H), 5.20 - 5.52 (m, 1H), 4.68 - 5.02 (m, 1H),
3.72 - 4.31 (m, 2H), 2.93 - 3.44 (m, 2H), 1.97 - 2.22 (m, 1H), 1.88 (br. s.,
1H), 1.54 (s, 3H), 0.75 - 0.97 (m, 2H), 0.52 - 0.70 (m, 2H).

1-methylcyclopropyl (racemic) of (3R, 4S) -4- (6-chloropyrimidin-4-yloxy) -3-fluoropiperidine-1-carboxylic acid is 4-[(6-chloro-pyrimidine-4 -Yl) oxy] piperidine-1-carboxylate. ¹ H NMR (deuterated chloroform) δ 8.52 (d, J = 0.8
Hz, 1H), 6.83 (d, J = 0.8 Hz, 1H), 5.20-5.52 (m, 1H), 4.68-5.02 (m, 1H),
3.72-4.31 (m, 2H), 2.93-3.44 (m, 2H), 1.97-2.22 (m, 1H), 1.88 (br. S.,
1H), 1.54 (s, 3H), 0.75-0.97 (m, 2H), 0.52-0.70 (m, 2H).

Preparation Example 35: Methyl 2,3-dihydro-1H-pyrrolo [3,2-b] pyridine-5-carboxylate and methyl 5-methyl-2,3-dihydro-1H-pyrrolo [3,2-b] pyridine-1 , 5-Dicarboxylic acid 1-tert-butyl

１Ｈ−ピロロ［３，２−ｂ］ピリジン−５−カルボン酸メチル（Ａｄｅｓｉｓ Ｉｎｃ．、デラウェア州Ｎｅｗ Ｃａｓｔｌｅ）（１．０ｇ、５．６８ｍｍｏｌ）および二炭酸ジ−ｔｅｒｔ−ブチル（１．７５ｇ、７．９５ｍｍｏｌ）をメタノール（３０ｍＬ）に溶かした溶液を、１０％Ｐｄ／Ｃカートリッジを備え付けたＨ−ｃｕｂｅ水素化装置に、８０℃、８０バールにて１．０ｍＬ／分で通した。次いで流出液をＨ−ｃｕｂｅ装置にさらに３回通した。未精製材料を濃縮し、残渣を、ヘプタンに対して５０％〜９０％の酢酸エチルからなる勾配混合物を溶離液とするシリカゲルクロマトグラフィーによって精製して、２３０ｍｇの２，３−ジヒドロ−１Ｈ−ピロロ［３，２−ｂ］ピリジン−５−カルボン酸メチルおよび３００ｍｇの５−メチル２，３−ジヒドロ−１Ｈ−ピロロ［３，２−ｂ］ピリジン−１，５−ジカルボン酸１−ｔｅｒｔ−ブチルを得た。
２，３−ジヒドロ−１Ｈ−ピロロ［３，２−ｂ］ピリジン−５−カルボン酸メチル：¹H NMR (重水素化クロロホルム) δ 7.77 (d, J = 8.2
Hz, 1H), 6.67 (d, J = 8.2 Hz, 1H), 4.42 (br. s., 1H), 3.88 (s, 3H), 3.69 (td, J
= 8.6, 1.5 Hz, 2H), 3.17 (t, J = 8.7 Hz, 2H).
５−メチル２，３−ジヒドロ−１Ｈ−ピロロ［３，２−ｂ］ピリジン−１，５−ジカルボン酸１−ｔｅｒｔ−ブチル：¹H NMR (重水素化クロロホルム) δ 7.92 (d, J = 8.2
Hz, 2H), 4.00 (t, J = 8.9 Hz, 2H), 3.91 (s, 3H), 3.25 (t, J = 1.0 Hz, 2H), 1.52
(br. s., 9H).

Methyl 1H-pyrrolo [3,2-b] pyridine-5-carboxylate (Acessis Inc., New Castle, Del.) (1.0 g, 5.68 mmol) and di-tert-butyl dicarbonate (1.75 g, 7 .95 mmol) in methanol (30 mL) was passed through an H-cube hydrogenator equipped with a 10% Pd / C cartridge at 80 ° C. and 80 bar at 1.0 mL / min. The effluent was then passed through the H-cube device three more times. The crude material was concentrated and the residue was purified by silica gel chromatography, eluting with a gradient mixture consisting of 50% to 90% ethyl acetate to heptane, to give 230 mg 2,3-dihydro-1H-pyrrolo. Methyl [3,2-b] pyridine-5-carboxylate and 300 mg of 1-tert-butyl 5-methyl 2,3-dihydro-1H-pyrrolo [3,2-b] pyridine-1,5-dicarboxylate Obtained.
Methyl 2,3-dihydro-1H-pyrrolo [3,2-b] pyridine-5-carboxylate: ¹ H NMR (deuterated chloroform) δ 7.77 (d, J = 8.2
Hz, 1H), 6.67 (d, J = 8.2 Hz, 1H), 4.42 (br. S., 1H), 3.88 (s, 3H), 3.69 (td, J
= 8.6, 1.5 Hz, 2H), 3.17 (t, J = 8.7 Hz, 2H).
1-tert-butyl 5-methyl-2,3-dihydro-1H-pyrrolo [3,2-b] pyridine-1,5-dicarboxylate: ¹ H NMR (deuterated chloroform) δ 7.92 (d, J = 8.2
Hz, 2H), 4.00 (t, J = 8.9 Hz, 2H), 3.91 (s, 3H), 3.25 (t, J = 1.0 Hz, 2H), 1.52
(br. s., 9H).

Preparation Example 36: N, N-dimethyl-2,3-dihydro-1H-pyrrolo [3,2-b] pyridine-5-carboxamide

ステップＡ：１−（ｔｅｒｔ−ブトキシカルボニル）−２，３−ジヒドロ−１Ｈ−ピロロ［３，２−ｂ］ピリジン−５−カルボン酸
５−メチル２，３−ジヒドロピロロ［３，２−ｂ］ピリジン−１，５−ジカルボン酸１−ｔｅｒｔ−ブチル（２５０ｍｇ、０．８９８ｍｍｏｌ）をテトラヒドロフランと水からなる溶液（３：１、４ｍＬ）に溶かした撹拌した溶液に、水酸化リチウム一水和物（５９ｍｇ、１．３５ｍｍｏｌ）を加えた。反応混合物を室温で１８時間撹拌した後、溶液がほぼｐＨ２になるまで１Ｎ塩酸水溶液を加えた。混合物を酢酸エチルで２回抽出し、硫酸マグネシウムで乾燥させ、濾過し、濾液を濃縮して、１−（ｔｅｒｔ−ブトキシカルボニル）−２，３−ジヒドロ−１Ｈ−ピロロ［３，２−ｂ］ピリジン−５−カルボン酸をピンク色の固体（２４０ｍｇ）として得た。この材料を精製せずに次のステップで使用した。¹H NMR (重水素化クロロホルム) δ 7.91 - 8.20 (m,
2H), 4.01 - 4.10 (m, 2H), 3.25 (t, J = 1.0 Hz, 2H), 1.48 - 1.67 (m, 9H).

Step A: 1- (tert-Butoxycarbonyl) -2,3-dihydro-1H-pyrrolo [3,2-b] pyridine-5-carboxylic acid 5-methyl 2,3-dihydropyrrolo [3,2-b] To a stirred solution of 1-tert-butyl pyridine-1,5-dicarboxylate (250 mg, 0.898 mmol) in a solution of tetrahydrofuran and water (3: 1, 4 mL) was added lithium hydroxide monohydrate ( 59 mg, 1.35 mmol) was added. After the reaction mixture was stirred at room temperature for 18 hours, 1N aqueous hydrochloric acid was added until the solution was approximately pH 2. The mixture was extracted twice with ethyl acetate, dried over magnesium sulfate, filtered, and the filtrate was concentrated to 1- (tert-butoxycarbonyl) -2,3-dihydro-1H-pyrrolo [3,2-b]. Pyridine-5-carboxylic acid was obtained as a pink solid (240 mg). This material was used in the next step without purification. ¹ H NMR (deuterated chloroform) δ 7.91-8.20 (m,
2H), 4.01-4.10 (m, 2H), 3.25 (t, J = 1.0 Hz, 2H), 1.48-1.67 (m, 9H).

Step B: 5- (Dimethylcarbamoyl) -2,3-dihydro-1H-pyrrolo [3,2-b] pyridine-1-carboxylate tert-butyl 1- (tert-butoxycarbonyl) -2,3-dihydro- To a stirred solution of 1H-pyrrolo [3,2-b] pyridine-5-carboxylic acid (120 mg, 0.45 mmol) in dichloromethane (3 mL) was added N- (3-dimethylaminopropyl) -N′-ethyl. Carbodiimide hydrochloride (131 mg, 0.68 mmol) and 1-hydroxybenzotriazole hydrate (104 mg, 0.68 mmol) were added. The resulting mixture was stirred for 5 minutes before dimethylamine (2M tetrahydrofuran solution, 0.91 mL, 1.82 mmol) was added. The resulting solution was stirred at room temperature for 18 hours and at 50 ° C. for 6 hours. The mixture was then cooled to room temperature and diluted with dichloromethane. The organic mixture was washed with saturated aqueous sodium bicarbonate and brine. The organic layer was dried over sodium sulfate, filtered and the filtrate was concentrated in vacuo. The residue was purified by silica gel chromatography eluting with a gradient mixture of 0% to 5% methanol consisting of dichloromethane and methanol to give 5- (dimethylcarbamoyl) -2,3-dihydro-1H-pyrrolo [3, 2-b] tert-butyl pyridine-1-carboxylate was obtained as a white solid (60 mg). MS (m / z): 292.1 (M + 1). ¹ H NMR (deuterated chloroform) δ 7.49-8.12 (m,
1H), 7.41 (d, J = 8.4 Hz, 1H), 4.01 (t, J = 8.8 Hz, 2H), 3.21 (t, J = 8.9 Hz,
2H), 3.08 (br.s., 6H), 1.54 (br.s., 9H).

Step C: N, N-dimethyl-2,3-dihydro-1H-pyrrolo [3,2-b] pyridine-5-carboxamide 5- (dimethylcarbamoyl) -2,3-dihydropyrrolo [3,2-b] To a stirred solution of tert-butyl pyridine-1-carboxylate (60 mg, 0.26 mmol) in dichloromethane (0.5 mL) was added trifluoroacetic acid (0.5 mL). The resulting solution was stirred at room temperature for 2 hours. The reaction mixture is concentrated in vacuo, the residue is dried in a high vacuum, and N, N-dimethyl-2,3-dihydro-1H-pyrrolo [3,2-b] pyridine-5-carboxamide is converted to a pink color. Obtained as a solid (39 mg). This material was used without purification.

Example 1
9-anti-({6- [5- (methylsulfonyl) -2,3-dihydro-1H-indol-1-yl] pyrimidin-4-yl} oxy) -3-oxa-7-azabicyclo [3.3 .1] Isopropyl nonane-7-carboxylate

９−アンチ−ヒドロキシ−３−オキサ−７−アザビシクロ［３．３．１］ノナン−７−カルボン酸イソプロピル（３０ｍｇ、０．１３ｍｍｏｌ）および１−（６−クロロピリミジン−４−イル）−５−（メチルスルホニル）インドリン（３４ｍｇ、０．１１ｍｍｏｌ）を無水１，４−ジオキサン（１ｍＬ）に溶解させた。褐色の混合物を１０５℃で加熱し、１Ｍのナトリウムビス（トリメチルシリル）アミドテトラヒドロフラン溶液（０．１３ｍＬ、０．１３ｍｍｏｌ）を加えた。混合物を１０５℃で１．５時間加熱し、次いで混合物を室温に冷却した。１０％リン酸水溶液（０．５ｍＬ）で反応を失活させた。減圧下で有機溶媒を濃縮し、得られる残渣をクロロホルムと水とに分配した。層を分離し、有機層を水およびブラインで順次洗浄し、次いで硫酸マグネシウムで乾燥させた。混合物を濾過し、濾液を減圧下で濃縮して褐色の泡沫を得た。未精製材料をカラムクロマトグラフィー（０〜１０％のアセトンジクロロメタン溶液）によって精製すると、９−アンチ−（｛６−［５−（メチルスルホニル）−２，３−ジヒドロ−１Ｈ−インドール−１−イル］ピリミジン−４−イル｝オキシ）−３−オキサ−７−アザビシクロ［３．３．１］ノナン−７−カルボン酸イソプロピルが白色の固体（３０ｍｇ、５４％）として得られた。¹H NMR (400 MHz, 重水素化クロロホルム) δ 1.25 (d, J=5.2 Hz, 3 H), 1.26 (d, J=5.2 Hz, 3 H), 2.01 - 2.06 (m, 2
H), 3.04 (s, 3 H), 3.32 (m, 2 H), 3.41 (d, J=13.4 Hz, 1 H), 3.48 (d, J=13.4 Hz,
1 H), 3.85 (m, 2 H), 4.06 - 4.20 (m, 5 H), 4.29 (d, J=13.4 Hz, 1 H), 4.97 (m, 1
H), 5.41 (br. s., 1 H), 6.05 (s, 1 H), 7.72 (s, 1 H), 7.79 (d, J=8.4 Hz 1 H),
8.50 (s, 1 H), 8.59 (d, J=8.4 Hz, 1 H); LCMS (ES +) 503.3 (M+1).

Isopropyl 9-anti-hydroxy-3-oxa-7-azabicyclo [3.3.1] nonane-7-carboxylate (30 mg, 0.13 mmol) and 1- (6-chloropyrimidin-4-yl) -5 (Methylsulfonyl) indoline (34 mg, 0.11 mmol) was dissolved in anhydrous 1,4-dioxane (1 mL). The brown mixture was heated at 105 ° C. and 1M sodium bis (trimethylsilyl) amide tetrahydrofuran solution (0.13 mL, 0.13 mmol) was added. The mixture was heated at 105 ° C. for 1.5 hours and then the mixture was cooled to room temperature. The reaction was quenched with 10% aqueous phosphoric acid (0.5 mL). The organic solvent was concentrated under reduced pressure, and the resulting residue was partitioned between chloroform and water. The layers were separated and the organic layer was washed sequentially with water and brine and then dried over magnesium sulfate. The mixture was filtered and the filtrate was concentrated under reduced pressure to give a brown foam. The crude material was purified by column chromatography (0-10% acetone in dichloromethane) to give 9-anti-({6- [5- (methylsulfonyl) -2,3-dihydro-1H-indol-1-yl ] Pyrimidin-4-yl} oxy) -3-oxa-7-azabicyclo [3.3.1] nonane-7-carboxylate was obtained as a white solid (30 mg, 54%). ¹ H NMR (400 MHz, deuterated chloroform) δ 1.25 (d, J = 5.2 Hz, 3 H), 1.26 (d, J = 5.2 Hz, 3 H), 2.01-2.06 (m, 2
H), 3.04 (s, 3 H), 3.32 (m, 2 H), 3.41 (d, J = 13.4 Hz, 1 H), 3.48 (d, J = 13.4 Hz,
1 H), 3.85 (m, 2 H), 4.06-4.20 (m, 5 H), 4.29 (d, J = 13.4 Hz, 1 H), 4.97 (m, 1
H), 5.41 (br. S., 1 H), 6.05 (s, 1 H), 7.72 (s, 1 H), 7.79 (d, J = 8.4 Hz 1 H),
8.50 (s, 1 H), 8.59 (d, J = 8.4 Hz, 1 H); LCMS (ES +) 503.3 (M + 1).

(Example 2)
9-Syn-({6- [5- (methylsulfonyl) -2,3-dihydro-1H-indol-1-yl] pyrimidin-4-yl} oxy) -3-oxa-7-azabicyclo [3.3 .1] Isopropyl nonane-7-carboxylate

この化合物は、９−シン−ヒドロキシ−３−オキサ−７−アザビシクロ［３．３．１］ノナン−７−カルボン酸イソプロピルと１−（６−クロロピリミジン−４−イル）−５−（メチルスルホニル）インドリンから、実施例１について記載したのと同様にして調製した。粗生成物をカラムクロマトグラフィー（０〜１０％のアセトンジクロロメタン溶液）によって精製して、９−シン−（｛６−［５−（メチルスルホニル）−２，３−ジヒドロ−１Ｈ−インドール−１−イル］ピリミジン−４−イル｝オキシ）−３−オキサ−７−アザビシクロ［３．３．１］ノナン−７−カルボン酸イソプロピルを白色の固体（収率２４％）として得た。¹H NMR (400 MHz, 重水素化クロロホルム) δ 1.27 (d, J=6.1 Hz, 6 H), 1.96 (d, J=18.0Hz, 2 H), 3.05 (s, 3 H),
3.24 (d, , J=13.7 Hz, 1 H), 3.33 (m, 3 H), 3.85 (d, J=11.2 Hz, 1 H), 3.92 (d,
J=11.4 Hz, 1 H), 4.08-4.12 (m, 4 H), 4.47 (d, J=13.9 Hz, 1 H), 4.63 (d, J=13.4
Hz, 1 H), 4.98 (m, 1 H), 5.36 (br. s., 1 H), 6.08 (s, 1 H), 7.73 (s, 1 H), 7.80
(d, J=8.4 Hz, 1 H), 8.51 (s, 1 H), 8.59 (d, J=8.4 Hz, 1 H); LCMS (ES +) 503.2
(M+1).

This compound is composed of isopropyl 9-syn-hydroxy-3-oxa-7-azabicyclo [3.3.1] nonane-7-carboxylate and 1- (6-chloropyrimidin-4-yl) -5- (methylsulfonyl). ) Prepared from indoline as described for Example 1. The crude product was purified by column chromatography (0-10% acetone in dichloromethane) to give 9-syn-({6- [5- (methylsulfonyl) -2,3-dihydro-1H-indole-1- [Ill] pyrimidin-4-yl} oxy) -3-oxa-7-azabicyclo [3.3.1] nonane-7-carboxylate was obtained as a white solid (24% yield). ¹ H NMR (400 MHz, deuterated chloroform) δ 1.27 (d, J = 6.1 Hz, 6 H), 1.96 (d, J = 18.0 Hz, 2 H), 3.05 (s, 3 H),
3.24 (d,, J = 13.7 Hz, 1 H), 3.33 (m, 3 H), 3.85 (d, J = 11.2 Hz, 1 H), 3.92 (d,
J = 11.4 Hz, 1 H), 4.08-4.12 (m, 4 H), 4.47 (d, J = 13.9 Hz, 1 H), 4.63 (d, J = 13.4
Hz, 1 H), 4.98 (m, 1 H), 5.36 (br. S., 1 H), 6.08 (s, 1 H), 7.73 (s, 1 H), 7.80
(d, J = 8.4 Hz, 1 H), 8.51 (s, 1 H), 8.59 (d, J = 8.4 Hz, 1 H); LCMS (ES +) 503.2
(M + 1).

(Example 3)
4-({6- [5- (methylsulfonyl) -2,3-dihydro-1H-indol-1-yl] pyrimidin-4-yl} oxy) piperidine-1-carboxylate

この化合物は、４−ヒドロキシピペリジン−１−カルボン酸イソプロピルと１−（６−クロロピリミジン−４−イル）−５−（メチルスルホニル）インドリンから、実施例１について記載したのと同様にして調製した。この化合物は、カラムクロマトグラフィー（１：１のジクロロメタンアセトン溶液）によって精製して、濃黄褐色の固体を得、これをメチルエチルケトン中で加熱してさらに精製した。室温に冷却した後、混合物をメチルｔｅｒｔ−ブチルエーテルで希釈し、続いて濾過した。収集した材料をメチルｔｅｒｔ−ブチルエーテルで洗浄し、次いで真空中で乾燥させて、４−（｛６−［５−（メチルスルホニル）−２，３−ジヒドロ−１Ｈ−インドール−１−イル］ピリミジン−４−イル｝オキシ）ピペリジン−１−カルボン酸イソプロピル（７．８９ｇ、６０％）を白色の固体として得た。¹H NMR (500 MHz, 重水素化クロロホルム) δ 1.27 (d, J=6.1 Hz, 6 H), 1.70 - 1.80 (m, 2 H), 1.97 - 2.07 (m, 2
H), 3.05 (s, 3 H), 3.28-3.38 (m, 2 H), 3.33 (d, J=8.8 Hz, 2 H), 3.78 - 3.89 (m,
2 H), 4.07 (t, J=8.7 Hz, 2 H), 4.88 - 4.98 (m, 1 H), 5.34 (dd, J=8.0, 3.9 Hz, 1
H), 5.99 (s, 1 H), 7.73 (s, 1 H), 7.79 (dd, J=8.5, 1.7 Hz, 1 H), 8.52 (s, 1 H),
8.58 (d, J=8.5 Hz, 1 H); LCMS (ES+): 461 (M+1).

This compound was prepared from isopropyl 4-hydroxypiperidine-1-carboxylate and 1- (6-chloropyrimidin-4-yl) -5- (methylsulfonyl) indoline as described for Example 1. . The compound was purified by column chromatography (1: 1 dichloromethane acetone solution) to give a dark tan solid which was further purified by heating in methyl ethyl ketone. After cooling to room temperature, the mixture was diluted with methyl tert-butyl ether and subsequently filtered. The collected material was washed with methyl tert-butyl ether and then dried in vacuo to give 4-({6- [5- (methylsulfonyl) -2,3-dihydro-1H-indol-1-yl] pyrimidine- 4-Il} oxy) piperidine-1-carboxylate (7.89 g, 60%) was obtained as a white solid. ¹ H NMR (500 MHz, deuterated chloroform) δ 1.27 (d, J = 6.1 Hz, 6 H), 1.70-1.80 (m, 2 H), 1.97-2.07 (m, 2
H), 3.05 (s, 3 H), 3.28-3.38 (m, 2 H), 3.33 (d, J = 8.8 Hz, 2 H), 3.78-3.89 (m,
2 H), 4.07 (t, J = 8.7 Hz, 2 H), 4.88-4.98 (m, 1 H), 5.34 (dd, J = 8.0, 3.9 Hz, 1
H), 5.99 (s, 1 H), 7.73 (s, 1 H), 7.79 (dd, J = 8.5, 1.7 Hz, 1 H), 8.52 (s, 1 H),
8.58 (d, J = 8.5 Hz, 1 H); LCMS (ES +): 461 (M + 1).

Example 4
9-Syn-({5-cyano-6- [5- (methylsulfonyl) -1H-indol-1-yl] pyrimidin-4-yl} oxy) -3-oxa-7-azabicyclo [3.3.1 Nonane-7-carboxylate isopropyl

ステップＡ：９−シン−（｛５−シアノ−６−［５−（メチルチオ）−１Ｈ−インドール−１−イル］ピリミジン−４−イル｝オキシ）−３−オキサ−７−アザビシクロ［３．３．１］ノナン−７−カルボン酸イソプロピル

Step A: 9-Syn-({5-cyano-6- [5- (methylthio) -1H-indol-1-yl] pyrimidin-4-yl} oxy) -3-oxa-7-azabicyclo [3.3 .1] Isopropyl nonane-7-carboxylate

９−シン−ヒドロキシ−３−オキサ−７−アザビシクロ［３．３．１］ノナン−７−カルボン酸イソプロピル（９５ｍｇ、０．４１ｍｍｏｌ）を含有するテトラヒドロフラン（１ｍＬ）を、１Ｍのナトリウムビス（トリメチルシリル）アミドテトラヒドロフラン溶液（０．６９ｍＬ、０．４１ｍｍｏｌ）で処理した。反応液を３０分間撹拌し、次いで４−クロロ−６−［５−（メチルチオ）−２，３−ジヒドロ−１Ｈ−インドール−１−イル］ピリミジン−５−カルボニトリル（５０ｍｇ、０．１６ｍｍｏｌ）のテトラヒドロフラン（１．５ｍＬ）溶液に滴下した。得られる混合物を７０℃で３０分間撹拌した。反応混合物を室温に冷まし、飽和塩化アンモニウム水溶液を加えて失活させた。反応混合物をジクロロメタンおよび水で希釈した。有機層を分離し、飽和炭酸水素ナトリウム水溶液およびブラインで順次洗浄し、次いで硫酸ナトリウムで乾燥させた。混合物を濾過し、濾液を減圧下で濃縮した。粗生成物をカラムクロマトグラフィー（２０〜１００％の酢酸エチルヘプタン溶液）によって精製して、９−シン−（｛５−シアノ−６−［５−（メチルチオ）−１Ｈ−インドール−１−イル］ピリミジン−４−イル｝オキシ）−３−オキサ−７−アザビシクロ［３．３．１］ノナン−７−カルボン酸イソプロピルを白色の固体（５０ｍｇ、６１％）として得た。¹H NMR (400 MHz, 重水素化クロロホルム) δ 8.38 (s, 1 H,), 8.14 (d, 1 H, J=8.6 Hz), 7.17 (d, 1 H, J=1.9 Hz),
7.11 - 7.16 (m, 1 H), 5.47 (t, 1 H, J=3.7 Hz), 4.91 - 5.01 (m, 1 H,), 4.54 (dd,
2 H, J=8.6, 7.9 Hz), 4.35 (d, 1 H, J=14 Hz), 4.21 (br. s., 1 H), 4.18 (s, 1 H),
4.10 - 4.15 (m, 1 H), 3.78 - 3.87 (m, 2 H), 3.53 - 3.61 (m, 1 H), 3.24 (t, 2 H,
J=8.2 Hz), 2.47 (s, 3 H), 2.07 (br. s.,1 H), 1.98 (1 br. s., 1 H), 1.25 (d, 6
H, J=6.8 Hz). LCMS (ES+) = 517.8 (M+Na).

Tetrahydrofuran (1 mL) containing 9-syn-hydroxy-3-oxa-7-azabicyclo [3.3.1] nonane-7-carboxylate (95 mg, 0.41 mmol) was added to 1M sodium bis (trimethylsilyl). Treated with amide tetrahydrofuran solution (0.69 mL, 0.41 mmol). The reaction was stirred for 30 minutes, then 4-chloro-6- [5- (methylthio) -2,3-dihydro-1H-indol-1-yl] pyrimidine-5-carbonitrile (50 mg, 0.16 mmol). The solution was added dropwise to a tetrahydrofuran (1.5 mL) solution. The resulting mixture was stirred at 70 ° C. for 30 minutes. The reaction mixture was cooled to room temperature and quenched by adding saturated aqueous ammonium chloride. The reaction mixture was diluted with dichloromethane and water. The organic layer was separated and washed sequentially with saturated aqueous sodium bicarbonate and brine, then dried over sodium sulfate. The mixture was filtered and the filtrate was concentrated under reduced pressure. The crude product was purified by column chromatography (20-100% ethyl acetate heptane solution) to give 9-cin-({5-cyano-6- [5- (methylthio) -1H-indol-1-yl]. Pyrimidin-4-yl} oxy) -3-oxa-7-azabicyclo [3.3.1] nonane-7-carboxylate was obtained as a white solid (50 mg, 61%). ¹ H NMR (400 MHz, deuterated chloroform) δ 8.38 (s, 1 H,), 8.14 (d, 1 H, J = 8.6 Hz), 7.17 (d, 1 H, J = 1.9 Hz),
7.11-7.16 (m, 1 H), 5.47 (t, 1 H, J = 3.7 Hz), 4.91-5.01 (m, 1 H,), 4.54 (dd,
2 H, J = 8.6, 7.9 Hz), 4.35 (d, 1 H, J = 14 Hz), 4.21 (br. S., 1 H), 4.18 (s, 1 H),
4.10-4.15 (m, 1 H), 3.78-3.87 (m, 2 H), 3.53-3.61 (m, 1 H), 3.24 (t, 2 H,
J = 8.2 Hz), 2.47 (s, 3 H), 2.07 (br. S., 1 H), 1.98 (1 br. S., 1 H), 1.25 (d, 6
H, J = 6.8 Hz). LCMS (ES +) = 517.8 (M + Na).

Step B: 9-Syn-({5-cyano-6- [5- (methylsulfonyl) -1H-indol-1-yl] pyrimidin-4-yl} oxy) -3-oxa-7-azabicyclo [3. 3.1] Nonane-7-carboxylic acid ester 9-cin-({5-cyano-6- [5- (methylthio) -1H-indol-1-yl] pyrimidin-4-yl} oxy) -3-oxa To a solution of -7-azabicyclo [3.3.1] -nonane-7-carboxylate (50 mg, 0.10 mmol) in dichloromethane (10 mL) is added meta-chloroperoxybenzoic acid (67 mg, 0.27 mmol) once. Added in. After 1 hour, the reaction was quenched with 3 drops of dimethyl sulfide. The reaction mixture was diluted with dichloromethane and washed with 0.5M aqueous sodium hydroxide. The organic layer was separated and dried over sodium sulfate. The mixture was filtered and the filtrate was concentrated in vacuo to give a white powder which was purified by column chromatography (20-90% ethyl acetate heptane solution) to give 9-syn-({5-cyano- 6- [5- (Methylsulfonyl) -1H-indol-1-yl] pyrimidin-4-yl} oxy) -3-oxa-7-azabicyclo [3.3.1] nonane-7-carboxylic acid ester yellow As a solid (35 mg, 66%). A portion of this material was further purified by dissolving a sample of impure material in dichloromethane and adding heptane to precipitate the product as a white solid. ¹ H NMR (400 MHz, deuterated chloroform) δ 8.47 (s, 1 H), 8.32 (d, 1 H, J = 8.6 Hz), 7.72-7.86 (m, 2 H), 5.45
(t, 1 H, J = 3.5 Hz), 4.87-5.05 (m, 1 H), 4.56-4.72 (m, 3 H), 4.48 (d, 1 H,
J = 14 Hz), 4.07-4.27 (m, 2 H), 3.93 (d, 1 H, J = 12 Hz), 3.86 (d, 1 H, J = 12 Hz),
3.15-3.41 (m, 4 H), 3.04 (s, 3 H), 2.00 (br. S., 1 H), 1.94 (br. S., 1 H),
1.25 (d, 6 H, J = 7.0Hz): LCMS (ES +) = 528.0 (M + 1).

(Example 5)
9-anti-({5-cyano-6- [5- (methylsulfonyl) -1H-indol-1-yl] pyrimidin-4-yl} oxy) -3-oxa-7-azabicyclo [3.3.1 Nonane-7-carboxylate isopropyl

この化合物は、９−シン−（｛５−シアノ−６−［５−（メチルスルホニル）−１Ｈ−インドール−１−イル］ピリミジン−４−イル｝オキシ）−３−オキサ−７−アザビシクロ［３．３．１］ノナン−７−カルボン酸エステルの調製手順と同様の２ステップ手順で調製した。最初のステップでは、９−アンチ−ヒドロキシ−３−オキサ−７−アザビシクロ［３．３．１］ノナン−７−カルボン酸エステルを４−クロロ−６−［５−（メチルチオ）−２，３−ジヒドロ−１Ｈ−インドール−１−イル］ピリミジン−５−カルボニトリルと合わせて、９−アンチ−（｛５−シアノ−６−［５−（メチルチオ）−１Ｈ−インドール−１−イル］ピリミジン−４−イル｝オキシ）−３−オキサ−７−アザビシクロ［３．３．１］ノナン−７−カルボン酸イソプロピルを得た。次のステップでは、この中間体を酸化して、９−アンチ−（｛５−シアノ−６−［５−（メチルスルホニル）−１Ｈ−インドール−１−イル］ピリミジン−４−イル｝オキシ）−３−オキサ−７−アザビシクロ［３．３．１］ノナン−７−カルボン酸イソプロピルを得、これをカラムクロマトグラフィー（３０％〜１００％の酢酸エチルヘプタン溶液）によって精製して、生成物を白色の固体（４５ｍｇ、８４％）として得た。¹H NMR (400 MHz, 重水素化クロロホルム) δ 8.47 (s, 1 H) 8.27 - 8.38 (m, 1 H) 7.72 - 7.88 (m, 2 H) 5.51 (t, 1
H, J=3.6 Hz) 4.89 - 5.02 (m, 1 H) 4.63 (t, 2 H, J=8.5 Hz) 4.37 (d, 1 H, J=14
Hz) 4.17 - 4.28 (m, 2 H) 4.14 (d, 1 H, J=11 Hz) 3.77 - 3.88 (m, 2 H) 3.51 -
3.63 (m, 1 H) 3.39 - 3.49 (m, 1 H) 3.34 (t, 2 H, J=8.4 Hz) 3.04 (s, 3 H) 2.07
(br. s., 1 H) 2.00 (br. s., 1 H) 1.25 (d, 6 H, J=6.2 Hz); LCMS (ES+) = 528.0
(M+1).

This compound is 9-syn-({5-cyano-6- [5- (methylsulfonyl) -1H-indol-1-yl] pyrimidin-4-yl} oxy) -3-oxa-7-azabicyclo [3 3.1] Prepared in a two-step procedure similar to the procedure for the preparation of nonane-7-carboxylic acid ester. In the first step, 9-anti-hydroxy-3-oxa-7-azabicyclo [3.3.1] nonane-7-carboxylic acid ester is converted to 4-chloro-6- [5- (methylthio) -2,3- Combined with dihydro-1H-indol-1-yl] pyrimidine-5-carbonitrile, 9-anti-({5-cyano-6- [5- (methylthio) -1H-indol-1-yl] pyrimidine-4 -Il} oxy) -3-oxa-7-azabicyclo [3.3.1] nonane-7-carboxylate isopropyl was obtained. In the next step, this intermediate is oxidized to 9-anti-({5-cyano-6- [5- (methylsulfonyl) -1H-indol-1-yl] pyrimidin-4-yl} oxy)- Isopropyl 3-oxa-7-azabicyclo [3.3.1] nonane-7-carboxylate was obtained, which was purified by column chromatography (30% to 100% ethyl acetate heptane solution) to give the product as white As a solid (45 mg, 84%). ¹ H NMR (400 MHz, deuterated chloroform) δ 8.47 (s, 1 H) 8.27-8.38 (m, 1 H) 7.72-7.88 (m, 2 H) 5.51 (t, 1
H, J = 3.6 Hz) 4.89-5.02 (m, 1 H) 4.63 (t, 2 H, J = 8.5 Hz) 4.37 (d, 1 H, J = 14
Hz) 4.17-4.28 (m, 2 H) 4.14 (d, 1 H, J = 11 Hz) 3.77-3.88 (m, 2 H) 3.51-
3.63 (m, 1 H) 3.39-3.49 (m, 1 H) 3.34 (t, 2 H, J = 8.4 Hz) 3.04 (s, 3 H) 2.07
(br. s., 1 H) 2.00 (br. s., 1 H) 1.25 (d, 6 H, J = 6.2 Hz); LCMS (ES +) = 528.0
(M + 1).

(Example 6)
4-({5-cyano-6- [5- (methylsulfonyl) -2,3-dihydro-1H-indol-1-yl] pyrimidin-4-yl} oxy) piperidine-1-carboxylate

この化合物は、９−シン−（｛５−シアノ−６−［５−（メチルスルホニル）−１Ｈ−インドール−１−イル］ピリミジン−４−イル｝オキシ）−３−オキサ−７−アザビシクロ［３．３．１］ノナン−７−カルボン酸エステルの調製に使用した手順と同様の２ステップ手順で調製した。最初のステップでは、４−ヒドロキシピペリジン−１−カルボン酸イソプロピルを４−クロロ−６−［５−（メチルチオ）−２，３−ジヒドロ−１Ｈ−インドール−１−イル］ピリミジン−５−カルボニトリルと合わせて、４−（｛５−シアノ−６−［５−（メチルチオ）−２，３−ジヒドロ−１Ｈ−インドール−１−イル］ピリミジン−４−イル｝オキシ）ピペリジン−１−カルボン酸イソプロピルを得た。次のステップでは、この中間体を酸化して、４−（｛５−シアノ−６−［５−（メチルスルホニル）−２，３−ジヒドロ−１Ｈ−インドール−１−イル］ピリミジン−４−イル｝オキシ）ピペリジン−１−カルボン酸エステルを得、これをカラムクロマトグラフィー（２０〜９０％の酢酸エチルヘプタン溶液）によって精製して、４−（｛５−シアノ−６−［５−（メチルスルホニル）−２，３−ジヒドロ−１Ｈ−インドール−１−イル］ピリミジン−４−イル｝オキシ）ピペリジン−１−カルボン酸イソプロピルを固体として得た。この化合物をジクロロメタンとヘプタンからなる溶液から沈殿させることによりさらに精製して、黄色の固体（３０ｍｇ、８２％）を得た。¹H NMR (400 MHz, 重水素化クロロホルム) δ 8.46 (s, 1 H), 8.29 (d, J=8.60 Hz, 1 H), 7.73 - 7.85 (m, 2 H), 5.40
- 5.54 (m, 1 H), 4.86 - 5.00 (m, 1 H), 4.61 (t, J=8.40 Hz, 2 H), 3.66 - 3.82
(m, 2 H), 3.40 - 3.53 (m, 2 H), 3.33 (t, J=8.40 Hz, 2 H), 3.04 (s, 3 H), 1.92 -
2.09 (m, 2 H), 1.76 - 1.90 (m, 2 H), 1.25 (d, J=6.25 Hz, 6 H); LCMS (ES+):
486.3 (M+1).

This compound is 9-syn-({5-cyano-6- [5- (methylsulfonyl) -1H-indol-1-yl] pyrimidin-4-yl} oxy) -3-oxa-7-azabicyclo [3 3.1] Prepared in a two step procedure similar to that used for the preparation of nonane-7-carboxylic acid ester. In the first step, isopropyl 4-hydroxypiperidine-1-carboxylate is combined with 4-chloro-6- [5- (methylthio) -2,3-dihydro-1H-indol-1-yl] pyrimidine-5-carbonitrile. Combined with isopropyl 4-({5-cyano-6- [5- (methylthio) -2,3-dihydro-1H-indol-1-yl] pyrimidin-4-yl} oxy) piperidine-1-carboxylate Obtained. In the next step, this intermediate is oxidized to 4-({5-cyano-6- [5- (methylsulfonyl) -2,3-dihydro-1H-indol-1-yl] pyrimidin-4-yl. } Oxy) piperidine-1-carboxylic acid ester, which was purified by column chromatography (20-90% ethyl acetate in heptane) to give 4-({5-cyano-6- [5- (methylsulfonyl) ) -2,3-Dihydro-1H-indol-1-yl] pyrimidin-4-yl} oxy) piperidine-1-carboxylate was obtained as a solid. The compound was further purified by precipitation from a solution consisting of dichloromethane and heptane to give a yellow solid (30 mg, 82%). ¹ H NMR (400 MHz, deuterated chloroform) δ 8.46 (s, 1 H), 8.29 (d, J = 8.60 Hz, 1 H), 7.73-7.85 (m, 2 H), 5.40
-5.54 (m, 1 H), 4.86-5.00 (m, 1 H), 4.61 (t, J = 8.40 Hz, 2 H), 3.66-3.82
(m, 2 H), 3.40-3.53 (m, 2 H), 3.33 (t, J = 8.40 Hz, 2 H), 3.04 (s, 3 H), 1.92-
2.09 (m, 2 H), 1.76-1.90 (m, 2 H), 1.25 (d, J = 6.25 Hz, 6 H); LCMS (ES +):
486.3 (M + 1).

(Example 7)
4-({5-methoxy-6- [5- (methylsulfonyl) -2,3-dihydro-1H-indol-1-yl] pyrimidin-4-yl} oxy) piperidine-1-carboxylate

ステップＡ：４−（｛５−メトキシ−６−［５−（メチルチオ）−２，３−ジヒドロ−１Ｈ−インドール−１−イル］ピリミジン−４−イル｝オキシ）ピペリジン−１−カルボン酸イソプロピル

Step A: 4-({5-Methoxy-6- [5- (methylthio) -2,3-dihydro-1H-indol-1-yl] pyrimidin-4-yl} oxy) piperidine-1-carboxylate

Ｔｅｆｌｏｎセプタムを収容しているキャップで密封したバイアルに、Ｐｄ_２（ｄｂａ）_３（４３ｍｇ、０．０４６ｍｍｏｌ）、２−ジシクロヘキシルホスフィノ−２’，４’，６’−トリイソプロピルビフェニル（３３ｍｇ、０．０６８ｍｍｏｌ）、ナトリウムｔｅｒｔ−ブトキシド（２１ｍｇ、０．２１３ｍｍｏｌ）、４−［（６−クロロ−５−メトキシピリミジン−４−イル）オキシ］ピペリジン−１−カルボン酸イソプロピル（５０ｍｇ、０．１５ｍｍｏｌ）、および５−（メチルチオ）インドリン（３０ｍｇ ０．１８２ｍｍｏｌ）を投入した。脱気した（酸素をパージした）トルエン（２ｍＬ）を加え、得られる混合物を１２０℃で１２時間加熱した。得られる混合物を酢酸エチル（３０ｍＬ）で希釈し、水、飽和炭酸水素ナトリウム、およびブラインで順次洗浄した。次いで有機溶液を硫酸ナトリウムで乾燥させ、濾過し、濾液を減圧下で濃縮した。未精製材料をカラムクロマトグラフィー（１０〜９０％の酢酸エチルヘプタン溶液）によって精製して、不純な４−（｛５−メトキシ−６−［５−（メチルチオ）−２，３−ジヒドロ−１Ｈ−インドール−１−イル］ピリミジン−４−イル｝オキシ）ピペリジン−１−カルボン酸イソプロピルを固体（５５ｍｇ、７５％）として得、これをそれ以上精製せずに次のステップで使用した。LCMS (ES+): 459.0 (M+1).

A vial sealed with a cap containing Teflon septum was charged with Pd ₂ (dba) ₃ (43 mg, 0.046 mmol), 2-dicyclohexylphosphino-2 ′, 4 ′, 6′-triisopropylbiphenyl (33 mg, 0 .068 mmol), sodium tert-butoxide (21 mg, 0.213 mmol), isopropyl 4-[(6-chloro-5-methoxypyrimidin-4-yl) oxy] piperidine-1-carboxylate (50 mg, 0.15 mmol), And 5- (methylthio) indoline (30 mg 0.182 mmol) was added. Degassed (oxygen purged) toluene (2 mL) was added and the resulting mixture was heated at 120 ° C. for 12 hours. The resulting mixture was diluted with ethyl acetate (30 mL) and washed sequentially with water, saturated sodium bicarbonate, and brine. The organic solution was then dried over sodium sulfate, filtered and the filtrate was concentrated under reduced pressure. The crude material was purified by column chromatography (10-90% ethyl acetate heptane solution) to give impure 4-({5-methoxy-6- [5- (methylthio) -2,3-dihydro-1H- Indol-1-yl] pyrimidin-4-yl} oxy) piperidine-1-carboxylate was obtained as a solid (55 mg, 75%), which was used in the next step without further purification. LCMS (ES +): 459.0 (M + 1).

Step B: 4-({5-Methoxy-6- [5- (methylsulfonyl) -2,3-dihydro-1H-indol-1-yl] pyrimidin-4-yl} oxy) piperidine-1-carboxylate This compound is isopropyl 4-({5-methoxy-6- [5- (methylthio) -2,3-dihydro-1H-indol-1-yl] pyrimidin-4-yl} oxy) piperidine-1-carboxylate Is used as a starting material and 9-syn-({5-cyano-6- [5- (methylsulfonyl) -1H-indol-1-yl] pyrimidin-4-yl} oxy) -3-oxa-7- Prepared similarly to the preparation of azabicyclo [3.3.1] nonane-7-carboxylic acid ester (Example 4, Step B). The crude material was purified by column chromatography (20-90% ethyl acetate heptane solution) followed by precipitation from a solution consisting of ethyl acetate and heptane to give 4-({5-methoxy-6- [5 -(Methylsulfonyl) -2,3-dihydro-1H-indol-1-yl] pyrimidin-4-yl} oxy) piperidine-1-carboxylate was obtained as a white solid (25 mg, 42%). ¹ H NMR (400 MHz, deuterated chloroform) δ 8.21 (1 H, s), 7.65-7.73 (3 H, m), 5.31-5.42 (1 H, m), 4.86-
4.97 (1 H, m), 4.32 (2 H, t, J = 8.59 Hz), 3.77-3.86 (2 H, m), 3.75 (3 H, s),
3.33-3.44 (2 H, m), 3.22 (2 H, t, J = 8.59 Hz), 3.01 (3 H, s), 1.97-2.11 (2
H, m), 1.73-1.91 (2 H, m), 1.25 (6 H, d, J = 6.25 Hz); LCMS (ES +): 491.2 (M + 1).

(Example 8)
4-({5-Methyl-6- [5- (methylsulfonyl) -2,3-dihydro-1H-indol-1-yl] pyrimidin-4-yl} oxy) piperidine-1-carboxylate

この化合物は、４−（｛５−メトキシ−６−［５−（メチルスルホニル）−２，３−ジヒドロ−１Ｈ−インドール−１−イル］ピリミジン−４−イル｝オキシ）ピペリジン−１−カルボン酸イソプロピル（実施例７）の調製に使用した手順と同様の２ステップ手順で調製した。最初のステップでは、４−［（６−クロロ−５−メチルピリミジン−４−イル）オキシ］ピペリジン−１−カルボン酸イソプロピルを５−（メチルチオ）インドリンと合わせて、４−（｛５−メチル−６−［５−（メチルチオ）−２，３−ジヒドロ−１Ｈ−インドール−１−イル］ピリミジン−４−イル｝オキシ）ピペリジン−１−カルボン酸イソプロピルを得た。次のステップでは、この中間体を酸化して、４−（｛５−メチル−６−［５−（メチルスルホニル）−２，３−ジヒドロ−１Ｈ−インドール−１−イル］ピリミジン−４−イル｝オキシ）ピペリジン−１−カルボン酸イソプロピルを得、これをカラムクロマトグラフィー（５０〜７０％の酢酸エチルヘプタン溶液）によって精製して、オフホワイトの固体（８８ｍｇ、８１％）を得た。¹H NMR (400 MHz, 重水素化クロロホルム) δ 1.22 (d, J=6.3 Hz, 6 H) 1.71 - 1.85 (m, 2 H) 2.01 (br. s., 5 H)
2.98 (s, 3 H) 3.17 (t, J=8.3 Hz, 2 H) 3.39 (br. s., 2 H) 3.73 (br. s., 2 H)
4.15 (t, J=8.3 Hz, 2 H) 4.84 - 4.97 (m, 1 H) 5.30 - 5.41 (m, 1 H) 6.66 (d,
J=8.2 Hz, 1 H) 7.63 (d, J=8.4 Hz, 1 H) 7.66 (s, 1 H) 8.38 (s, 1 H). LCMS (ES+):
475.4 (M+1).

This compound is 4-({5-methoxy-6- [5- (methylsulfonyl) -2,3-dihydro-1H-indol-1-yl] pyrimidin-4-yl} oxy) piperidine-1-carboxylic acid Prepared in a two step procedure similar to that used to prepare isopropyl (Example 7). In the first step, isopropyl 4-[(6-chloro-5-methylpyrimidin-4-yl) oxy] piperidine-1-carboxylate is combined with 5- (methylthio) indoline to give 4-({5-methyl- 6- [5- (Methylthio) -2,3-dihydro-1H-indol-1-yl] pyrimidin-4-yl} oxy) piperidine-1-carboxylate was obtained. In the next step, this intermediate is oxidized to 4-({5-methyl-6- [5- (methylsulfonyl) -2,3-dihydro-1H-indol-1-yl] pyrimidin-4-yl. } Oxy) piperidine-1-carboxylate was obtained, which was purified by column chromatography (50-70% ethyl acetate in heptane) to give an off-white solid (88 mg, 81%). ¹ H NMR (400 MHz, deuterated chloroform) δ 1.22 (d, J = 6.3 Hz, 6 H) 1.71-1.85 (m, 2 H) 2.01 (br. S., 5 H)
2.98 (s, 3 H) 3.17 (t, J = 8.3 Hz, 2 H) 3.39 (br. S., 2 H) 3.73 (br. S., 2 H)
4.15 (t, J = 8.3 Hz, 2 H) 4.84-4.97 (m, 1 H) 5.30-5.41 (m, 1 H) 6.66 (d,
J = 8.2 Hz, 1 H) 7.63 (d, J = 8.4 Hz, 1 H) 7.66 (s, 1 H) 8.38 (s, 1 H). LCMS (ES +):
475.4 (M + 1).

Example 9
4- [6- (5-Dimethylcarbamoyl-2,3-dihydroindol-1-yl) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid isopropyl ester

ステップＡ：１−［６−（１−イソプロポキシカルボニル−ピペリジン−４−イルオキシ）−ピリミジン−４−イル］−２，３−ジヒドロ−１Ｈ−インドール−５−カルボン酸

Step A: 1- [6- (1-Isopropoxycarbonyl-piperidin-4-yloxy) -pyrimidin-4-yl] -2,3-dihydro-1H-indole-5-carboxylic acid

１−（６−クロロ−ピリミジン−４−イル）−２，３−ジヒドロ−１Ｈ−インドール−５−カルボン酸（６２．０ｍｇ、０．２２５ｍｍｏｌ）および４−ヒドロキシピペリジン−１−カルボン酸イソプロピルエステル（５４．９ｍｇ、０．２９３ｍｍｏｌ）を無水１，４−ジオキサン（２．０ｍＬ）に混ぜた混合物を１０５℃に加熱した。５分間撹拌した後、１Ｍのナトリウムビス（トリメチルシリル）アミドテトラヒドロフラン溶液（０．５４ｍＬ、０．５４ｍｍｏｌ）を加えた。２時間後、反応混合物を水で希釈し、減圧下で濃縮した。得られる残渣をジクロロメタンに溶かし、飽和炭酸水素ナトリウム水溶液で洗浄した。水相をジクロロメタンで３回抽出し、有機層を合わせて硫酸ナトリウムで乾燥させ、濾過した。濾液を減圧下で濃縮し、未精製残渣をカラムクロマトグラフィー（２０〜７０％の酢酸エチルヘプタン溶液）によって精製して、１−［６−（１−イソプロポキシカルボニル−ピペリジン−４−イルオキシ）−ピリミジン−４−イル］−２，３−ジヒドロ−１Ｈ−インドール−５−カルボン酸（３０ｍｇ、３１％）を白色の泡沫として得た。¹H NMR (400 MHz, 重水素化クロロホルム) δ 1.24 (d, J=6.25 Hz, 6 H) 1.67 - 1.79 (m, 2 H) 1.93 - 2.05 (m, 2 H)
3.22 - 3.36 (m, 4 H) 3.75 - 3.87 (m, 2 H) 4.03 (t, J=8.69 Hz, 2 H) 4.87 - 4.97
(m, 1 H) 5.27 - 5.35 (m, 1 H) 5.97 (s, 1 H) 7.89 (s, 1 H) 7.98 (d, J=10.15 Hz,
1 H) 8.43 (d, J=8.00 Hz, 1 H) 8.49 (s, 1 H)

1- (6-Chloro-pyrimidin-4-yl) -2,3-dihydro-1H-indole-5-carboxylic acid (62.0 mg, 0.225 mmol) and 4-hydroxypiperidine-1-carboxylic acid isopropyl ester ( A mixture of 54.9 mg, 0.293 mmol) in anhydrous 1,4-dioxane (2.0 mL) was heated to 105 ° C. After stirring for 5 minutes, 1M sodium bis (trimethylsilyl) amide tetrahydrofuran solution (0.54 mL, 0.54 mmol) was added. After 2 hours, the reaction mixture was diluted with water and concentrated under reduced pressure. The resulting residue was dissolved in dichloromethane and washed with saturated aqueous sodium bicarbonate. The aqueous phase was extracted 3 times with dichloromethane and the combined organic layers were dried over sodium sulfate and filtered. The filtrate was concentrated under reduced pressure and the crude residue was purified by column chromatography (20-70% ethyl acetate in heptane) to give 1- [6- (1-isopropoxycarbonyl-piperidin-4-yloxy)- Pyrimidin-4-yl] -2,3-dihydro-1H-indole-5-carboxylic acid (30 mg, 31%) was obtained as a white foam. ¹ H NMR (400 MHz, deuterated chloroform) δ 1.24 (d, J = 6.25 Hz, 6 H) 1.67-1.79 (m, 2 H) 1.93-2.05 (m, 2 H)
3.22-3.36 (m, 4 H) 3.75-3.87 (m, 2 H) 4.03 (t, J = 8.69 Hz, 2 H) 4.87-4.97
(m, 1 H) 5.27-5.35 (m, 1 H) 5.97 (s, 1 H) 7.89 (s, 1 H) 7.98 (d, J = 10.15 Hz,
1 H) 8.43 (d, J = 8.00 Hz, 1 H) 8.49 (s, 1 H)

Step B: 4- [6- (5-Dimethylcarbamoyl-2,3-dihydroindol-1-yl) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid isopropyl ester carboxylic acid (30 mg, 0.07 mmol) , Diisopropylethylamine (0.024 mL, 0.14 mmol), and O-benzotriazole-N, N, N ′, N′-tetramethyl-uronium-hexafluoro-phosphate (35 mg, 0.091 mmol) in N, N— To a mixture of dimethylformamide (1.0 mL) was added 2M dimethylamine tetrahydrofuran solution (0.052 mL, 0.105 mmol). After 2 hours, the reaction mixture was diluted with water and extracted three times with ethyl acetate. The organic layers were combined, dried over sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The crude residue was purified by column chromatography (20-70% ethyl acetate heptane solution) to give 4- [6- (5-dimethylcarbamoyl-2,3-dihydroindol-1-yl) -pyrimidine-4- [Iloxy] -piperidine-1-carboxylic acid isopropyl ester (8 mg, 30%) was obtained as a white solid. ¹ H NMR (400 MHz, deuterated chloroform) δ 1.25 (d, J = 6.05 Hz, 6 H) 1.68-1.78 (m, 2 H) 1.95-2.04 (m, 2 H)
3.06 (br. S., 6 H) 3.24 (t, J = 8.69 Hz, 2 H) 3.28-3.36 (m, 2 H) 3.81 (wide s., 2 H) 3.99 (t, J = 8.59 Hz, 2 H) 4.89-
4.96 (m, 1 H) 5.27-5.34 (m, 1 H) 5.93 (s, 1 H) 7.29 (d, 1 H) 7.32 (s, 1 H)
8.36 (d, J = 8.40 Hz, 1 H) 8.46 (s, 1 H). LCMS (ES +): 454.4 (M + 1).

(Example 10)
4-{[6- (5-Cyano-2,3-dihydro-1H-indol-1-yl) pyrimidin-4-yl] oxy} piperidine-1-carboxylate

４−（６−クロロ−ピリミジン−４−イルオキシ）−ピペリジン−１−カルボン酸イソプロピルエステル（５０．４ｍｇ、０．１６８ｍｍｏｌ）および２，３−ジヒドロ−１Ｈ−インドール−５−カルボニトリル（２２．０ｍｇ、０．１５ｍｍｏｌ）を無水１，４−ジオキサン（２．０ｍＬ）に混ぜた混合物を１０５℃に加熱した。５分間撹拌した後、１Ｍのナトリウムビス（トリメチルシリル）アミドテトラヒドロフラン溶液（０．１８４ｍＬ、０．１８４ｍｍｏｌ）を加えた。３０分後、反応混合物を飽和塩化アンモニウム水溶液で失活させ、減圧下で濃縮した。得られる残渣をジクロロメタンに溶解させ、飽和炭酸水素ナトリウム水溶液で洗浄した。水相をジクロロメタンで３回抽出し、有機層を合わせて硫酸ナトリウムで乾燥させ、濾過した。濾液を減圧下で濃縮し、未精製残渣をカラムクロマトグラフィー（２０〜６０％の酢酸エチルヘプタン溶液）によって精製して、４−｛［６−（５−シアノ−２，３−ジヒドロ−１Ｈ−インドール−１−イル）ピリミジン−４−イル］オキシ｝ピペリジン−１−カルボン酸イソプロピル（３８ｍｇ、６１％）を白色の固体として得た。¹H NMR (400 MHz, 重水素化クロロホルム) δ 1.25 (d, J=6.25 Hz, 6 H) 1.68 - 1.78 (m, 2 H) 1.96 - 2.04 (m, 2 H)
3.24 - 3.36 (m, 4 H) 3.78 - 3.87 (m, 2 H) 4.03 (t, J=8.79 Hz, 2 H) 4.89 - 4.97
(m, 1 H) 5.29 - 5.36 (m, 1 H) 5.96 (s, 1 H) 7.43 (s, 1 H) 7.51 (dd, J=8.79,
1.17 Hz, 1 H) 8.48 - 8.53 (m, 2 H). LCMS (ES+): 408.4 (M+1).

4- (6-Chloro-pyrimidin-4-yloxy) -piperidine-1-carboxylic acid isopropyl ester (50.4 mg, 0.168 mmol) and 2,3-dihydro-1H-indole-5-carbonitrile (22.0 mg) , 0.15 mmol) in anhydrous 1,4-dioxane (2.0 mL) was heated to 105 ° C. After stirring for 5 minutes, 1M sodium bis (trimethylsilyl) amide tetrahydrofuran solution (0.184 mL, 0.184 mmol) was added. After 30 minutes, the reaction mixture was quenched with saturated aqueous ammonium chloride and concentrated under reduced pressure. The resulting residue was dissolved in dichloromethane and washed with saturated aqueous sodium bicarbonate. The aqueous phase was extracted 3 times with dichloromethane and the combined organic layers were dried over sodium sulfate and filtered. The filtrate was concentrated under reduced pressure and the crude residue was purified by column chromatography (20-60% ethyl acetate heptane solution) to give 4-{[6- (5-cyano-2,3-dihydro-1H- Indol-1-yl) pyrimidin-4-yl] oxy} piperidine-1-carboxylate (38 mg, 61%) was obtained as a white solid. ¹ H NMR (400 MHz, deuterated chloroform) δ 1.25 (d, J = 6.25 Hz, 6 H) 1.68-1.78 (m, 2 H) 1.96-2.04 (m, 2 H)
3.24-3.36 (m, 4 H) 3.78-3.87 (m, 2 H) 4.03 (t, J = 8.79 Hz, 2 H) 4.89-4.97
(m, 1 H) 5.29-5.36 (m, 1 H) 5.96 (s, 1 H) 7.43 (s, 1 H) 7.51 (dd, J = 8.79,
1.17 Hz, 1 H) 8.48-8.53 (m, 2 H). LCMS (ES +): 408.4 (M + 1).

(Example 11)
4-[(6- {5-[(2-hydroxyethyl) sulfonyl] -2,3-dihydro-1H-indol-1-yl} pyrimidin-4-yl) oxy] piperidine-1-carboxylate

ステップＡ：４−［（６−｛５−［（２−｛［ｔｅｒｔ−ブチル（ジメチル）シリル］オキシ｝エチル）チオ］−２，３−ジヒドロ−１Ｈ−インドール−１−イル｝ピリミジン−４−イル）オキシ］ピペリジン−１−カルボン酸イソプロピル

Step A: 4-[(6- {5-[(2-{[tert-butyl (dimethyl) silyl] oxy} ethyl) thio] -2,3-dihydro-1H-indol-1-yl} pyrimidine-4 -Yl) oxy] piperidine-1-carboxylate isopropyl

Ｔｅｆｌｏｎセプタム付きのバイアルにおいて、化合物５−［（２−｛［ｔｅｒｔ−ブチル（ジメチル）シリル］オキシ｝エチル）チオ］インドリン（１４３ｍｇ、０．４６２ｍｍｏｌ）と４−［（６−クロロ−ピリミジン−４−イル）オキシ］ピペリジン−１−カルボン酸イソプロピル（１４６．９ｍｇ、０．４９ｍｍｏｌ）を無水１，４−ジオキサン（２．０ｍＬ）中で合わせた。溶液を５分間１００℃に加熱し、次いで１Ｍのナトリウムビス（トリメチルシリル）アミドテトラヒドロフラン溶液（０．５５ｍＬ、０．５５ｍｍｏｌ）を加えた。混合物を１００℃で１時間撹拌した。次いで反応液を室温に冷まし、減圧下で濃縮し、残渣を酢酸エチル（４０ｍＬ）で希釈した。次いで溶液を飽和炭酸水素ナトリウム（２５ｍＬ）で２回洗浄し、硫酸マグネシウムで乾燥させた。混合物を濾過し、濾液を減圧下で濃縮して褐色の油状物を得、これをカラムクロマトグラフィーによって精製して、４−［（６−｛５−［（２−｛［ｔｅｒｔ−ブチル（ジメチル）シリル］オキシ｝エチル）チオ］−２，３−ジヒドロ−１Ｈ−インドール−１−イル｝ピリミジン−４−イル）オキシ］ピペリジン−１−カルボン酸イソプロピル（１６４．１ｍｇ、６２％）を得た。¹H NMR (400 MHz, 重水素化クロロホルム) δ 0.02 (s, 6 H) 0.86 (s, 9 H) 1.24 (d, 6 H) 1.65 - 1.77 (m, 2 H) 1.92
- 2.04 (m, 2 H) 2.94 - 2.99 (m, 2 H) 3.19 (t, J=8.59 Hz, 2 H) 3.26 - 3.35 (m, 2
H) 3.71 - 3.77 (m, 2 H) 3.77 - 3.88 (m, 2 H) 3.95 (t, J=8.59 Hz, 2 H) 4.87 -
4.96 (m, 1 H) 5.27 - 5.29 (m, 1 H) 5.89 (d, J=0.98 Hz, 1 H) 7.24 - 7.25 (m, 2
H) 8.25 (d, J=8.98 Hz, 1 H) 8.43 (d, J=0.78 Hz, 1 H).

In a vial with a Teflon septum, the compounds 5-[(2-{[tert-butyl (dimethyl) silyl] oxy} ethyl) thio] indoline (143 mg, 0.462 mmol) and 4-[(6-chloro-pyrimidine-4 -Iyl) oxy] piperidine-1-carboxylate (146.9 mg, 0.49 mmol) was combined in anhydrous 1,4-dioxane (2.0 mL). The solution was heated to 100 ° C. for 5 minutes, then 1M sodium bis (trimethylsilyl) amide tetrahydrofuran solution (0.55 mL, 0.55 mmol) was added. The mixture was stirred at 100 ° C. for 1 hour. The reaction was then cooled to room temperature, concentrated under reduced pressure, and the residue was diluted with ethyl acetate (40 mL). The solution was then washed twice with saturated sodium bicarbonate (25 mL) and dried over magnesium sulfate. The mixture was filtered and the filtrate was concentrated under reduced pressure to give a brown oil which was purified by column chromatography to give 4-[(6- {5-[(2-{[tert-butyl (dimethyl ) Silyl] oxy} ethyl) thio] -2,3-dihydro-1H-indol-1-yl} pyrimidin-4-yl) oxy] piperidine-1-carboxylate (164.1 mg, 62%) was obtained. . ¹ H NMR (400 MHz, deuterated chloroform) δ 0.02 (s, 6 H) 0.86 (s, 9 H) 1.24 (d, 6 H) 1.65-1.77 (m, 2 H) 1.92
-2.04 (m, 2 H) 2.94-2.99 (m, 2 H) 3.19 (t, J = 8.59 Hz, 2 H) 3.26-3.35 (m, 2
H) 3.71-3.77 (m, 2 H) 3.77-3.88 (m, 2 H) 3.95 (t, J = 8.59 Hz, 2 H) 4.87-
4.96 (m, 1 H) 5.27-5.29 (m, 1 H) 5.89 (d, J = 0.98 Hz, 1 H) 7.24-7.25 (m, 2
H) 8.25 (d, J = 8.98 Hz, 1 H) 8.43 (d, J = 0.78 Hz, 1 H).

Step B: 4-[(6- {5-[(2-{[tert-Butyl (dimethyl) silyl] oxy} ethyl) sulfonyl] -2,3-dihydro-1H-indol-1-yl} pyrimidine-4 -Yl) oxy] piperidine-1-carboxylate isopropyl

４−［（６−｛５−［（２−｛［ｔｅｒｔ−ブチル（ジメチル）シリル］オキシ｝エチル）チオ］−２，３−ジヒドロ−１Ｈ−インドール−１−イル｝ピリミジン−４−イル）オキシ］ピペリジン−１−カルボン酸イソプロピル（８０ｍｇ、０．１４ｍｍｏｌ）をクロロホルム（３．０ｍＬ）に溶解させ、−５℃に冷却した。ｍｅｔａ−クロロ過安息香酸（８１．６ｍｇ、０．３６ｍｍｏｌ）を１回で加え、反応液を４５分かけてゆっくりと室温に温めた。次いで反応混合物を減圧下で濃縮し、未精製残渣をカラムクロマトグラフィーによって精製して、４−［（６−｛５−［（２−｛［ｔｅｒｔ−ブチル（ジメチル）シリル］オキシ｝エチル）スルホニル］−２，３−ジヒドロ−１Ｈ−インドール−１−イル｝ピリミジン−４−イル）オキシ］ピペリジン−１−カルボン酸イソプロピル（７８ｍｇ、９２％）を透明な油状物として得た。¹H NMR (400 MHz, 重水素化クロロホルム) δ 0.03 (s, 6 H) 0.77 (s, 9 H) 1.23 (s, 3 H) 1.25 (s, 3 H) 1.66 - 1.79
(m, 2 H) 1.97 (br. s., 2 H) 3.24 - 3.30 (m, 2 H) 3.29 - 3.35 (m, 4 H) 3.75 -
3.87 (m, 2 H) 3.96 (t, J=6.54 Hz, 2 H) 4.03 (t, J=8.78 Hz, 2 H) 4.86 - 4.97 (m,
1 H) 5.27 - 5.35 (m, 1 H) 5.96 (d, J=0.78 Hz, 1 H) 7.66 (d, J=1.56 Hz, 1 H)
7.72 (dd, J=8.69, 2.05 Hz, 1 H) 8.49 (d, J=0.78 Hz, 1 H) 8.53 (d, J=8.78 Hz, 1
H).

4-[(6- {5-[(2-{[tert-butyl (dimethyl) silyl] oxy} ethyl) thio] -2,3-dihydro-1H-indol-1-yl} pyrimidin-4-yl) Isopropyl oxy] piperidine-1-carboxylate (80 mg, 0.14 mmol) was dissolved in chloroform (3.0 mL) and cooled to −5 ° C. Meta-chloroperbenzoic acid (81.6 mg, 0.36 mmol) was added in one portion and the reaction was slowly warmed to room temperature over 45 minutes. The reaction mixture was then concentrated under reduced pressure and the crude residue was purified by column chromatography to give 4-[(6- {5-[(2-{[tert-butyl (dimethyl) silyl] oxy} ethyl) sulfonyl. ] -2,3-Dihydro-1H-indol-1-yl} pyrimidin-4-yl) oxy] piperidine-1-carboxylate (78 mg, 92%) was obtained as a clear oil. ¹ H NMR (400 MHz, deuterated chloroform) δ 0.03 (s, 6 H) 0.77 (s, 9 H) 1.23 (s, 3 H) 1.25 (s, 3 H) 1.66-1.79
(m, 2 H) 1.97 (br. s., 2 H) 3.24-3.30 (m, 2 H) 3.29-3.35 (m, 4 H) 3.75-
3.87 (m, 2 H) 3.96 (t, J = 6.54 Hz, 2 H) 4.03 (t, J = 8.78 Hz, 2 H) 4.86-4.97 (m,
1 H) 5.27-5.35 (m, 1 H) 5.96 (d, J = 0.78 Hz, 1 H) 7.66 (d, J = 1.56 Hz, 1 H)
7.72 (dd, J = 8.69, 2.05 Hz, 1 H) 8.49 (d, J = 0.78 Hz, 1 H) 8.53 (d, J = 8.78 Hz, 1
H).

Step C: 4-[(6- {5-[(2-hydroxyethyl) sulfonyl] -2,3-dihydro-1H-indol-1-yl} pyrimidin-4-yl) oxy] piperidine-1-carboxylic acid Isopropyl 4-[(6- {5-[(2-{[tert-butyl (dimethyl) silyl] oxy} ethyl) sulfonyl] -2,3-dihydro-1H-indol-1-yl} pyrimidin-4-yl ) Isopropyl oxy] piperidine-1-carboxylate (75 mg, 0.12 mmol) was dissolved in 1,4-dioxane (3 mL) and 4M hydrochloric acid 1,4-dioxane solution (0.25 mL) was added. The reaction was stirred for 25 minutes and then filtered to give 4-[(6- {5-[(2-hydroxyethyl) sulfonyl] -2,3-dihydro-1H-indol-1-yl} pyrimidine-4- Yl) oxy] piperidine-1-carboxylate (21 mg, 35%) was obtained as a white solid. ¹ H NMR (400 MHz, deuterated chloroform) δ 1.24 (d, J = 6.25 Hz, 6 H) 1.70-1.82 (m, 2 H) 2.05-2.14 (m, 2 H)
3.31-3.43 (m, 6 H) 3.84-3.93 (m, 2 H) 3.99-4.03 (m, 2 H) 4.20-4.27 (m,
2 H) 4.91 (q, 1 H) 5.52-5.59 (m, 1 H) 6.14 (s, 1 H) 7.80 (s, 1 H) 7.84 (d,
J = 8.59 Hz, 1 H) 8.43 (d, J = 8.39 Hz, 1 H) 8.69 (s, 1 H). LCMS (ES +): 491 (M + 1).

(Example 12)
4-{[6- (2,3-Dihydro-1H-pyrrolo [3,2-b] pyridin-1-yl) pyrimidin-4-yl] oxy} piperidine-1-carboxylate

４−ヒドロキシピペリジンカルボン酸イソプロピル（８０．５ｍｇ、０．４３ｍｍｏｌ）と無水Ｎ，Ｎ−ジメチルホルムアミド（５ｍＬ）からなる溶液に、水素化ナトリウム（１９ｍｇ、０．４７ｍｍｏｌ）を加え、混合物を２０分間撹拌した。１−（６−クロロピリミジン−４−イル）−２，３−ジヒドロ−１Ｈ−ピロロ［３，２−ｂ］ピリジン（１００ｍｇ、０．４３ｍｍｏｌ）を加え、反応液を６０℃で１４時間加熱した。反応液をメチルｔｅｒｔ−ブチルエーテルで希釈し、水で洗浄した。相を分離し、水層をメチルｔｅｒｔ−ブチルエーテルおよび酢酸エチルで順次抽出した。有機抽出物を合わせて水に続いてブラインで洗浄し、次いで硫酸ナトリウムで乾燥させた。混合物を濾過し、濾液を減圧下で濃縮した。残渣をカラムクロマトグラフィー（５％のメタノール／０．５％のトリエチルアミン酢酸エチル溶液）によって精製して、４−｛［６−（２，３−ジヒドロ−１Ｈ−ピロロ［３，２−ｂ］ピリジン−１−イル）ピリミジン−４−イル］オキシ｝ピペリジン−１−カルボン酸イソプロピルを濃厚な油状物（９０ｍｇ、５５％）として得た。¹H NMR (400 MHz, 重水素化クロロホルム): δ 8.63 (d, J=8.3 Hz, 0.5 H), 8.57 (d, J=8.3 Hz, 0.5 H), 8.60 (s, 0.5
H), 8.45 (s, 0.5 H), 8.16 (d, J=4.98 Hz, 0.5 H), 8.07 (d, J=4.98 Hz, 0.5 H),
7.10-7.15 (m, 1H), 6.62 (s, 0.5 H), 5.92 (s, 0.5 H), 4.87-4.94 (m, 2 H),
4.00-4.13 (m, 2 H), 3.81-3.98 (m, 2 H), 3.30-3.4 (m, 2 H), 3.03-3.11 (m, 2 H),
1.83-2.03 (m, 2 H), 1.41-1.51 (m, 2 H), 1.17-1.26 (m, 6 H). LCMS (ES+): 384
(M+1).

To a solution consisting of isopropyl 4-hydroxypiperidinecarboxylate (80.5 mg, 0.43 mmol) and anhydrous N, N-dimethylformamide (5 mL) was added sodium hydride (19 mg, 0.47 mmol) and the mixture was stirred for 20 minutes. did. 1- (6-Chloropyrimidin-4-yl) -2,3-dihydro-1H-pyrrolo [3,2-b] pyridine (100 mg, 0.43 mmol) was added and the reaction heated at 60 ° C. for 14 hours. . The reaction solution was diluted with methyl tert-butyl ether and washed with water. The phases were separated and the aqueous layer was extracted sequentially with methyl tert-butyl ether and ethyl acetate. The organic extracts were combined and washed with water followed by brine and then dried over sodium sulfate. The mixture was filtered and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography (5% methanol / 0.5% triethylamine ethyl acetate solution) to give 4-{[6- (2,3-dihydro-1H-pyrrolo [3,2-b] pyridine. -1-yl) pyrimidin-4-yl] oxy} piperidine-1-carboxylate was obtained as a thick oil (90 mg, 55%). ¹ H NMR (400 MHz, deuterated chloroform): δ 8.63 (d, J = 8.3 Hz, 0.5 H), 8.57 (d, J = 8.3 Hz, 0.5 H), 8.60 (s, 0.5
H), 8.45 (s, 0.5 H), 8.16 (d, J = 4.98 Hz, 0.5 H), 8.07 (d, J = 4.98 Hz, 0.5 H),
7.10-7.15 (m, 1H), 6.62 (s, 0.5 H), 5.92 (s, 0.5 H), 4.87-4.94 (m, 2 H),
4.00-4.13 (m, 2 H), 3.81-3.98 (m, 2 H), 3.30-3.4 (m, 2 H), 3.03-3.11 (m, 2 H),
1.83-2.03 (m, 2 H), 1.41-1.51 (m, 2 H), 1.17-1.26 (m, 6 H). LCMS (ES +): 384
(M + 1).

(Example 13)
4-{[6- (2,3-dihydro-1H-pyrrolo [3,2-b] pyridin-1-yl) -5-methylpyrimidin-4-yl] oxy} -piperidine-1-carboxylate

この化合物は、１−（６−クロロ−５−メチルピリミジン−４−イル）−２，３−ジヒドロ−１Ｈ−ピロロ［３，２−ｂ］ピリジンと４−ヒドロキシピペリジンカルボン酸イソプロピルから、４−｛［６−（２，３−ジヒドロ−１Ｈ−ピロロ［３，２−ｂ］ピリジン−１−イル）ピリミジン−４−イル］オキシ｝ピペリジン−１−カルボン酸イソプロピル（実施例１２）の調製について記載したのと同様にして調製した。粗生成物をジエチルエーテルに溶解させた。ヘプタンをゆっくりと加え、純粋な−４−｛［６−（２，３−ジヒドロ−１Ｈ−ピロロ［３，２−ｂ］ピリジン−１−イル）−５−メチルピリミジン−４−イル］オキシ｝−ピペリジン−１−カルボン酸イソプロピル（７５ｍｇ、８５％）を溶液から油状物として生じさせた。¹H NMR (400 MHz, 重水素化クロロホルム): δ 8.37 (s, 1H), 8.00 (d, J=5.8 Hz, 1H), 6.97-7.04 (m, 2 H), 4.87-4.96
(m, 2 H), 4.14 (t, 1H), 3.72-3.88 (m, 3 H), 3.37-3.42 (m,1H), 3.28 (t, 1H), 3.03-3.09
(m, 2 H), 2.05 (s, 3 H), 1.74-1.87 (m, 2 H), 1.42-1.50 (m, 2 H),1.02-1.26 (m. 6
H). LCMS (ES+): 398 (M+1).

This compound is composed of 1- (6-chloro-5-methylpyrimidin-4-yl) -2,3-dihydro-1H-pyrrolo [3,2-b] pyridine and isopropyl 4-hydroxypiperidinecarboxylate. Preparation of {[6- (2,3-dihydro-1H-pyrrolo [3,2-b] pyridin-1-yl) pyrimidin-4-yl] oxy} piperidine-1-carboxylate (Example 12) Prepared as described. The crude product was dissolved in diethyl ether. Slowly add heptane and add pure-4-{[6- (2,3-dihydro-1H-pyrrolo [3,2-b] pyridin-1-yl) -5-methylpyrimidin-4-yl] oxy} -Isopropylpiperidine-1-carboxylate (75 mg, 85%) was produced as an oil from the solution. ¹ H NMR (400 MHz, deuterated chloroform): δ 8.37 (s, 1H), 8.00 (d, J = 5.8 Hz, 1H), 6.97-7.04 (m, 2 H), 4.87-4.96
(m, 2 H), 4.14 (t, 1H), 3.72-3.88 (m, 3 H), 3.37-3.42 (m, 1H), 3.28 (t, 1H), 3.03-3.09
(m, 2 H), 2.05 (s, 3 H), 1.74-1.87 (m, 2 H), 1.42-1.50 (m, 2 H), 1.02-1.26 (m. 6
H). LCMS (ES +): 398 (M + 1).

(Example 14)
4-({6- [5- (methylsulfonyl) -2,3-dihydro-1H-pyrrolo [2,3-b] pyridin-1-yl] pyrimidin-4-yl} oxy) piperidine-1-carboxylic acid Isopropyl

この化合物は、４−ヒドロキシピペリジン−１−カルボン酸イソプロピルと１−（６−クロロピリミジン−４−イル）−５−（メチルスルホニル）−２，３−ジヒドロ−１Ｈ−ピロロ［２，３−ｂ］ピリジンから、実施例１について記載したのと同様にして調製した。粗生成物をカラムクロマトグラフィー（酢酸エチルヘプタン溶液の勾配）によって精製して白色の固体を得、これをアセトニトリル中で加熱し、冷ました。混合物を濾過し、単離した白色の固体を真空中で乾燥させて、４−（｛６−［５−（メチルスルホニル）−２，３−ジヒドロ−１Ｈ−ピロロ［２，３−ｂ］ピリジン−１−イル］ピリミジン−４−イル｝オキシ）ピペリジン−１−カルボン酸エステル（２８２ｍｇ、収率５２％）を得た。¹H NMR (400 MHz, 重水素化クロロホルム): δ 1.27 (d, J=6.2 Hz, 6 H), 1.73 - 1.84 (m, 2 H), 1.96 - 2.06 (m, 2
H), 3.09 (s, 3 H), 3.24 (t, J=8.7 Hz, 2 H), 3.31 - 3.41 (m, 2 H), 3.78 - 3.89
(m, 2 H), 4.44 (dd, J=9.4, 8.1 Hz, 2 H), 4.90 - 4.99 (m, 1 H), 5.32 (tt, J=7.9,
3.8 Hz, 1 H), 7.84 (dt, J=2.4, 1.3 Hz, 1 H), 8.12 (d, J=1.0 Hz, 1 H), 8.53 (d,
J=1.0 Hz, 1 H), 8.70 (dt, J=2.1, 0.7 Hz, 1 H). LCMS (ES+): 462 (M+1).

This compound consists of isopropyl 4-hydroxypiperidine-1-carboxylate and 1- (6-chloropyrimidin-4-yl) -5- (methylsulfonyl) -2,3-dihydro-1H-pyrrolo [2,3-b Prepared from pyridine as described for Example 1. The crude product was purified by column chromatography (gradient of ethyl acetate heptane solution) to give a white solid which was heated in acetonitrile and cooled. The mixture was filtered and the isolated white solid was dried in vacuo to give 4-({6- [5- (methylsulfonyl) -2,3-dihydro-1H-pyrrolo [2,3-b] pyridine. -1-yl] pyrimidin-4-yl} oxy) piperidine-1-carboxylic acid ester (282 mg, yield 52%) was obtained. ¹ H NMR (400 MHz, deuterated chloroform): δ 1.27 (d, J = 6.2 Hz, 6 H), 1.73-1.84 (m, 2 H), 1.96-2.06 (m, 2
H), 3.09 (s, 3 H), 3.24 (t, J = 8.7 Hz, 2 H), 3.31-3.41 (m, 2 H), 3.78-3.89
(m, 2 H), 4.44 (dd, J = 9.4, 8.1 Hz, 2 H), 4.90-4.99 (m, 1 H), 5.32 (tt, J = 7.9,
3.8 Hz, 1 H), 7.84 (dt, J = 2.4, 1.3 Hz, 1 H), 8.12 (d, J = 1.0 Hz, 1 H), 8.53 (d,
J = 1.0 Hz, 1 H), 8.70 (dt, J = 2.1, 0.7 Hz, 1 H). LCMS (ES +): 462 (M + 1).

(Example 15)
3-Fluoro-4-({6- [5- (methylsulfonyl) -2,3-dihydro-1H-indol-1-yl] pyrimidin-4-yl} oxy) piperidine-1-carboxylate tert-butyl

１−（６−クロロピリミジン−４−イル）−５−（メチルスルホニル）インドリン（３３．８ｍｇ、０．１０９ｍｍｏｌ）および３−フルオロ−４−ヒドロキシピペリジン−１−カルボン酸ｔｅｒｔ−ブチル（シスおよびトランス異性体のラセミ混合物）（２０ｍｇ、０．０９１ｍｍｏｌ）を１．５ｍＬの１，４−ジオキサンに溶かした、マイクロ波バイアル中の熱（１０５℃）溶液に、ナトリウムビス（トリメチルシリル）アミド（０．１４ｍＬ、１Ｍテトラヒドロフラン溶液）を加えた。撹拌した混合物を窒素雰囲気中にて１０５℃で４時間加熱した後、これを室温に冷却し、水および酢酸エチルで希釈した。有機相を取り出し、飽和炭酸水素ナトリウム水溶液で洗浄した。水相を合わせて酢酸エチルで抽出した。有機層を合わせて硫酸マグネシウムで乾燥させ、濾過し、濾液を真空中で濃縮した。残渣をジメチルスルホキシド（１ｍＬ）に溶解させ、逆相ＨＰＬＣ（カラム：Ｗａｔｅｒｓ ＸＢｒｉｄｇｅ Ｃ_１８ １９×１００ｍｍ、５マイクロメートル；移動相Ａ：０．０３％の水酸化アンモニウム水溶液（ｖ／ｖ）；移動相Ｂ：０．０３％の水酸化アンモニウムアセトニトリル溶液（ｖ／ｖ）；勾配：８０％の水／２０％のアセトニトリルから８．５分で線形に０％の水／１００％のアセトニトリル、０％の水／１００％のアセトニトリルで１０．０分まで保持；流量：２５ｍＬ／分）によって精製した。この方法で精製すると、１７ｍｇの３−フルオロ−４−（｛６−［５−（メチルスルホニル）−２，３−ジヒドロ−１Ｈ−インドール−１−イル］ピリミジン−４−イル｝オキシ）ピペリジン−１−カルボン酸ｔｅｒｔ−ブチルが得られた。LCMS (M+H)): 493.0

1- (6-Chloropyrimidin-4-yl) -5- (methylsulfonyl) indoline (33.8 mg, 0.109 mmol) and tert-butyl 3-fluoro-4-hydroxypiperidine-1-carboxylate (cis and trans Racemic mixture of isomers) (20 mg, 0.091 mmol) dissolved in 1.5 mL 1,4-dioxane in a hot (105 ° C.) solution in a microwave vial was added sodium bis (trimethylsilyl) amide (0.14 mL). 1M tetrahydrofuran solution) was added. The stirred mixture was heated at 105 ° C. in a nitrogen atmosphere for 4 hours before it was cooled to room temperature and diluted with water and ethyl acetate. The organic phase was removed and washed with saturated aqueous sodium bicarbonate. The aqueous phases were combined and extracted with ethyl acetate. The organic layers were combined, dried over magnesium sulfate, filtered, and the filtrate was concentrated in vacuo. The residue was dissolved in dimethyl sulfoxide (1 mL) and reverse phase HPLC (column: Waters XBridge C ₁₈ 19 × 100 mm, 5 micrometers; mobile phase A: 0.03% aqueous ammonium hydroxide solution (v / v); mobile phase B: 0.03% ammonium hydroxide acetonitrile solution (v / v); Gradient: 80% water / 20% acetonitrile to 8.5% linearly in 8.5 minutes from 0% water / 100% acetonitrile, 0% Purified by water / 100% acetonitrile up to 10.0 min; flow rate: 25 mL / min). When purified in this way, 17 mg of 3-fluoro-4-({6- [5- (methylsulfonyl) -2,3-dihydro-1H-indol-1-yl] pyrimidin-4-yl} oxy) piperidine- Tert-butyl 1-carboxylate was obtained. LCMS (M + H)): 493.0

(Example 16)
(3R, 4S) -4-{[6- (2,3-dihydro-1H-pyrrolo [3,2-b] pyridin-1-yl) -5-methylpyrimidin-4-yl] oxy} -3- Tert-Butyl fluoropiperidine-1-carboxylate (racemic)

ラセミ体の（３Ｒ，４Ｓ）−３−フルオロ−４−ヒドロキシピペリジン−１−カルボン酸ｔｅｒｔ−ブチル（３１．３ｍｇ、０．０８１ｍｍｏｌ）を３ｍＬの無水Ｎ，Ｎ−ジメチルホルムアミドに溶かした撹拌した溶液に、水素化ナトリウム（６．５ｍｇ、０．１６ｍｍｏｌ）を室温で加えた。混合物を窒素中にて室温で２０分間撹拌した。１−（６−クロロ−５−メチルピリミジン−４−イル）−２，３−ジヒドロ−１Ｈ−ピロロ［３，２−ｂ］ピリジン（２０ｍｇ、０．０８１ｍｍｏｌ）を加え、反応液を窒素中にて１６時間６０℃に加熱した。混合物を室温に冷却し、水で希釈し、酢酸エチルで抽出した。抽出物を合わせて水、ブラインで洗浄し、硫酸ナトリウムで乾燥させ、濾過し、濾液を真空中で濃縮した。残渣を、２０〜８０％の酢酸エチルとヘプタンからなる定組成混合物を溶離液とするフラッシュクロマトグラフィーによって精製して、黄色のゴム質（１２ｍｇ）を得た。このゴム質をジメチルスルホキシド（１ｍＬ）に溶解させ、逆相ＨＰＬＣカラム：Ｗａｔｅｒｓ Ｓｕｎｆｉｒｅ Ｃ_１８ １９×１００ｍｍ、５マイクロメートル；移動相Ａ：０．０５％のトリフルオロ酢酸水溶液（ｖ／ｖ）；移動相Ｂ：０．０５％のトリフルオロ酢酸アセトニトリル溶液（ｖ／ｖ）；勾配：９５％の水／５％のアセトニトリルから８．５分で線形に０％の水／１００％のアセトニトリル、０％の水／１００％のアセトニトリルで１０．０分まで保持；流量：２５ｍＬ／分によって精製した。LCMS (M+H): 430.2.

A stirred solution of racemic tert-butyl (3R, 4S) -3-fluoro-4-hydroxypiperidine-1-carboxylate (31.3 mg, 0.081 mmol) in 3 mL anhydrous N, N-dimethylformamide. To the solution was added sodium hydride (6.5 mg, 0.16 mmol) at room temperature. The mixture was stirred at room temperature for 20 minutes under nitrogen. 1- (6-Chloro-5-methylpyrimidin-4-yl) -2,3-dihydro-1H-pyrrolo [3,2-b] pyridine (20 mg, 0.081 mmol) was added and the reaction was brought into nitrogen. For 16 hours. The mixture was cooled to room temperature, diluted with water and extracted with ethyl acetate. The extracts were combined, washed with water, brine, dried over sodium sulfate, filtered, and the filtrate was concentrated in vacuo. The residue was purified by flash chromatography eluting with an isocratic mixture of 20-80% ethyl acetate and heptane to give a yellow gum (12 mg). This gum was dissolved in dimethyl sulfoxide (1 mL) and reversed phase HPLC column: Waters Sunfire C ₁₈ 19 × 100 mm, 5 micrometers; Mobile phase A: 0.05% aqueous trifluoroacetic acid solution (v / v); Phase B: 0.05% trifluoroacetic acid acetonitrile solution (v / v); gradient: 95% water / 5% acetonitrile to 8.5% linearly in 8.5 minutes / 100% acetonitrile, 0% Of water / 100% acetonitrile until 10.0 min; flow rate: purified by 25 mL / min. LCMS (M + H): 430.2.

This example was also prepared as follows.
In a 3-neck round bottom flask, 1- (6-chloro-5-methylpyrimidin-4-yl) -2,3-dihydro-1H-pyrrolo [3,2-b] pyridine (1.0 g 4.05 mmol), Tert-Butyl (3R, 4S) -3-fluoro-4-hydroxypiperidine-1-carboxylate (0.98 g, 4.47 mmol), cesium carbonate (1.58 g, 4.85 mmol), and acetonitrile (5 mL). added. The mixture was heated at reflux for about 48 hours. Water (3 volumes) was added and the mixture was then concentrated in vacuo to remove acetonitrile. The residue was diluted with ethyl acetate (10 volumes) and the layers were separated. The aqueous layer was extracted with ethyl acetate (1 volume). The combined organic layers were dried over magnesium sulfate, filtered, and the filtrate was concentrated to (3R, 4S) -4-{[6- (2,3-dihydro-1H-pyrrolo [3,2-b] pyridine. -1-yl) -5-methylpyrimidin-4-yl] oxy} -3-fluoropiperidine-1-carboxylate tert-butyl (racemate) as a dark brown oil (unpurified 1.6 g, 92%) Got as.

This example was also prepared as follows.
A 3-neck round bottom flask was charged with 1- (6-chloro-5-methylpyrimidin-4-yl) -2,3-dihydro-1H-pyrrolo [3,2-b] pyridine (19 g, 77.02 mmol) and 2 -Methyltetrahydrofuran (95 mL) was added. The flask was purged with nitrogen and the mixture was heated to reflux. In a separate flask, tert-butyl (3R, 4S) -3-fluoro-4-hydroxypiperidine-1-carboxylate (chiral) (18.6 g, 84.83 mmol) and 2-methyltetrahydrofuran (19 mL) were combined. A thick slurry was obtained. Sodium bis (trimethylsilyl) amide (92.4 mL, 92.40 mmol) was added. The solution was stirred for a few minutes and the color became orange over time. This resulting orange solution is added to a hot (refluxed) solution of 1- (6-chloro-5-methylpyrimidin-4-yl) -2,3-dihydro-1H-pyrrolo [3,2-b] pyridine for 15 minutes. The solution was slowly added dropwise. The resulting solution was heated to reflux for about 1.5 hours. The reaction was then cooled to room temperature and diluted with water (76 mL). The mixture was stirred at room temperature overnight. The layers were separated. The aqueous layer was extracted with 2-methyltetrahydrofuran (40 mL). The organic layers were combined and washed with cold 1N hydrochloric acid (60 mL) at 0 ° C. The layers were separated. The orange aqueous layer was immediately adjusted to pH 9-10 with 1N sodium hydroxide. This layer was extracted with 2-methyltetrahydrofuran (110 mL). The final organic extract is dried over magnesium sulfate, filtered, and the filtrate is concentrated in vacuo to give (3R, 4S) -4- (6- (2,3-dihydro-1H-pyrrolo [3,2- b] Pyridin-1-yl) -5-methylpyrimidin-4-yloxy) -3-fluoropiperidine-1-carboxylate tert-butyl was obtained as an orange oil (unpurified 39 g, 117.9%). This material was used in subsequent steps without further purification.

(Example 17)
(3R, 4S) -4-{[6- (2,3-dihydro-1H-pyrrolo [3,2-b] pyridin-1-yl) -5-methylpyrimidin-4-yl] oxy} -3- 1-methylcyclopropyl fluoropiperidine-1-carboxylate

ステップＡ：１−（６−（（３Ｒ，４Ｓ）−３−フルオロピペリジン−４−イルオキシ）−５−メチルピリミジン−４−イル）−２，３−ジヒドロ−１Ｈ−ピロロ［３，２−ｂ］ピリジン

Step A: 1- (6-((3R, 4S) -3-fluoropiperidin-4-yloxy) -5-methylpyrimidin-4-yl) -2,3-dihydro-1H-pyrrolo [3,2-b ] Pyridine

（３Ｒ，４Ｓ）−４−（６−（２，３−ジヒドロ−１Ｈ−ピロロ［３，２−ｂ］ピリジン−１−イル）−５−メチルピリミジン−４−イルオキシ）−３−フルオロピペリジン−１−カルボン酸ｔｅｒｔ−ブチル（３１．７ｇ、７３．８１ｍｍｏｌ）とｐ−トルエンスルホン酸一水和物（５６．１６ｇ、２９５．２４ｍｍｏｌ）を、テトラヒドロフラン（３１７ｍＬ、３．９０モル）および水（３１ｍＬ、１．７２モル）の中で合わせた。得られる溶液を３時間還流加熱した。遊離アミン生成物は単離せず、次のステップにそのまま進めた。

(3R, 4S) -4- (6- (2,3-dihydro-1H-pyrrolo [3,2-b] pyridin-1-yl) -5-methylpyrimidin-4-yloxy) -3-fluoropiperidine- Tert-butyl 1-carboxylate (31.7 g, 73.81 mmol) and p-toluenesulfonic acid monohydrate (56.16 g, 295.24 mmol) were added to tetrahydrofuran (317 mL, 3.90 mol) and water (31 mL). 1,72 mol). The resulting solution was heated at reflux for 3 hours. The free amine product was not isolated and proceeded directly to the next step.

Step B: (3R, 4S) -4-{[6- (2,3-dihydro-1H-pyrrolo [3,2-b] pyridin-1-yl) -5-methylpyrimidin-4-yl] oxy} 1-3-fluoropiperidine-1-carboxylic acid 1-methylcyclopropyl

ステップＡからの１−（６−（（３Ｒ，４Ｓ）−３−フルオロピペリジン−４−イルオキシ）−５−メチルピリミジン−４−イル）−２，３−ジヒドロ−１Ｈ−ピロロ［３，２−ｂ］ピリジンの混合物を撹拌したものに、トリエチルアミン（６１．７３ｍＬ、４４２．８５ｍｍｏｌ）を室温で加えた。この撹拌した溶液（ｐＨ９〜１０）に、４−ニトロフェニル炭酸１−メチルシクロプロピル（１７．６６ｇ、７３．８１ｍｍｏｌ）を加えた。反応混合物を４０℃で３時間撹拌した。次いで混合物を１Ｎ水酸化ナトリウム（３体積）で希釈し、溶液を濃縮してテトラヒドロフランを除去した。水層を２−メチルテトラヒドロフラン（５体積）で抽出した。有機抽出物を合わせて１Ｎ水酸化ナトリウム（２体積）、飽和炭酸ナトリウム水溶液（１体積）、およびブライン（１体積）で２回洗浄し、硫酸マグネシウムで乾燥させ、濾過し、濾液を真空中で濃縮して油状物とした。油状物をｔｅｒｔ−ブチルメチルエーテル中で１６時間撹拌して粒状化した。黄色の固体を濾過によって収集した。これらの固体を０．２Ｎ水酸化ナトリウム（２体積）懸濁液として２時間撹拌した。濾過すると、１９．８ｇの（３Ｒ，４Ｓ）−４−｛［６−（２，３−ジヒドロ−１Ｈ−ピロロ［３，２−ｂ］ピリジン−１−イル）−５−メチルピリミジン−４−イル］オキシ｝−３−フルオロピペリジン−１−カルボン酸１−メチルシクロプロピル（６３％）が得られた。¹H NMR (400 MHz, 重水素化クロロホルム) δ 0.56 - 0.68 (m, 2 H) 0.83 - 0.93 (m, 2 H) 1.54 (s, 3 H) 1.83 - 2.22
(m, 5 H) 3.04 - 3.49 (m, 4 H) 3.96 - 4.29 (m, 4 H) 4.74 - 4.99 (m, 1 H) 5.30 -
5.46 (m, 1 H) 6.98 (dd, J=8.10, 4.98 Hz, 1 H) 7.03 - 7.11 (m, 1 H) 8.00 (dd,
J=4.88, 1.37 Hz, 1 H) 8.33 (s, 1 H).

1- (6-((3R, 4S) -3-fluoropiperidin-4-yloxy) -5-methylpyrimidin-4-yl) -2,3-dihydro-1H-pyrrolo [3,2- from step A b] To a stirred mixture of pyridine was added triethylamine (61.73 mL, 442.85 mmol) at room temperature. To this stirred solution (pH 9-10) was added 4-nitrophenyl 1-methylcyclopropyl carbonate (17.66 g, 73.81 mmol). The reaction mixture was stirred at 40 ° C. for 3 hours. The mixture was then diluted with 1N sodium hydroxide (3 volumes) and the solution was concentrated to remove the tetrahydrofuran. The aqueous layer was extracted with 2-methyltetrahydrofuran (5 volumes). The combined organic extracts were washed twice with 1N sodium hydroxide (2 volumes), saturated aqueous sodium carbonate (1 volume), and brine (1 volume), dried over magnesium sulfate, filtered and the filtrate in vacuo. Concentrated to an oil. The oil was granulated by stirring in tert-butyl methyl ether for 16 hours. A yellow solid was collected by filtration. These solids were stirred as a 0.2N sodium hydroxide (2 volumes) suspension for 2 hours. Upon filtration, 19.8 g of (3R, 4S) -4-{[6- (2,3-dihydro-1H-pyrrolo [3,2-b] pyridin-1-yl) -5-methylpyrimidine-4- Yl] oxy} -3-fluoropiperidine-1-carboxylic acid 1-methylcyclopropyl (63%) was obtained. ¹ H NMR (400 MHz, deuterated chloroform) δ 0.56-0.68 (m, 2 H) 0.83-0.93 (m, 2 H) 1.54 (s, 3 H) 1.83-2.22
(m, 5 H) 3.04-3.49 (m, 4 H) 3.96-4.29 (m, 4 H) 4.74-4.99 (m, 1 H) 5.30-
5.46 (m, 1 H) 6.98 (dd, J = 8.10, 4.98 Hz, 1 H) 7.03-7.11 (m, 1 H) 8.00 (dd,
J = 4.88, 1.37 Hz, 1 H) 8.33 (s, 1 H).

(Example 18)
(3S, 4R) -4-{[6- (2,3-Dihydro-1H-pyrrolo [3,2-b] pyridin-1-yl) -5-methylpyrimidin-4-yl] oxy} -3- 1-methylcyclopropyl fluoropiperidine-1-carboxylate

実施例１８は、適切な出発材料を用い、実施例１７と同様にして調製した。1H NMR (400 MHz, 重水素化クロロホルム) δ 0.56 - 0.68 (m,
2 H) 0.83 - 0.93 (m, 2 H) 1.54 (s, 3 H) 1.83 - 2.22 (m, 5 H) 3.04 - 3.49 (m, 4
H) 3.96 - 4.29 (m, 4 H) 4.74 - 4.99 (m, 1 H) 5.30 - 5.46 (m, 1 H) 6.98 (dd,
J=8.10, 4.98 Hz, 1 H) 7.03 - 7.11 (m, 1 H) 8.00 (dd, J=4.88, 1.37 Hz, 1 H) 8.33
(s, 1 H)

Example 18 was prepared in the same manner as Example 17 using the appropriate starting materials. 1H NMR (400 MHz, deuterated chloroform) δ 0.56-0.68 (m,
2 H) 0.83-0.93 (m, 2 H) 1.54 (s, 3 H) 1.83-2.22 (m, 5 H) 3.04-3.49 (m, 4
H) 3.96-4.29 (m, 4 H) 4.74-4.99 (m, 1 H) 5.30-5.46 (m, 1 H) 6.98 (dd,
J = 8.10, 4.98 Hz, 1 H) 7.03-7.11 (m, 1 H) 8.00 (dd, J = 4.88, 1.37 Hz, 1 H) 8.33
(s, 1 H)

(Example 19)
(3R, 4S) -4-{[6- (2,3-dihydro-1H-pyrrolo [3,2-b] pyridin-1-yl) -5-methylpyrimidin-4-yl] oxy} -3- Fluoropiperidine-1-carboxylic acid 1-methylcyclopropyl (racemic)

実施例１９（実施例１７および１８のラセミ混合物）は、ラセミ体の（３Ｒ，４Ｓ）−４−（６−（２，３−ジヒドロ−１Ｈ−ピロロ［３，２−ｂ］ピリジン−１−イル）−５−メチルピリミジン−４−イルオキシ）−３−フルオロピペリジン−１−カルボン酸ｔｅｒｔ−ブチルを使用したことを除き、実施例１７と同様にして調製した。未精製材料をジメチルスルホキシド（１ｍＬ）に溶解させ、逆相ＨＰＬＣ（カラム：Ｗａｔｅｒｓ ＸＢｒｉｄｇｅ Ｃ_１８ １９×１００ｍｍ、５マイクロメートル；移動相Ａ：０．０３％の水酸化アンモニウム水溶液（ｖ／ｖ）；移動相Ｂ：０．０３％の水酸化アンモニウムアセトニトリル溶液（ｖ／ｖ）；勾配：９０％の水／１０％のアセトニトリルから８．５分で線形に０％の水／１００％のアセトニトリル、０％の水／１００％のアセトニトリルで１０．０分まで保持；流量：２５ｍＬ／分）によって精製した。LCMS (M+H): 428.2

Example 19 (the racemic mixture of Examples 17 and 18) was prepared as racemic (3R, 4S) -4- (6- (2,3-dihydro-1H-pyrrolo [3,2-b] pyridine-1- Yl) -5-methylpyrimidin-4-yloxy) Prepared in the same manner as in Example 17 except that tert-butyl 3-fluoropiperidine-1-carboxylate was used. The crude material was dissolved in dimethyl sulfoxide (1 mL) and reverse phase HPLC (column: Waters XBridge C ₁₈ 19 × 100 mm, 5 micrometers; mobile phase A: 0.03% aqueous ammonium hydroxide (v / v); Mobile phase B: 0.03% ammonium hydroxide acetonitrile solution (v / v); Gradient: 0% water / 100% acetonitrile linearly in 8.5 minutes from 90% water / 10% acetonitrile, 0 % Water / 100% acetonitrile up to 10.0 min; flow rate: 25 mL / min). LCMS (M + H): 428.2

(Example 20)
4-{[6- (5-carbamoyl-2,3-dihydro-1H-indol-1-yl) -5-methylpyrimidin-4-yl] oxy} -3-fluoropiperidine-1-carboxylate 1-methyl Cyclopropyl (racemic)

ステップＡ：１−（６−（１−（ｔｅｒｔ−ブトキシカルボニル）−３−フルオロピペリジン−４−イルオキシ）−５−メチルピリミジン−４−イル）インドリン−５−カルボン酸

Step A: 1- (6- (1- (tert-Butoxycarbonyl) -3-fluoropiperidin-4-yloxy) -5-methylpyrimidin-4-yl) indoline-5-carboxylic acid

３−フルオロ−４−ヒドロキシピペリジン−１−カルボン酸ｔｅｒｔ−ブチル（４８ｍｇ、０．２２ｍｍｏｌ）のテトラヒドロフラン（１ｍＬ）溶液に、ナトリウムビス（トリメチルシリル）アミド（０．２４ｍＬ、１Ｍテトラヒドロフラン溶液）を室温で滴下した。混合物を５分間撹拌した後、１−（６−クロロ−５−メチルピリミジン−４−イル）インドリン−５−カルボン酸メチル（６０ｍｇ、０．２ｍｍｏｌ）をテトラヒドロフラン（１ｍＬ）に溶かした撹拌した溶液に、これを６０℃で滴下した。反応混合物を６０℃で２時間撹拌した。反応混合物を室温に冷却し、水および酢酸エチルで希釈した。水層を酢酸エチルで抽出し、有機抽出物を合わせて硫酸マグネシウムで乾燥させ、濾過し、濾液を真空中で濃縮した。未精製の１−（６−（１−（ｔｅｒｔ−ブトキシカルボニル）−３−フルオロピペリジン−４−イルオキシ）−５−メチルピリミジン−４−イル）インドリン−５−カルボン酸を精製せずに次のステップで使用した。

Sodium bis (trimethylsilyl) amide (0.24 mL, 1M tetrahydrofuran solution) was added dropwise at room temperature to a solution of tert-butyl 3-fluoro-4-hydroxypiperidine-1-carboxylate (48 mg, 0.22 mmol) in tetrahydrofuran (1 mL). did. After the mixture was stirred for 5 minutes, methyl 1- (6-chloro-5-methylpyrimidin-4-yl) indoline-5-carboxylate (60 mg, 0.2 mmol) was dissolved in tetrahydrofuran (1 mL). This was added dropwise at 60 ° C. The reaction mixture was stirred at 60 ° C. for 2 hours. The reaction mixture was cooled to room temperature and diluted with water and ethyl acetate. The aqueous layer was extracted with ethyl acetate, the combined organic extracts were dried over magnesium sulfate, filtered and the filtrate was concentrated in vacuo. The crude 1- (6- (1- (tert-butoxycarbonyl) -3-fluoropiperidin-4-yloxy) -5-methylpyrimidin-4-yl) indoline-5-carboxylic acid was purified without purification. Used in step.

Step B: tert-Butyl 4- (6- (5-carbamoylindoline-1-yl) -5-methylpyrimidin-4-yloxy) -3-fluoropiperidine-1-carboxylate

１−（６−（１−（ｔｅｒｔ−ブトキシカルボニル）−３−フルオロピペリジン−４−イルオキシ）−５−メチルピリミジン−４−イル）インドリン−５−カルボン酸（３０ｍｇ、０．０６３ｍｍｏｌ）を１，４−ジオキサン（２ｍＬ）に溶かした撹拌した溶液に、炭酸ジ−ｔｅｒｔブチル（１８．４ｍｇ、０．０８２ｍｍｏｌ）に続いてピリジン（０．００５ｍＬ、０．０６３ｍｍｏｌ）を加えた。反応混合物を室温で３０分間撹拌した後、炭酸水素アンモニウム（６．５ｍｇ、０．０８２ｍｍｏｌ）を加えた。混合物を窒素中にて室温で１９時間撹拌した後、水および酢酸エチルで希釈した。水層を酢酸エチルで抽出し、有機抽出物を合わせて硫酸マグネシウムで乾燥させ、濾過し、濾液を真空中で濃縮した。未精製の４−（６−（５−カルバモイルインドリン−１−イル）−５−メチルピリミジン−４−イルオキシ）−３−フルオロピペリジン−１−カルボン酸ｔｅｒｔ−ブチルを精製せずに次のステップで使用した。

1- (6- (1- (tert-butoxycarbonyl) -3-fluoropiperidin-4-yloxy) -5-methylpyrimidin-4-yl) indoline-5-carboxylic acid (30 mg, 0.063 mmol) in 1, To a stirred solution in 4-dioxane (2 mL) was added di-tertbutyl carbonate (18.4 mg, 0.082 mmol) followed by pyridine (0.005 mL, 0.063 mmol). The reaction mixture was stirred at room temperature for 30 minutes before ammonium hydrogen carbonate (6.5 mg, 0.082 mmol) was added. The mixture was stirred at room temperature for 19 hours under nitrogen and then diluted with water and ethyl acetate. The aqueous layer was extracted with ethyl acetate, the combined organic extracts were dried over magnesium sulfate, filtered and the filtrate was concentrated in vacuo. The crude tert-butyl 4- (6- (5-carbamoylindolin-1-yl) -5-methylpyrimidin-4-yloxy) -3-fluoropiperidine-1-carboxylate was not purified in the next step. used.

Step C: 4-{[6- (5-carbamoyl-2,3-dihydro-1H-indol-1-yl) -5-methylpyrimidin-4-yl] oxy} -3-fluoropiperidine-1-carboxylic acid 1-methylcyclopropyl (racemic)
4- (6- (5-carbamoylindolin-1-yl) -5-methylpyrimidin-4-yloxy) -3-fluoropiperidine-1-carboxylate tert-butyl (30 mg, 0.064 mmol) was added to dichloromethane (0. To a stirred solution dissolved in 5 mL) was added trifluoroacetic acid (0.5 mL). The mixture was stirred at room temperature for 2 hours and then concentrated in vacuo. The residue was dissolved in tetrahydrofuran (1 mL) and triethylamine (0.05 mL) and 4-nitrophenyl carbonate 1-methylcyclopropyl (22 mg, 0.09 mmol) was added at room temperature. The reaction mixture was stirred at room temperature for 16 hours and then diluted with water and ethyl acetate. The aqueous layer was extracted twice with ethyl acetate. The combined organic extracts were washed with saturated aqueous sodium bicarbonate solution, brine, dried over sodium sulfate, filtered and the filtrate concentrated in vacuo. The residue was dissolved in dimethyl sulfoxide (1 mL) and reverse phase HPLC (column: Waters XBridge C ₁₈ 19 × 100 mm, 5 micrometers; mobile phase A: 0.03% aqueous ammonium hydroxide solution (v / v); mobile phase B: 0.03% ammonium hydroxide acetonitrile solution (v / v); Gradient: 0% water / 100% acetonitrile, 0% linearly in 10.5 minutes from 80% water / 20% acetonitrile Purified by water / 100% acetonitrile up to 12.0 min; flow rate: 25 mL / min). LCMS (M + H): 470.1

(Example 21)
(9-anti) -9-{[6- (2,3-dihydro-1H-pyrrolo [3,2-b] pyridin-1-yl) -5-methylpyrimidin-4-yl] oxy} -3- Tert-Butyl oxa-7-azabicyclo [3.3.1] nonane-7-carboxylate

１−（６−クロロ−５−メチルピリミジン−４−イル）−２，３−ジヒドロ−１Ｈ−ピロロ［３，２−ｂ］ピリジン（１．０ｇ、４．０５ｍｍｏｌ）および９−アンチ−ヒドロキシ−３−オキサ−７−アザビシクロ［３．３．１］ノナン−７−カルボン酸ｔｅｒｔ−ブチル（１．０８ｇ、４．４６ｍｍｏｌ）を２０ｍＬの１，４−ジオキサンに溶かした撹拌した熱（１００℃）溶液に、窒素雰囲気中でナトリウムビス（トリメチルシリル）アミドの溶液（４．８６ｍＬ、４．８６ｍｍｏｌ、１．０Ｍテトラヒドロフラン溶液）を５分かけて滴下した。混合物を９０℃で２時間撹拌した後、室温に冷却し、水で希釈した。水相を酢酸エチルで３回抽出した。抽出物を合わせて硫酸ナトリウムで乾燥させ、濾過し、濾液を真空中で濃縮した。残渣を、ヘプタンに対して５０％〜１００％の酢酸エチルからなる勾配混合物を溶離液とする８０ｇシリカゲルカラムでのフラッシュクロマトグラフィーによって精製して、（９−アンチ）−９−｛［６−（２，３−ジヒドロ−１Ｈ−ピロロ［３，２−ｂ］ピリジン−１−イル）−５−メチルピリミジン−４−イル］オキシ｝−３−オキサ−７−アザビシクロ［３．３．１］ノナン−７−カルボン酸ｔｅｒｔ−ブチルを黄色の固体（１．３５ｇ）として得た。LCMS: 2.05分で454.5.
1H NMR (500 MHz, 重水素化クロロホルム) δ 1.50 (s, 9 H) 1.98 - 2.10 (m, 2 H) 2.11 -
2.18 (m, 3 H) 3.31 (t, J=8.54 Hz, 2 H) 3.38 (d, J=13.66 Hz, 1 H) 3.50 (d,
J=13.66 Hz, 1 H) 3.88 (dd, J=14.39, 12.69 Hz, 2 H) 4.08 - 4.26 (m, 5 H) 4.33
(d, J=13.66 Hz, 1 H) 5.45 (t, J=3.66 Hz, 1 H) 6.96 - 7.05 (m, 1 H) 7.05 - 7.12
(m, 1 H) 8.04 (dd, J=4.88, 1.22 Hz, 1 H) 8.38 (s, 1 H).

1- (6-Chloro-5-methylpyrimidin-4-yl) -2,3-dihydro-1H-pyrrolo [3,2-b] pyridine (1.0 g, 4.05 mmol) and 9-anti-hydroxy- 3-Oxa-7-azabicyclo [3.3.1] nonane-7-carboxylate tert-butyl (1.08 g, 4.46 mmol) dissolved in 20 mL 1,4-dioxane and stirred heat (100 ° C.) To the solution, a solution of sodium bis (trimethylsilyl) amide (4.86 mL, 4.86 mmol, 1.0 M tetrahydrofuran solution) was added dropwise over 5 minutes in a nitrogen atmosphere. The mixture was stirred at 90 ° C. for 2 hours, then cooled to room temperature and diluted with water. The aqueous phase was extracted 3 times with ethyl acetate. The extracts were combined, dried over sodium sulfate, filtered, and the filtrate was concentrated in vacuo. The residue was purified by flash chromatography on an 80 g silica gel column eluting with a gradient mixture consisting of 50% to 100% ethyl acetate to heptane to give (9-anti) -9-{[6- ( 2,3-dihydro-1H-pyrrolo [3,2-b] pyridin-1-yl) -5-methylpyrimidin-4-yl] oxy} -3-oxa-7-azabicyclo [3.3.1] nonane Tert-Butyl-7-carboxylate was obtained as a yellow solid (1.35 g). LCMS: 454.5 in 2.05 minutes.
1H NMR (500 MHz, deuterated chloroform) δ 1.50 (s, 9 H) 1.98-2.10 (m, 2 H) 2.11-
2.18 (m, 3 H) 3.31 (t, J = 8.54 Hz, 2 H) 3.38 (d, J = 13.66 Hz, 1 H) 3.50 (d,
J = 13.66 Hz, 1 H) 3.88 (dd, J = 14.39, 12.69 Hz, 2 H) 4.08-4.26 (m, 5 H) 4.33
(d, J = 13.66 Hz, 1 H) 5.45 (t, J = 3.66 Hz, 1 H) 6.96-7.05 (m, 1 H) 7.05-7.12
(m, 1 H) 8.04 (dd, J = 4.88, 1.22 Hz, 1 H) 8.38 (s, 1 H).

(Example 22)
(9-anti) -9-{[6- (2,3-dihydro-1H-pyrrolo [3,2-b] pyridin-1-yl) -5-methylpyrimidin-4-yl] oxy} -3- Isopropyl oxa-7-azabicyclo [3.3.1] nonane-7-carboxylate

９−アンチ−ヒドロキシ−３−オキサ−７−アザビシクロ［３．３．１］ノナン−７−カルボン酸イソプロピル（１３９ｍｇ、０．６１ｍｍｏｌ）を１ｍＬのテトラヒドロフランに溶かした撹拌した溶液に、ナトリウムビス（トリメチルシリル）アミド（０．８１ｍＬ、０．８１ｍｍｏｌ、１．０Ｍテトラヒドロフラン溶液）を室温で滴下した。混合物を５分間撹拌した後、１−（６−クロロ−５−メチルピリミジン−４−イル）−２，３−ジヒドロ−１Ｈ−ピロロ［３，２−ｂ］ピリジン（１００ｍｇ、０．４０ｍｍｏｌ）を１ｍＬのテトラヒドロフランに溶かした撹拌した熱（６０℃）溶液に加えた。反応混合物を６０℃で２時間撹拌した後、室温に冷却し、水および酢酸エチルで希釈した。水相を酢酸エチルで抽出し、有機層を合わせて硫酸マグネシウムで乾燥させ、濾過し、濾液を真空中で濃縮した。残渣を、ヘプタンに対して５０％〜１００％の酢酸エチルからなる勾配混合物を使用するフラッシュクロマトグラフィーによって精製して、（９−アンチ）−９−｛［６−（２，３−ジヒドロ−１Ｈ−ピロロ［３，２−ｂ］ピリジン−１−イル）−５−メチルピリミジン−４−イル］オキシ｝−３−オキサ−７−アザビシクロ［３．３．１］ノナン−７−カルボン酸イソプロピルを白色の固体（１１０ｍｇ）として得た。LCMS: 440.3. 1H NMR (500 MHz, 重水素化クロロホルム) δ 1.23 - 1.32 (m,
6 H) 2.02 - 2.07 (m, 1 H) 2.07 - 2.12 (m, 1 H) 2.13 (s, 3 H) 3.32 (t, J=8.42
Hz, 2 H) 3.37 - 3.48 (m, 1 H) 3.51 (d, J=13.91 Hz, 1 H) 3.88 (t, J=11.59 Hz, 2
H) 4.11 - 4.27 (m, 5 H) 4.36 (d, J=13.42 Hz, 1 H) 4.93 - 5.06 (m, 1 H) 5.47 (t,
J=3.66 Hz, 1 H) 6.96 - 7.05 (m, 1 H) 7.06 - 7.14 (m, 1 H) 8.05 (dd, J=5.00,
1.34 Hz, 1 H) 8.39 (s, 1 H).

To a stirred solution of isopropyl 9-anti-hydroxy-3-oxa-7-azabicyclo [3.3.1] nonane-7-carboxylate (139 mg, 0.61 mmol) in 1 mL of tetrahydrofuran was added sodium bis (trimethylsilyl). ) Amide (0.81 mL, 0.81 mmol, 1.0 M tetrahydrofuran solution) was added dropwise at room temperature. After the mixture was stirred for 5 minutes, 1- (6-chloro-5-methylpyrimidin-4-yl) -2,3-dihydro-1H-pyrrolo [3,2-b] pyridine (100 mg, 0.40 mmol) was added. To a stirred hot (60 ° C.) solution in 1 mL of tetrahydrofuran was added. The reaction mixture was stirred at 60 ° C. for 2 hours, then cooled to room temperature and diluted with water and ethyl acetate. The aqueous phase was extracted with ethyl acetate, the combined organic layers were dried over magnesium sulfate, filtered and the filtrate was concentrated in vacuo. The residue was purified by flash chromatography using a gradient mixture consisting of 50% to 100% ethyl acetate relative to heptane to give (9-anti) -9-{[6- (2,3-dihydro-1H -Pyrrolo [3,2-b] pyridin-1-yl) -5-methylpyrimidin-4-yl] oxy} -3-oxa-7-azabicyclo [3.3.1] nonane-7-carboxylate Obtained as a white solid (110 mg). LCMS: 440.3. 1H NMR (500 MHz, deuterated chloroform) δ 1.23-1.32 (m,
6 H) 2.02-2.07 (m, 1 H) 2.07-2.12 (m, 1 H) 2.13 (s, 3 H) 3.32 (t, J = 8.42
Hz, 2 H) 3.37-3.48 (m, 1 H) 3.51 (d, J = 13.91 Hz, 1 H) 3.88 (t, J = 11.59 Hz, 2
H) 4.11-4.27 (m, 5 H) 4.36 (d, J = 13.42 Hz, 1 H) 4.93-5.06 (m, 1 H) 5.47 (t,
J = 3.66 Hz, 1 H) 6.96-7.05 (m, 1 H) 7.06-7.14 (m, 1 H) 8.05 (dd, J = 5.00,
1.34 Hz, 1 H) 8.39 (s, 1 H).

(Example 23)
(9-Syn) -9-({5-methyl-6- [5- (methylsulfonyl) -2,3-dihydro-1H-indol-1-yl] pyrimidin-4-yl} oxy) -3-oxa -7-Azabicyclo [3.3.1] nonane-7-carboxylate

実施例２３は、適切な出発材料を用い、実施例１と同様にして調製した。粗生成物を、ヘプタンと酢酸エチルからなる３０％〜１００％の酢酸エチルの勾配混合物を溶離液とするシリカゲルクロマトグラフィーによって精製した。これによって、２００ｍｇの（９−シン）−９−（｛５−メチル−６−［５−（メチルスルホニル）−２，３−ジヒドロ−１Ｈ−インドール−１−イル］ピリミジン−４−イル｝オキシ）−３−オキサ−７−アザビシクロ［３．３．１］ノナン−７−カルボン酸イソプロピルが得られた。¹H NMR (400 MHz, 重水素化クロロホルム) δ 1.23 - 1.31 (m, 6 H) 1.95 - 2.03 (m, 2 H) 2.12 - 2.15 (m, 2 H) 3.04
(s, 3 H) 3.19 - 3.29 (m, 2H) 3.34 (d, J=13.66 Hz, 1 H) 3.89 (d, J=14.45 Hz, 1
H) 3.97 (d, J=12.30 Hz, 1 H) 4.25 (br. s., 6 H) 4.50 (d, J=13.86 Hz, 1 H) 4.66
(d, J=12.30 Hz, 1 H) 4.95 - 5.03 (m, 1 H) 5.39 - 5.43 (m, 1 H) 6.74 (d, J=8.39
Hz, 1 H) 7.70 (dd, J=8.49, 1.85 Hz, 1 H) 7.73 (d, J=1.95 Hz, 1 H) 8.44 (s, 1
H).

Example 23 was prepared in the same manner as Example 1 using the appropriate starting materials. The crude product was purified by silica gel chromatography, eluting with a gradient mixture of 30% to 100% ethyl acetate consisting of heptane and ethyl acetate. This gave 200 mg (9-cin) -9-({5-methyl-6- [5- (methylsulfonyl) -2,3-dihydro-1H-indol-1-yl] pyrimidin-4-yl} oxy ) -3-Oxa-7-azabicyclo [3.3.1] nonane-7-carboxylate was obtained. ¹ H NMR (400 MHz, deuterated chloroform) δ 1.23-1.31 (m, 6 H) 1.95-2.03 (m, 2 H) 2.12-2.15 (m, 2 H) 3.04
(s, 3 H) 3.19-3.29 (m, 2H) 3.34 (d, J = 13.66 Hz, 1 H) 3.89 (d, J = 14.45 Hz, 1
H) 3.97 (d, J = 12.30 Hz, 1 H) 4.25 (br. S., 6 H) 4.50 (d, J = 13.86 Hz, 1 H) 4.66
(d, J = 12.30 Hz, 1 H) 4.95-5.03 (m, 1 H) 5.39-5.43 (m, 1 H) 6.74 (d, J = 8.39
Hz, 1 H) 7.70 (dd, J = 8.49, 1.85 Hz, 1 H) 7.73 (d, J = 1.95 Hz, 1 H) 8.44 (s, 1
H).

(Example 24)
(9-anti) -9-({5-methyl-6- [5- (methylsulfonyl) -2,3-dihydro-1H-indol-1-yl] pyrimidin-4-yl} oxy) -3-oxa -7-Azabicyclo [3.3.1] nonane-7-carboxylate

実施例２４は、適切な出発材料を用い、実施例１と同様にして調製した。粗生成物を、ヘプタンと酢酸エチルからなる３０％〜１００％の酢酸エチルの勾配混合物を溶離液とするシリカゲルクロマトグラフィーによって精製した。これによって、１００ｍｇの（９−アンチ）−９−（｛５−メチル−６−［５−（メチルスルホニル）−２，３−ジヒドロ−１Ｈ−インドール−１−イル］ピリミジン−４−イル｝オキシ）−３−オキサ−７−アザビシクロ［３．３．１］ノナン−７−カルボン酸イソプロピルが得られた。¹H NMR (400 MHz, 重水素化クロロホルム) δ 1.23 - 1.31 (m, 6 H) 1.95 - 2.03 (m, 2 H) 2.12 - 2.15 (m, 2 H) 3.04
(s, 3 H) 3.19 - 3.29 (m, 2H) 3.34 (d, J=13.66 Hz, 1 H) 3.40 (d, J=14.45 Hz, 1
H) 3.50 (d, J=12.30 Hz, 1 H) 3.90 (d, J=13.86 Hz, 2 H) 4.18-4.38 (br. s., 6H)
4.95 - 5.03 (m, 1 H) 5.39 - 5.43 (m, 1 H) 6.74 (d, J=8.39 Hz, 1 H) 7.70 (dd,
J=8.49, 1.85 Hz, 1 H) 7.73 (d, J=1.95 Hz, 1 H) 8.44 (s, 1 H).

Example 24 was prepared in the same manner as Example 1 using the appropriate starting materials. The crude product was purified by silica gel chromatography, eluting with a gradient mixture of 30% to 100% ethyl acetate consisting of heptane and ethyl acetate. This gave 100 mg of (9-anti) -9-({5-methyl-6- [5- (methylsulfonyl) -2,3-dihydro-1H-indol-1-yl] pyrimidin-4-yl} oxy ) -3-Oxa-7-azabicyclo [3.3.1] nonane-7-carboxylate was obtained. ¹ H NMR (400 MHz, deuterated chloroform) δ 1.23-1.31 (m, 6 H) 1.95-2.03 (m, 2 H) 2.12-2.15 (m, 2 H) 3.04
(s, 3 H) 3.19-3.29 (m, 2H) 3.34 (d, J = 13.66 Hz, 1 H) 3.40 (d, J = 14.45 Hz, 1
H) 3.50 (d, J = 12.30 Hz, 1 H) 3.90 (d, J = 13.86 Hz, 2 H) 4.18-4.38 (br. S., 6H)
4.95-5.03 (m, 1 H) 5.39-5.43 (m, 1 H) 6.74 (d, J = 8.39 Hz, 1 H) 7.70 (dd,
J = 8.49, 1.85 Hz, 1 H) 7.73 (d, J = 1.95 Hz, 1 H) 8.44 (s, 1 H).

(Example 25)
(9-anti) -9-{[6- (2,3-dihydro-1H-pyrrolo [3,2-b] pyridin-1-yl) -5-methylpyrimidin-4-yl] oxy} -3- Oxa-7-azabicyclo [3.3.1] nonane-7-carboxylic acid 1-methylcyclopropyl

ステップＡ：（９−アンチ）−９−｛［６−（２，３−ジヒドロ−１Ｈ−ピロロ［３，２−ｂ］ピリジン−１−イル）−５−メチルピリミジン−４−イル］オキシ｝−３−オキサ−７−アザビシクロ［３．３．１］ノナン

Step A: (9-Anti) -9-{[6- (2,3-dihydro-1H-pyrrolo [3,2-b] pyridin-1-yl) -5-methylpyrimidin-4-yl] oxy} -3-Oxa-7-azabicyclo [3.3.1] nonane

（９−アンチ）−９−｛［６−（２，３−ジヒドロ−１Ｈ−ピロロ［３，２−ｂ］ピリジン−１−イル）−５−メチルピリミジン−４−イル］オキシ｝−３−オキサ−７−アザビシクロ［３．３．１］ノナン−７−カルボン酸ｔｅｒｔ−ブチル（１．３０ｇ、２．８７ｍｍｏｌ）を６ｍＬのジクロロメタンに溶かした撹拌した溶液に、３ｍＬのトリフルオロ酢酸（ＴＦＡ）を室温で加えた。得られる溶液を室温で２時間撹拌し、次いで真空中で濃縮した。残渣を精製せずに次のステップで使用した。

(9-anti) -9-{[6- (2,3-dihydro-1H-pyrrolo [3,2-b] pyridin-1-yl) -5-methylpyrimidin-4-yl] oxy} -3- To a stirred solution of tert-butyl oxa-7-azabicyclo [3.3.1] nonane-7-carboxylate (1.30 g, 2.87 mmol) in 6 mL dichloromethane was added 3 mL trifluoroacetic acid (TFA). Was added at room temperature. The resulting solution was stirred at room temperature for 2 hours and then concentrated in vacuo. The residue was used in the next step without purification.

Step B: (9-Anti) -9-{[6- (2,3-dihydro-1H-pyrrolo [3,2-b] pyridin-1-yl) -5-methylpyrimidin-4-yl] oxy} -3-Oxa-7-azabicyclo [3.3.1] nonane-7-carboxylic acid 1-methylcyclopropyl (9-anti) -9-{[6- (2,3-dihydro-1H-pyrrolo [3 , 2-b] pyridin-1-yl) -5-methylpyrimidin-4-yl] oxy} -3-oxa-7-azabicyclo [3.3.1] nonane (60 mg, 0.10 mmol) in 1 mL tetrahydrofuran. To a stirred solution in was added triethylamine (0.06 mL, 0.41 mmol) followed by 4-nitrophenyl carbonate 1-methylcyclopropyl (49 mg, 0.21 mmol) at room temperature. The reaction mixture was stirred for 16 hours in a nitrogen atmosphere, then diluted with water and extracted with ethyl acetate. The combined organic layers were washed twice with saturated aqueous sodium bicarbonate solution, brine, dried over sodium sulfate, filtered and the filtrate concentrated in vacuo. The crude residue was purified by flash chromatography (4 g silica, 50% to 100% heptane to ethyl acetate) to give (9-anti) -9-{[6- (2,3-dihydro-1H- 1-methyl pyrrolo [3,2-b] pyridin-1-yl) -5-methylpyrimidin-4-yl] oxy} -3-oxa-7-azabicyclo [3.3.1] nonane-7-carboxylate Cyclopropyl was obtained as a white solid (20 mg). LCMS m / z: 452.3. ¹ H NMR (500 MHz, deuterated chloroform) δ 0.58-0.70 (m,
2 H) 0.84-1.01 (m, 2 H) 1.59 (s, 3 H) 2.01 (br. S., 1 H) 2.04-2.10 (m, 1 H)
2.10-2.17 (m, 3 H) 3.31 (t, J = 8.42 Hz, 2 H) 3.37-3.54 (m, 2 H) 3.86 (t,
J = 11.34 Hz, 2 H) 4.06-4.26 (m, 5 H) 4.30-4.44 (m, 1 H) 4.36 (d, J = 13.66 Hz,
1 H) 5.45 (t, J = 3.66 Hz, 1 H) 6.95-7.05 (m, 1 H) 7.05-7.13 (m, 1 H) 8.04
(dd, J = 4.88, 0.98 Hz, 1 H) 8.38 (s, 1 H).

(Example 26)
(9-anti) -9-{[6- (2,3-dihydro-1H-pyrrolo [3,2-b] pyridin-1-yl) -5-methylpyrimidin-4-yl] oxy} -3- Oxa-7-azabicyclo [3.3.1] nonane-7-carboxylic acid 1-ethylcyclopropyl

実施例２６は、４−ニトロフェニル炭酸１−エチルシクロプロピルを使用し、実施例２５と同様にして調製した。未精製材料をジメチルスルホキシド（１ｍＬ）に溶解させ、逆相ＨＰＬＣ（カラム：Ｗａｔｅｒｓ Ｓｕｎｆｉｒｅ Ｃ_１８ １９×１００ｍｍ、５マイクロメートル；移動相Ａ：０．０５％のトリフルオロ酢酸水溶液（ｖ／ｖ）；移動相Ｂ：０．０５％のトリフルオロ酢酸アセトニトリル溶液（ｖ／ｖ）；勾配：８５％の水／１５％のアセトニトリルから８．５分で線形に０％の水／１００％のアセトニトリル、０％の水／１００％のアセトニトリルで１０．０分まで保持；流量：２５ｍＬ／分）によって精製した。この方法で精製すると、２３ｍｇの（９−アンチ）−９−｛［６−（２，３−ジヒドロ−１Ｈ−ピロロ［３，２−ｂ］ピリジン−１−イル）−５−メチルピリミジン−４−イル］オキシ｝−３−オキサ−７−アザビシクロ［３．３．１］ノナン−７−カルボン酸１−エチルシクロプロピルが得られた。LCMS (M+H): 466.3

Example 26 was prepared in the same manner as Example 25 using 4-nitrophenyl carbonate 1-ethylcyclopropyl. The crude material was dissolved in dimethyl sulfoxide (1 mL) and reverse phase HPLC (column: Waters Sunfire C ₁₈ 19 × 100 mm, 5 micrometers; mobile phase A: 0.05% aqueous trifluoroacetic acid (v / v); Mobile phase B: 0.05% trifluoroacetic acid acetonitrile solution (v / v); gradient: 0% water / 100% acetonitrile linearly in 8.5 minutes from 85% water / 15% acetonitrile, 0 % Water / 100% acetonitrile up to 10.0 min; flow rate: 25 mL / min). Purified in this way, 23 mg of (9-anti) -9-{[6- (2,3-dihydro-1H-pyrrolo [3,2-b] pyridin-1-yl) -5-methylpyrimidine-4 -Iyl] oxy} -3-oxa-7-azabicyclo [3.3.1] nonane-7-carboxylic acid 1-ethylcyclopropyl was obtained. LCMS (M + H): 466.3

(Example 27)
(9-anti) -9-{[6- (2,3-dihydro-1H-pyrrolo [3,2-b] pyridin-1-yl) -5-methylpyrimidin-4-yl] oxy} -3- 1-methylcyclobutyl oxa-7-azabicyclo [3.3.1] nonane-7-carboxylate

実施例２７は、４−ニトロフェニル炭酸１−メチルシクロブチルを使用し、実施例２５と同様にして調製した。未精製残渣をジメチルスルホキシド（１ｍＬ）に溶解させ、逆相ＨＰＬＣ（カラム：Ｗａｔｅｒｓ Ｓｕｎｆｉｒｅ Ｃ_１８ １９×１００ｍｍ、５マイクロメートル；移動相Ａ：０．０５％のトリフルオロ酢酸水溶液（ｖ／ｖ）；移動相Ｂ：０．０５％のトリフルオロ酢酸アセトニトリル溶液（ｖ／ｖ）；勾配：８５％の水／１５％のアセトニトリルから８．５分で線形に０％の水／１００％のアセトニトリル、０％の水／１００％のアセトニトリルで１０．０分まで保持；流量：２５ｍＬ／分）によって精製した。この方法で精製すると、１８ｍｇの（９−アンチ）−９−｛［６−（２，３−ジヒドロ−１Ｈ−ピロロ［３，２−ｂ］ピリジン−１−イル）−５−メチルピリミジン−４−イル］オキシ｝−３−オキサ−７−アザビシクロ［３．３．１］ノナン−７−カルボン酸１−メチルシクロブチルが得られた。LCMS (M+H): 466.3

Example 27 was prepared in the same manner as Example 25 using 4-nitrophenyl carbonate 1-methylcyclobutyl. The crude residue was dissolved in dimethyl sulfoxide (1 mL) and reverse phase HPLC (column: Waters Sunfire C ₁₈ 19 × 100 mm, 5 micrometers; mobile phase A: 0.05% aqueous trifluoroacetic acid (v / v); Mobile phase B: 0.05% trifluoroacetic acid acetonitrile solution (v / v); gradient: 0% water / 100% acetonitrile linearly in 8.5 minutes from 85% water / 15% acetonitrile, 0 % Water / 100% acetonitrile up to 10.0 min; flow rate: 25 mL / min). When purified in this way, 18 mg of (9-anti) -9-{[6- (2,3-dihydro-1H-pyrrolo [3,2-b] pyridin-1-yl) -5-methylpyrimidine-4 -Iyl] oxy} -3-oxa-7-azabicyclo [3.3.1] nonane-7-carboxylate 1-methylcyclobutyl was obtained. LCMS (M + H): 466.3

(Example 28)
(9-Sin) -9-{[6- (2,3-Dihydro-1H-pyrrolo [3,2-b] pyridin-1-yl) -5-methylpyrimidin-4-yl] oxy} -3- Oxa-7-azabicyclo [3.3.1] nonane-7-carboxylic acid 1-methylcyclopropyl

実施例２８は、９−シン−ヒドロキシ−３−オキサ−７−アザビシクロ［３．３．１］ノナン−７−カルボン酸ｔｅｒｔ−ブチルを使用し、実施例２５と同様にして調製した。
¹H NMR (400 MHz, 重水素化クロロホルム) δ 0.55 - 0.65 (m,
2 H) 0.82 - 0.97 (m, 2 H) 1.55 (s, 3 H) 1.87 - 2.01 (m, 2 H) 2.11 (s, 3 H) 3.18
(d, J=13.68 Hz, 1 H) 3.22 - 3.34 (m, 3 H) 3.79 (d, J=11.53 Hz, 1 H) 3.93 (d,
J=11.33 Hz, 1 H) 4.02 - 4.21 (m, 4 H) 4.35 (d, J=13.88 Hz, 1 H) 4.61 (d,
J=13.68 Hz, 1 H) 5.34 (t, J=3.32 Hz, 1 H) 6.92 - 7.02 (m, 1 H) 7.02 - 7.10 (m,
1 H) 8.00 (dd, J=4.98, 1.47 Hz, 1 H) 8.34 (s, 1 H).

Example 28 was prepared in the same manner as Example 25 using tert-butyl 9-syn-hydroxy-3-oxa-7-azabicyclo [3.3.1] nonane-7-carboxylate.
¹ H NMR (400 MHz, deuterated chloroform) δ 0.55-0.65 (m,
2 H) 0.82-0.97 (m, 2 H) 1.55 (s, 3 H) 1.87-2.01 (m, 2 H) 2.11 (s, 3 H) 3.18
(d, J = 13.68 Hz, 1 H) 3.22-3.34 (m, 3 H) 3.79 (d, J = 11.53 Hz, 1 H) 3.93 (d,
J = 11.33 Hz, 1 H) 4.02-4.21 (m, 4 H) 4.35 (d, J = 13.88 Hz, 1 H) 4.61 (d,
J = 13.68 Hz, 1 H) 5.34 (t, J = 3.32 Hz, 1 H) 6.92-7.02 (m, 1 H) 7.02-7.10 (m,
1 H) 8.00 (dd, J = 4.98, 1.47 Hz, 1 H) 8.34 (s, 1 H).

(Example 29)
(9-Sin) -9-{[6- (2,3-Dihydro-1H-pyrrolo [3,2-b] pyridin-1-yl) -5-methylpyrimidin-4-yl] oxy} -3- Isopropyl oxa-7-azabicyclo [3.3.1] nonane-7-carboxylate

実施例２９は、９−シン−ヒドロキシ−３−オキサ−７−アザビシクロ［３．３．１］ノナン−７−カルボン酸イソプロピルを使用し、実施例２８と同様にして調製した。未精製残渣をジメチルスルホキシド（１ｍＬ）に溶解させ、逆相ＨＰＬＣ（カラム：Ｗａｔｅｒｓ Ｓｕｎｆｉｒｅ Ｃ_１８ １９×１００ｍｍ、５マイクロメートル；移動相Ａ：０．０５％のトリフルオロ酢酸水溶液（ｖ／ｖ）；移動相Ｂ：０．０５％のトリフルオロ酢酸アセトニトリル溶液（ｖ／ｖ）；勾配：８０％の水／２０％のアセトニトリルから１０．０分かけて線形に４０％の水／６０％のアセトニトリル、１０．５分で０％の水／１００％のアセトニトリル、０％の水／１００％のアセトニトリルで１２．０分まで保持；流量：２５ｍＬ／分）によって精製した。この方法で精製すると、１４ｍｇの（９−シン）−９−｛［６−（２，３−ジヒドロ−１Ｈ−ピロロ［３，２−ｂ］ピリジン−１−イル）−５−メチルピリミジン−４−イル］オキシ｝−３−オキサ−７−アザビシクロ［３．３．１］ノナン−７−カルボン酸イソプロピルがトリフルオロ酢酸塩として得られた。LCMS (M+H): 440.3.

Example 29 was prepared in the same manner as Example 28, using isopropyl 9-syn-hydroxy-3-oxa-7-azabicyclo [3.3.1] nonane-7-carboxylate. The crude residue was dissolved in dimethyl sulfoxide (1 mL) and reverse phase HPLC (column: Waters Sunfire C ₁₈ 19 × 100 mm, 5 micrometers; mobile phase A: 0.05% aqueous trifluoroacetic acid (v / v); Mobile phase B: 0.05% trifluoroacetic acid acetonitrile solution (v / v); gradient: 40% water / 60% acetonitrile linearly over 10.0 minutes from 80% water / 20% acetonitrile, 10.5 min 0% water / 100% acetonitrile, 0% water / 100% acetonitrile held up to 12.0 min; flow rate: 25 mL / min). When purified in this manner, 14 mg of (9-cin) -9-{[6- (2,3-dihydro-1H-pyrrolo [3,2-b] pyridin-1-yl) -5-methylpyrimidine-4 -Iyl] oxy} -3-oxa-7-azabicyclo [3.3.1] nonane-7-carboxylate isopropyl was obtained as the trifluoroacetate salt. LCMS (M + H): 440.3.

(Example 30)
(3S, 4R) -4-{[6- (6,7-Dihydro-5H-pyrrolo [3,2-c] pyridazin-5-yl) -5-methylpyrimidin-4-yl] oxy} -3- Tert-Butyl fluoropiperidine-1-carboxylate

（３Ｓ，４Ｒ）−３−フルオロ−４−ヒドロキシピペリジン−１−カルボン酸ｔｅｒｔ−ブチル（３４ｍｇ、０．１６ｍｍｏｌ）をテトラヒドロフラン（０．５ｍＬ）に溶かした撹拌した溶液に、ナトリウムｔｅｒｔ−ブトキシド（０．１７ｍＬ、０．１７ｍｍｏｌ、１Ｍテトラヒドロフラン溶液）を室温で加えた。２０分後、この混合物を、５−（６−クロロ−５−メチルピリミジン−４−イル）−６，７−ジヒドロ−５Ｈ−ピロロ［３，２−ｃ］ピリダジン（調製例３２）（３５ｍｇ、０．１４ｍｍｏｌ）をテトラヒドロフラン（０．５ｍＬ）に溶かした撹拌した冷（０℃）懸濁液に加えた。得られる溶液を０℃で８０分間撹拌した。冷浴を取り外し、反応液を室温に温めた。室温で５．５時間経過後、反応混合物を水およびブラインで希釈し、酢酸エチル（３×１５ｍＬ）で抽出した。有機抽出物を合わせてブラインで洗浄し、１体積の水で希釈し、乾燥させ（硫酸ナトリウム）、濾過し、濾液を真空中でで濃縮して淡黄色の残渣６０ｍｇとした。この材料を、４０ｇの塩基性アルミナを使用し、２０％のメタノールジクロロメタン溶液を溶離液とするクロマトグラフィーによって精製した。得られる材料をジメチルスルホキシド（１ｍＬ）に溶解させ、逆相ＨＰＬＣ（カラム：Ｗａｔｅｒｓ ＸＢｒｉｄｇｅ Ｃ１８ １９×１００ｍｍ、５マイクロメートル；移動相Ａ：０．０３％の水酸化アンモニウム水溶液（ｖ／ｖ）；移動相Ｂ：０．０３％の水酸化アンモニウムアセトニトリル溶液（ｖ／ｖ）；勾配：８５％の水／１５％のアセトニトリルから８．５分で線形に０％の水／１００％のアセトニトリル、０％の水／１００％のアセトニトリルで１０．０分まで保持；流量：２５ｍＬ／分）によって精製した。LCMS (M+H): 431.28.

To a stirred solution of tert-butyl (3S, 4R) -3-fluoro-4-hydroxypiperidine-1-carboxylate (34 mg, 0.16 mmol) in tetrahydrofuran (0.5 mL) was added sodium tert-butoxide (0 .17 mL, 0.17 mmol, 1M tetrahydrofuran solution) was added at room temperature. After 20 minutes, the mixture was dissolved in 5- (6-chloro-5-methylpyrimidin-4-yl) -6,7-dihydro-5H-pyrrolo [3,2-c] pyridazine (Preparation 32) (35 mg, 0.14 mmol) was added to a stirred cold (0 ° C.) suspension in tetrahydrofuran (0.5 mL). The resulting solution was stirred at 0 ° C. for 80 minutes. The cold bath was removed and the reaction was warmed to room temperature. After 5.5 hours at room temperature, the reaction mixture was diluted with water and brine and extracted with ethyl acetate (3 × 15 mL). The combined organic extracts were washed with brine, diluted with 1 volume of water, dried (sodium sulfate), filtered, and the filtrate was concentrated in vacuo to a pale yellow residue of 60 mg. This material was purified by chromatography using 40 g of basic alumina and eluting with 20% methanol in dichloromethane. The resulting material was dissolved in dimethyl sulfoxide (1 mL) and reverse phase HPLC (column: Waters XBridge C18 19 × 100 mm, 5 micrometers; mobile phase A: 0.03% aqueous ammonium hydroxide (v / v); Phase B: 0.03% ammonium hydroxide acetonitrile solution (v / v); Gradient: 85% water / 15% acetonitrile to 8.5% linearly in 8.5 minutes / 100% acetonitrile, 0% Of water / 100% acetonitrile up to 10.0 min; flow rate: 25 mL / min). LCMS (M + H): 431.28.

(Example 31)
(3S, 4R) -4-{[6- (6,7-Dihydro-5H-pyrrolo [3,2-c] pyridazin-5-yl) -5-methylpyrimidin-4-yl] oxy} -3- 1-methylcyclopropyl fluoropiperidine-1-carboxylate

実施例３１は、（３Ｓ，４Ｒ）−４−｛［６−（６，７−ジヒドロ−５Ｈ−ピロロ［３，２−ｃ］ピリダジン−５−イル）−５−メチルピリミジン−４−イル］オキシ｝−３−フルオロピペリジン−１−カルボン酸ｔｅｒｔ−ブチルを出発材料とし、実施例１７と同様にして調製した。MS (M+H): 429.2.¹H NMR (400 MHz, 重水素化クロロホルム) δ 0.66 (br. s., 2
H) 0.91 (br. s., 2 H) 1.58 (s, 3 H) 1.93 (br. s., 1 H) 2.09 (s, 3 H) 2.17 (d,
J=11.53 Hz, 1 H) 3.19 (br. s., 1 H) 3.41 (br. s., 1 H) 3.52 (t, J=8.40 Hz, 2 H)
3.79 - 4.12 (m, 1 H) 4.14 - 4.35 (m, 3 H) 4.75 - 5.05 (m, 1 H) 5.44 (d, J=14.07
Hz, 1 H) 6.59 (d, J=5.86 Hz, 1 H) 8.44 (s, 1 H) 8.69 (d, J=5.67 Hz, 1 H).

Example 31 is (3S, 4R) -4-{[6- (6,7-dihydro-5H-pyrrolo [3,2-c] pyridazin-5-yl) -5-methylpyrimidin-4-yl] Prepared in the same manner as in Example 17 using tert-butyl oxy} -3-fluoropiperidine-1-carboxylate as a starting material. MS (M + H): 429.2. ¹ H NMR (400 MHz, deuterated chloroform) δ 0.66 (br. S., 2
H) 0.91 (br. S., 2 H) 1.58 (s, 3 H) 1.93 (br. S., 1 H) 2.09 (s, 3 H) 2.17 (d,
J = 11.53 Hz, 1 H) 3.19 (br. S., 1 H) 3.41 (br. S., 1 H) 3.52 (t, J = 8.40 Hz, 2 H)
3.79-4.12 (m, 1 H) 4.14-4.35 (m, 3 H) 4.75-5.05 (m, 1 H) 5.44 (d, J = 14.07
Hz, 1 H) 6.59 (d, J = 5.86 Hz, 1 H) 8.44 (s, 1 H) 8.69 (d, J = 5.67 Hz, 1 H).

(Example 32)
(3R, 4S) -4-{[6- (5-carbamoyl-2,3-dihydro-1H-pyrrolo [3,2-b] pyridin-1-yl) pyrimidin-4-yl] oxy} -3- 1-methylcyclopropyl fluoropiperidine-1-carboxylate

ステップＡ：１−（６−（（３Ｒ，４Ｓ）−３−フルオロ−１−（（１−メチルシクロプロポキシ）カルボニル）ピペリジン−４−イルオキシ）ピリミジン−４−イル）−２，３−ジヒドロ−１Ｈ−ピロロ［３，２−ｂ］ピリジン−５−カルボン酸メチル（ラセミ体）
２，３−ジヒドロ−１Ｈ−ピロロ［３，２−ｂ］ピリジン−５−カルボン酸メチル（３５ｍｇ、０．２０ｍｍｏｌ）および（３Ｒ，４Ｓ）−４−（６−クロロピリミジン−４−イルオキシ）−３−フルオロピペリジン−１−カルボン酸１−メチルシクロプロピル（ラセミ体）（６４．６ｍｇ、０．０２０ｍｍｏｌ）をｔｅｒｔ−ブタノール（１ｍＬ）およびトルエン（１ｍＬ）に溶かした溶液に、炭酸セシウム（１６３ｍｇ）を加えた。混合物を窒素ガス流で脱気した。ビス（トリフェニルホスフィン）パラジウム（ＩＩ）ジクロリド（１４ｍｇ）を加え、混合物を窒素で数分間再び脱気した。得られる混合物を１８時間還流加熱した（１１５℃）。混合物を室温に冷却し、酢酸エチルで希釈し、混合物を珪藻土で濾過した。濾液を水で洗浄し、硫酸マグネシウムで乾燥させ、濾過し、濾液を真空中で濃縮した。残渣を、ヘプタンに対して５０％〜９０％の酢酸エチルからなる勾配混合物を溶離液とするシリカゲルクロマトグラフィーによって精製して、１−（６−（（３Ｒ，４Ｓ）−３−フルオロ−１−（（１−メチルシクロプロポキシ）カルボニル）ピペリジン−４−イルオキシ）ピリミジン−４−イル）−２，３−ジヒドロ−１Ｈ−ピロロ［３，２−ｂ］ピリジン−５−カルボン酸メチル（ラセミ体）を淡黄色の固体（８０ｍｇ）として得た。LCMS (M+H): 472.0.

Step A: 1- (6-((3R, 4S) -3-fluoro-1-((1-methylcyclopropoxy) carbonyl) piperidin-4-yloxy) pyrimidin-4-yl) -2,3-dihydro- 1H-pyrrolo [3,2-b] pyridine-5-carboxylate methyl (racemate)
2,3-Dihydro-1H-pyrrolo [3,2-b] pyridine-5-carboxylate methyl (35 mg, 0.20 mmol) and (3R, 4S) -4- (6-chloropyrimidin-4-yloxy)- To a solution of 3-fluoropiperidine-1-carboxylate 1-methylcyclopropyl (racemic) (64.6 mg, 0.020 mmol) in tert-butanol (1 mL) and toluene (1 mL) was added cesium carbonate (163 mg). Was added. The mixture was degassed with a stream of nitrogen gas. Bis (triphenylphosphine) palladium (II) dichloride (14 mg) was added and the mixture was degassed again with nitrogen for several minutes. The resulting mixture was heated to reflux (115 ° C.) for 18 hours. The mixture was cooled to room temperature, diluted with ethyl acetate and the mixture was filtered through diatomaceous earth. The filtrate was washed with water, dried over magnesium sulfate, filtered and the filtrate was concentrated in vacuo. The residue was purified by silica gel chromatography eluting with a gradient mixture consisting of 50% to 90% ethyl acetate to heptane to give 1- (6-((3R, 4S) -3-fluoro-1- ((1-Methylcyclopropoxy) carbonyl) piperidin-4-yloxy) pyrimidin-4-yl) -2,3-dihydro-1H-pyrrolo [3,2-b] pyridine-5-carboxylate methyl (racemate) Was obtained as a pale yellow solid (80 mg). LCMS (M + H): 472.0.

Step B: 1- (6-((3R, 4S) -3-fluoro-1-((1-methylcyclopropoxy) carbonyl) piperidin-4-yloxy) pyrimidin-4-yl) -2,3-dihydro- 1H-pyrrolo [3,2-b] pyridine-5-carboxylic acid (racemate)
1- (6-((3R, 4S) -3-fluoro-1-((1-methylcyclopropoxy) carbonyl) piperidin-4-yloxy) pyrimidin-4-yl) -2,3-dihydro-1H-pyrrolo To a stirred solution of methyl [3,2-b] pyridine-5-carboxylate (racemic) (50 mg, 0.11 mmol) in a 3: 1 solution (2 mL) of tetrahydrofuran and water was added lithium hydroxide. Monohydrate (10 mg, 0.22 mmol) was added. After the reaction mixture was stirred at room temperature for 18 hours, 1N aqueous hydrochloric acid was added until the solution was approximately pH 2. The precipitate was collected by filtration and 40 mg of 1- (6-((3R, 4S) -3-fluoro-1-((1-methylcyclopropoxy) carbonyl) piperidin-4-yloxy) pyrimidine-4 -Yl) -2,3-dihydro-1H-pyrrolo [3,2-b] pyridine-5-carboxylic acid (racemic) was obtained as a white solid. This material was used in subsequent steps without purification.

Step C: (3R, 4S) -4-{[6- (5-carbamoyl-2,3-dihydro-1H-pyrrolo [3,2-b] pyridin-1-yl) pyrimidin-4-yl] oxy} 1-3-fluoropiperidine-1-carboxylic acid 1-methylcyclopropyl (racemic)
1- (6-((3R, 4S) -3-fluoro-1-((1-methylcyclopropoxy) carbonyl) piperidin-4-yloxy) pyrimidin-4-yl) -2,3-dihydro-1H-pyrrolo To a stirred solution of [3,2-b] pyridine-5-carboxylic acid (racemic) (25 mg, 0.055 mmol) in 1,4-dioxane (2 mL) was added di-tert-butyl carbonate (25 mg, 0.11 mmol) and pyridine (8.9 microliters, 0.11 mmol) were added. After the mixture was stirred at room temperature for 30 minutes, ammonium bicarbonate (8.7 mg, 0.11 mmol) was added. The mixture was stirred at room temperature for 19 hours in a nitrogen atmosphere. The solid from the reaction mixture was collected by filtration, rinsed, dried in vacuo and then (3R, 4S) -4-{[6- (5-carbamoyl-2,3-dihydro-1H-pyrrolo [3, 2-b] pyridin-1-yl) pyrimidin-4-yl] oxy} -3-fluoropiperidine-1-carboxylate 1-methylcyclopropyl (racemic) was obtained as a white solid (20 mg). LCMS (M + H): 457.1. ¹ H NMR (methanol-d4) δ 8.71 (d, J =
8.4 Hz, 1H), 8.46 (d, J = 0.8 Hz, 1H), 7.90 (d, J = 8.6 Hz, 1H), 6.23 (d, J =
0.8 Hz, 1H), 5.29-5.45 (m, 1H), 4.84-5.03 (m, 1H), 4.22 (br. S., 1H), 4.07
-4.14 (m, 2H), 3.94 (br.S., 1H), 3.36 (t, J = 8.6 Hz, 2H), 3.11 (br.S., 2H),
1.87-2.02 (m, 2H), 1.51 (s, 3H), 0.81-0.91 (m, 2H), 0.58-0.68 (m, 2H).

(Example 33)
4-({6- [5- (Dimethylcarbamoyl) -2,3-dihydro-1H-pyrrolo [3,2-b] pyridin-1-yl] pyrimidin-4-yl} oxy) piperidine-1-carboxylic acid 1-methylcyclopropyl

実施例３３は、Ｎ，Ｎ−ジメチル−２，３−ジヒドロ−１Ｈ−ピロロ［３，２−ｂ］ピリジン−５−カルボキサミドと４−（６−クロロピリミジン−４−イルオキシ）ピペリジン−１−カルボン酸１−メチルシクロプロピルから、実施例３２、ステップＡと同様にして調製した。未精製材料をジメチルスルホキシド（１ｍＬ）に溶解させ、逆相ＨＰＬＣ（カラム：Ｗａｔｅｒｓ ＸＢｒｉｄｇｅ Ｃ１８ １９×１００ｍｍ、５マイクロメートル）；移動相Ａ：０．０５％のトリフルオロ酢酸水溶液（ｖ／ｖ）；移動相Ｂ：０．０５％のトリフルオロ酢酸アセトニトリル溶液（ｖ／ｖ）；勾配：８５％の水／１５％のアセトニトリルから８．５分で線形に０％の水／１００％のアセトニトリル、０％の水／１００％のアセトニトリルで１０．０分まで保持；流量：２５ｍＬ／分）によって精製した。LCMS (M+H): 467.3.

Example 33 shows N, N-dimethyl-2,3-dihydro-1H-pyrrolo [3,2-b] pyridine-5-carboxamide and 4- (6-chloropyrimidin-4-yloxy) piperidine-1-carboxyl Prepared as in Example 32, Step A, from the acid 1-methylcyclopropyl. The crude material was dissolved in dimethyl sulfoxide (1 mL) and reverse phase HPLC (column: Waters XBridge C18 19 × 100 mm, 5 micrometers); mobile phase A: 0.05% aqueous trifluoroacetic acid (v / v); Mobile phase B: 0.05% trifluoroacetic acid acetonitrile solution (v / v); gradient: 0% water / 100% acetonitrile linearly in 8.5 minutes from 85% water / 15% acetonitrile, 0 % Water / 100% acetonitrile up to 10.0 min; flow rate: 25 mL / min). LCMS (M + H): 467.3.

  Throughout this application, various publications are cited as references. The disclosures of those publications are incorporated herein by reference in their entirety for all purposes.

  It will be apparent to those skilled in the art that various modifications and variations can be made in the present invention without departing from the scope or spirit of the invention. Other embodiments of the invention will be apparent to those skilled in the art from consideration of the specification and practice of the invention disclosed herein. It is intended that the specification and examples be considered as exemplary only, with a true scope and spirit of the invention being indicated by the following claims.

Claims (22)

Compound of formula (I)

[Where:
X is

And
R ¹ is —C (O) —O—R ⁵ or

And
R ² is hydrogen, cyano, or methyl;
R ³ is hydrogen, OH, halogen, cyano, CF ₃ , OCF ₃ , C ₁ -C ₅ alkoxy, or C ₁ -C ₅ alkyl,
R ⁴ is absent or —CO—NR ⁸ R ⁹ , triazole, tetrazole, C ₁ -C ₅ alkyl, NH ₂ , —NH—C ₁ -C ₅ alkyl, —N (CH ₃ ) —CO—O -C ₁ -C _{5 alkyl, -NH-CO-C 1 ~C} 5 alkyl, or _-N (CH 3) a _-CO-C 1 ~C ₅ alkyl,
R ⁵ _is C 1 -C _{5 alkyl,} C 3 -C ₆ cycloalkyl or one carbon atom may be substituted with methyl or ethyl _C 3 -C ₆ cycloalkyl cycloalkyl moiety,
R ⁶ is CF ₃ , C ₁ -C ₅ alkyl, halogen, cyano, or C ₃ -C ₆ cycloalkyl,
R ⁷ is C ₃ -C ₆ cycloalkyl, C ₁ -C ₅ alkyl, NH ₂ , or — (CH ₂ ) ₂ —OH,
R ⁸ is hydrogen or C ₁ -C ₅ alkyl;
R ⁹ is hydrogen, C ₁ -C ₅ alkyl, C ₃ -C ₆ cycloalkyl, —CH ₂ —CH ₂ —OH, —CH ₂ —CH ₂ —O—CH ₃ , —CH ₂ —CH ₂ —CH. _2- O—CH ₃ , —CH ₂ —CH ₂ —CH ₂ —OH, 3-oxetanyl, or 3-hydroxycyclobutyl,
R ¹⁰ is hydrogen, cyano, nitro, CF ₃ , OCF ₃ , C ₃ -C ₆ cycloalkyl, C ₁ -C ₅ alkoxy, or C ₁ -C ₅ alkyl,
R ¹¹ is hydrogen, C ₁ -C ₅ alkyl, or halogen;
A ¹ , A ² , A ³ and A ⁴ are each independently CH, N-oxide, or N;
However,
c) no more than ^{two of} A ¹ , A ² , A ³ and A ⁴ are N;
d) one or less of A ¹ , A ² , A ³ and A ⁴ is an N-oxide]
Or a pharmaceutically acceptable salt thereof. X is

The compound of claim 1, wherein X is

The compound of claim 1, wherein A ¹ to A ⁴ forms a phenyl ring, A compound according to claim 1, 2 or 3,. A ¹ to A ^{4 are,} A ^1, A 2, ^{A 3} and one or two of ^{A 4} is to form a ring which is N, A compound according to claim 1, 2 or 3,. The compound according to claim 1, 2, 3 or 5, wherein A ^{1 to} A ⁴ form a pyridyl ring. Or R ⁴ is absent or is ^-CO-NR 8 ^{R 9,} compounds according to any of claims 1 6. The compound according to any one of claims 1 to 6, wherein R ¹ is -C (O) -O-R ⁵ alkyl. R ³ is fluoro or hydrogen, R ² is hydrogen or cyano A compound according to any one of claims 1 to 8. (9-Sin) -9-{[6- (2,3-Dihydro-1H-pyrrolo [3,2-b] pyridin-1-yl) -5-methylpyrimidin-4-yl] oxy} -3- 1-methylcyclopropyl oxa-7-azabicyclo [3.3.1] nonane-7-carboxylate;
(9-anti) -9-{[6- (2,3-dihydro-1H-pyrrolo [3,2-b] pyridin-1-yl) -5-methylpyrimidin-4-yl] oxy} -3- 1-ethylcyclopropyl oxa-7-azabicyclo [3.3.1] nonane-7-carboxylate;
(9-anti) -9-{[6- (2,3-dihydro-1H-pyrrolo [3,2-b] pyridin-1-yl) -5-methylpyrimidin-4-yl] oxy} -3- 1-methylcyclopropyl oxa-7-azabicyclo [3.3.1] nonane-7-carboxylate;
(3S, 4R) -4-{[6- (2,3-Dihydro-1H-pyrrolo [3,2-b] pyridin-1-yl) -5-methylpyrimidin-4-yl] oxy} -3- 1-methylcyclopropyl fluoropiperidine-1-carboxylate;
(3R, 4S) -4-{[6- (2,3-dihydro-1H-pyrrolo [3,2-b] pyridin-1-yl) -5-methylpyrimidin-4-yl] oxy} -3- 1-methylcyclopropyl fluoropiperidine-1-carboxylate;
4-{[6- (5-cyano-2,3-dihydro-1H-indol-1-yl) pyrimidin-4-yl] oxy} piperidine-1-carboxylate;
(3R, 4S) -4-{[6- (2,3-dihydro-1H-pyrrolo [3,2-b] pyridin-1-yl) -5-methylpyrimidin-4-yl] oxy} -3- Fluoropiperidine-1-carboxylic acid 1-methylcyclopropyl (racemic);
4-{[6- (2,3-dihydro-1H-pyrrolo [3,2-b] pyridin-1-yl) -5-methylpyrimidin-4-yl] oxy} piperidine-1-carboxylate;
(9-anti) -9-{[6- (2,3-dihydro-1H-pyrrolo [3,2-b] pyridin-1-yl) -5-methylpyrimidin-4-yl] oxy} -3- 1-methylcyclobutyl oxa-7-azabicyclo [3.3.1] nonane-7-carboxylate; and 4-({6- [5- (dimethylcarbamoyl) -2,3-dihydro-1H-indole-1 -Yl] pyrimidin-4-yl} oxy) a compound selected from the group consisting of isopropylpiperidine-1-carboxylate, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable cocrystal.   11. A pharmaceutical composition comprising a compound according to any of claims 1 to 10 present in a therapeutically effective amount admixed with at least one pharmaceutically acceptable excipient.   12. The composition of claim 11, further comprising at least one additional agent selected from the group consisting of anti-obesity agents and anti-diabetic agents. The anti-obesity drug is zirlotapide, mitrapapide, imipritapide, R56918 (CAS No. 403987), CAS No. 913541-47-6, lorcaserine, cetiristat, PYY _3-36, naltrexone, oleoyl-estrone, obinetide, pramlintide, tesofensin, leptin 13. The composition of claim 12, wherein the composition is selected from the group consisting of: liraglutide, bromocriptine, orlistat, exenatide, AOD-9604 (CAS number 221231-10-3), and sibutramine.   The anti-diabetic drug is metformin, acetohexamide, chlorpropamide, diabinase, glibenclamide, glipizide, glyburide, glimepiride, gliclazide, glipentide, glyquidone, glisolamide, tolazamide, tolbutamide, tendamistat, trestatin, acarbose, adiposine, camiglibos, Emiglitate, miglitol, voglibose, pradimicin Q, salvostatin, baraglitazone, ciglitazone, darglitazone, englitazone, isaglitazone, pioglitazone, rosiglitazone, troglitazone, exendin 3, exendin 4, trodaschemin, reserbatol, hiruthiosarp extract , Vildagliptin, alogliptin, and saxagliptin It is selected from the composition of claim 12.   A method of treating diabetes comprising administering an effective amount of a compound according to any of claims 1 to 10 to a patient in need thereof.   11. A method of treating a metabolic or metabolic related disease, condition, or disorder comprising administering to a patient a therapeutically effective amount of a compound according to any one of claims 1-10.   Hyperlipidemia, type I diabetes, type II diabetes, idiopathic type I diabetes (type Ib), adult latent autoimmune diabetes (LADA), early-onset type 2 diabetes (EOD), juvenile atypical diabetes ( YOAD), juvenile-onset diabetes mellitus (MODY), malnutrition-related diabetes, gestational diabetes, coronary heart disease, ischemic stroke, restenosis after angioplasty, peripheral vascular disease, intermittent claudication, myocardial infarction (eg, necrosis) And apoptosis), dyslipidemia, postprandial lipemia, impaired glucose tolerance (IGT) state, fasting plasma glucose abnormal state, metabolic acidosis, ketosis, arthritis, obesity, osteoporosis, hypertension, congestive heart failure, left ventricular hypertrophy, Peripheral arterial disease, diabetic retinopathy, macular degeneration, cataract, diabetic nephropathy, glomerulosclerosis, chronic renal failure, diabetic neuropathy, metabolic syndrome, syndrome X, Pre-syndrome, coronary heart disease, angina pectoris, thrombosis, atherosclerosis, myocardial infarction, transient ischemic attack, stroke, vascular restenosis, hyperglycemia, hyperinsulinemia, hyperlipidemia Hypertriglyceridemia, insulin resistance, impaired glucose metabolism, impaired glucose tolerance, fasting plasma glucose abnormalities, obesity, erectile dysfunction, skin and connective tissue disorders, foot ulceration and ulcerative colitis, endothelium Selected from the group consisting of disorders and vasodilatory disorders, hyperapo B lipoproteinemia, Alzheimer's disease, schizophrenia, cognitive impairment, inflammatory bowel disease, ulcerative colitis, Crohn's disease, and irritable bowel syndrome A method for the treatment of a condition comprising the administration of an effective amount of a compound according to any of claims 1-10. A method of treating a metabolic or metabolic related disease, condition, or disorder, in a patient in need of such treatment,
(I) a first composition according to claim 13, and (ii) at least one additional agent selected from the group consisting of anti-obesity agents and anti-diabetic agents and at least one pharmaceutically acceptable agent. Administering two separate pharmaceutical compositions comprising a second composition comprising an excipient.   21. The method of claim 20, wherein the first composition and the second composition are administered simultaneously.   21. The method of claim 20, wherein the first composition and the second composition are administered sequentially in any order.   11. Use of a compound according to claims 1 to 10 in the manufacture of a medicament for treating a disease, condition or disorder that modulates the activity of the G protein coupled receptor GPR119.   Use of a compound according to any of claims 1 to 12 in the preparation of a medicament for the treatment of diabetes or pathological conditions associated with said diabetes.